



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Board Meeting

February 25, 2015

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 10:00 a.m. on Wednesday, February 25, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-22-2015

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Minutes
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Committee Reports
 - A. Finance – Mr. Pitre
 - Consideration of Interim Report for Fiscal Year 2014-2015
 - B. Application Review – Mr. Soileau
 - Consideration of Committee Recommendations re Applications
 - C. Reciprocity – Ms. Hall
 - Consideration of Committee Recommendations re Applications
 - D. Violations – Mr. Bond
 - Consideration of Proposed Voluntary Consent Agreements
 - E. Impairment – Mr. Rabb
 - Consideration of Committee Recommendations re Applications
 - F. Reinstatement – Ms. Melancon
 - Consideration of Committee Recommendations re Applications
 - G. Tripartite – Mr. Burch
 - H. Regulation Revision – Mr. McKay
 - Consideration of Comments & Testimony from Public Hearing
 - Consideration of Regulatory Proposal 2015-A ~ Electronic Product Verification (Draft #2)
 - Consideration of Legislative Proposal 2015-A ~ Public Records (Draft #2)
 - Consideration of Legislative Proposal 2015-B ~ CDS Schedule Update (Draft #1)
 - Consideration of Legislative Proposal 2015-C ~ PMP Interstate Sharing Update (Draft #2)
 - I. Executive – Mr. Aron
 - Consideration of Committee Recommendations re Contracts & Agreements
 - Consideration of Proposal for Approval of Pharmacy Law Update CE
 - Consideration of Proposed Travel Card Policy

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

10. Staff Reports
 - J. Assistant Executive Director – Mr. Fontenot
 - Consideration of Requests for Waivers from PMP Reporting Requirement
 - K. General Counsel – Mr. Finalet
 - Consideration of Proposed Voluntary Consent Agreements
 - L. Executive Director – Mr. Broussard
11. Announcements
12. Recess

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals

DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners

LSBN	Louisiana State Board of Nursing
LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America

PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Meeting

Thursday, November 13, 2014 at 9:00 a.m.

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	3
2.	Invocation & Pledge of Allegiance	3
3.	Quorum Call	3
4.	Adoption of Agenda	4
5.	Consideration of Minutes	4
6.	Report on Action Items	4
7.	Confirmation of Acts	4
8.	Opportunity for Public Comment	5
*	Statement of Purpose	5
*	Special Orders of the Day	
	Presentation of Pharmacist Gold Certificate	5
9.	Election of Officers	5
10.	Committee Reports	
	A. Finance	5
	B. Application Review	6
	C. Reciprocity	6
	D. Violations	6
	E. Impairment	9
	F. Reinstatement	10
	G. Tripartite	11
	H. Regulation Revision	11
	I. Executive	13
11.	Staff Reports	
	J. Assistant Executive Director	14
	K. General Counsel	15
	L. Executive Director	17
12.	Announcements	18
13.	Adjourn	18

A regular meeting of the Louisiana Board of Pharmacy was held on Thursday, November 13, 2014 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted.

1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 9:00 a.m.

2. Invocation & Pledge

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Mr. Richard Indovina then led the group in the recitation of the Pledge of Allegiance.

3. Quorum Call

Mr. Aron then called upon the Secretary, Mr. Bond, to call the roll.

Members Present:

Mr. Carl W. Aron
Mr. Brian A. Bond
Mr. Clovis S. Burch
Mr. Ryan M. Dartez
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina
Mr. Marty R. McKay
Ms. Chris B. Melancon
Ms. Diane G. Milano
Mr. Ronald E. Moore
Mr. Blake P. Pitre
Ms. Pamela G. Reed
Mr. Don L. Resweber
Dr. Deborah H. Simonson
Mr. Richard A. Soileau
Mr. Rhonny K. Valentine

Members Absent:

Mr. T. Morris Rabb

Staff Present:

Mr. Malcolm J. Broussard, Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. M. Joseph Fontenot, Assistant Executive Director

Guests:

Dr. John Foust – Oklahoma Board of Pharmacy
Dr. Cindy Hamilton – Oklahoma Board of Pharmacy
Mr. Nicholas R. LaBarbera – Albertsons Pharmacies
Mr. Edwin A. Britt – Britt's Pharmacy
Mr. Kofi Bissah – Xavier University of La.

Ms. Rosamaend Oglesbee – CVS Pharmacies
Ms. Tijonne Edmond – La. Pharmacists Association
Mr. David Ruckman – Target Pharmacies
Mr. Nick Cahanin – NACDS
Mr. Kevin LaGrange – Professional Arts Pharmacy
Mr. Jay Britt – Britt's Pharmacy
Mr. Jeff Britt – Britt's Pharmacy
Mr. Paul D'Aunoy – C.A.P.S. Pharmacy
Mr. Korey Patty – La. Independent Pharmacies Association
Dr. Camtu Ho – Cubist Pharmaceuticals
Ms. Linda Spradley – Spradley & Spradley

Mr. Bond certified 16 of the 17 members were present, constituting a quorum for the conduct of official business.

Mr. Aron noted the attendance of two guests from the Oklahoma Board of Pharmacy. In particular, he welcomed Dr. John Foust, Executive Director, and Dr. Cindy Hamilton, Chief Compliance Officer, to the meeting and encouraged their interaction

4. Call for Additional Agenda Items

Mr. Aron asked if there were any additional agenda items, but none were offered. With no requests for any additions, and without objection, the Board adopted the posted agenda for that meeting. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of adjusting the sequence of various reports or guests. There were no objections to that request.

5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on August 6, 2014 and the Administrative Hearing on August 7, 2014, both of which were held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. Hearing no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

6. Report on Action Items

Mr. Broussard reminded the members of their adoption of two guidance documents, relative to Medication Therapy Management and Pharmacy Immunization Recordkeeping, during the previous meeting; as they requested, both documents were posted on the Board's website. He also reminded the members of their regulatory activity at the previous meeting and reported on the further progress of those regulatory projects.

7. Confirmation of Acts

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. Moore moved,

Resolved, that the actions taken and decisions made by the Board

officers, Board committees, and Executive Director in the general conduct and transactions of Board business since August 7, 2014 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative.

8. *Opportunity for Public Comment*

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and no comments were offered.

Statement of Purpose

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their mission in mind as they considered all the matters before them.

Special Order of the Day – Presentation of Pharmacist Gold Certificate

Mr. Aron recognized Mr. Edwin E. Britt, holder of Pharmacist License No. PST.008851, noting he had achieved 50 years of continuous pharmacist licensure this year. The members recognized him with a standing ovation.

9. *Election of Officers*

Mr. Aron reminded the members of their duty to elect officers for the Board during the final Board meeting of the calendar year. He then conducted the election, and the following members assumed their respective offices immediately:

- President – Carl W. Aron
- First Vice President – T. Morris Rabb
- Second Vice President – Marty R. McKay
- Third Vice President – Chris B. Melancon
- Secretary – Brian A. Bond

10. *Committee Reports*

A. *Finance Committee*

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre reported the committee had met the previous day to review two documents prepared by the staff. Mr. Pitre directed the members to the interim report for the current fiscal year, reviewed the highlights, and indicated the report was presented for information only and required no action by the Board. He then directed the members to the *Proposed Budget for Fiscal Year 2015-2016*. He indicated the committee members had reviewed the proposal and voted to recommend the adoption of the proposed budget as presented. He then moved,

Resolved, to approve and adopt the *Proposed Budget for Fiscal Year 2015-2016*.

The motion was adopted after a unanimous vote in the affirmative.

Finally, he expressed his appreciation to the other committee members for their efforts the previous day.

B. Application Review Committee

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee had met on October 16 to consider three referrals from the staff. Following interviews and deliberations, the committee approved the issuance of one credential and deferred consideration of another application until their next meeting. He then offered the following file for their consideration of the committee's recommendation.

Medical Arts Pharmacy Services, Inc. d/b/a Medical Arts Pharmacy (Applicant for PHY-NR Permit) Mr. Soileau moved to deny the application and refuse to issue the permit. The motion was adopted after a unanimous vote in the affirmative. The Board denied the application and refused to issue the permit.

Finally, he expressed his appreciation to the other committee members for their ongoing efforts.

C. Reciprocity Committee

Mr. Aron called upon Ms. Hall for the committee report. She indicated 82 pharmacists had completed the reciprocity requirements since the last Board meeting, and that none of them had met the criteria warranting a mandatory personal interview. In conformance with the policies and procedures previously approved, the staff issued licenses to all of the applicants.

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on September 10-11 to consider their posted agenda which included 31 cases: 9 pharmacists, 2 pharmacy technicians, 18 pharmacy permits, one pharmacy technician candidate, and one pharmacy permit applicant. Following their interviews and deliberations, the committee took no action on 8 of the 31 cases. They referred one case for a formal administrative hearing in February 2015. He then presented the following proposed voluntary consent agreements for their consideration of the committee's recommendations.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5306 (PHY.005788 & CDS.039634-PHY) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the permit and CDS license for two years and suspended the execution of the suspension, then placed the permit and CDS license on probation for two years, effective November 13, 2014, subject to certain terms enumerated in the consent agreement; and further, the Board assessed a fine of \$100,000 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No.5612 (PHY.005769) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$25,000 plus administrative and investigative costs.

Norman August Higginbotham (PST.015468) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$2,500 plus administrative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 1939 (PHY.006316) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$15,000 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 8999 (PHY.006285) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was approved after a unanimous vote in the affirmative. The Board assessed a fine of \$15,000 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 1017 (PHY.006018) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$15,000 plus administrative and investigative costs.

Vital Care of Miss-Lou, Inc. d/b/a Vital Care of Miss-Lou (PHY.006301) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$5,000 plus administrative and investigative costs.

Charles Edward Maier (PST.015447) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand and assessed administrative costs.

Tanya Lynnette Black (CPT.006606) Mr. Bond moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for an indefinite period of time, effective September 10, 2014.

Institutional Pharmacy Solutions of Cameron (PHY.006424) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed

a fine of \$25,000 plus administrative and investigative costs.

OK Compounding, LLC (Applicant for PHY-NR Permit) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a permanent prohibition on the acceptance of any future application for a pharmacy permit from the applicant; and further, assessed a fine of \$5,000 plus administrative costs.

Crystal Tavaralynne Hobdy (CPT.008861) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for three years and suspended the execution of the suspension, then placed the certificate on probation for three years, effective November 13, 2014, subject to certain terms enumerated in the consent agreement; and further, assessed administrative costs.

Randal Riverside Corporation d/b/a Matlock Pharmacy (PHY.006883) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the permit for five years and suspended the execution of the suspension, then placed the permit on probation for five years, effective November 13, 2014, subject to certain terms enumerated in the consent agreement; and further, assessed a fine of \$50,000 plus administrative and investigative costs.

Medco Health Solutions of Willingboro, LLC d/b/a Medco Health Solutions of Willingboro (PHY.004730) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative and investigative costs.

Medco Health Solutions of Las Vegas, LLC d/b/a Medco Health Solutions of Las Vegas (PHY.003521) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Fairfield, LLC d/b/a Medco Health Solutions of Fairfield (PHY.004237) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Columbus West, Ltd. d/b/a Medco Health Solutions of Columbus West (PHY.003595) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a

unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Hidden River, LLC d/b/a Medco Health Solutions of Hidden River (PHY.004927) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Texas, LLC d/b/a Medco Health Solutions of Fort Worth (PHY.003606) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Columbus North, Ltd. d/b/a Medco Health Solutions of Columbus North (PHY.004530) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Medco Health Solutions of Netpark, LLC d/b/a Medco Health Solutions of Netpark (PHY.004853) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative and investigative costs.

Medco Health Solutions of North Versailles, LLC d/b/a Medco Health Solutions of North Versailles (PHY.003580) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$20,000 plus administrative costs.

Mr. Bond reported the committee will meet on December 10-11 to consider that docket, which included 7 pharmacists, 5 pharmacy technicians, 5 pharmacy technician candidates, and 10 pharmacy permits.

Finally, Mr. Bond concluded his report with appreciation to the other committee members for their ongoing efforts.

E. Impairment Committee

In the absence of the committee chair, Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee had met the previous day to consider four referrals from the staff. He then presented the following files to the members for their consideration of the committee's recommendations.

Tiffany Cathleen Luse Upshaw (PST.018936) Mr. Soileau moved to

approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and suspended the execution of the suspension, then placed the license on probation for five years, effective November 13, 2014, subject to certain terms enumerated in the consent agreement.

Casey Ann Kendall (PST.017305) Mr. Soileau moved to approve her request for termination of previously imposed probationary terms. The motion was adopted after a unanimous vote in the affirmative. The Board removed all previously imposed probationary terms and restored the license to active and unrestricted status.

Edward John Rabalais (PST.009897) Mr. Soileau moved to approve his request for termination of previously imposed probationary terms. The motion was adopted after a unanimous vote in the affirmative. The Board removed all previously imposed probationary terms and restored the license to active and unrestricted status.

Bobby Trondell Thompson (PST.020854) Mr. Soileau moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application for pharmacist licensure by reciprocity, authorized the issuance of the license, suspended that license for five years and suspended the execution of the suspension, then placed the license on probation for five years, effective November 13, 2014, subject to certain terms enumerated in the consent agreement.

Finally, he closed his report with appreciation to the other members of the committee for their ongoing efforts.

F. Reinstatement Committee

Mr. Aron called upon Ms. Melancon for the committee report. She reported the committee had met the previous day to consider seven referrals from the staff. Following interviews and deliberations, two of the requests for reinstatement were withdrawn in lieu of denial. Further, one of the requests was referred for a formal administrative hearing. She then presented the following files to the members for their consideration of the committee's recommendations.

Charles Jude Mitchell, Jr. (PST.016284) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board deferred further consideration of his request for reinstatement of the previously suspended license pending completion of certain requirements identified in the consent agreement.

Motilall Soodeen (PST.010721) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board deferred further consideration of his request for reinstatement of the previously revoked license pending completion of certain requirements identified in the consent agreement.

Christian Allen Reuter, Jr. (PST.014543) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board deferred further consideration of his request for reinstatement of the previously suspended license pending completion of certain requirements identified in the consent agreement.

Lequita LeJean Jackson (CPT.001366) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the request for reinstatement of the previously lapsed certificate, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Finally, she closed her report with appreciation to the other committee members for their ongoing efforts.

G. Tripartite Committee

Mr. Aron noted the committee had not met since the previous Board meeting.

At this point, Mr. Aron declared a recess. It was noted the members recessed at 10:30 a.m. and reconvened in open session at 10:50 a.m. He then continued with the sequence of the posted agenda.

H. Regulation Revision Committee

Mr. Aron called upon Mr. McKay for the committee report. He reported the committee met on October 16 to consider their posted agenda. During that meeting, the members voted to recommend two new regulatory proposals for the Board's consideration, and further, to return three assignments back to the Board with no action. Before addressing those proposals, Mr. McKay reminded the members the Board had conducted a public hearing on October 30 to receive comments and testimony on three current regulatory projects. Without objection, he proposed to review the comments and testimony for those three items and then review the two new proposals.

Mr. McKay directed the members to the meeting binder containing a summary of the comments and testimony offered during the October 30 public hearing concerning Regulatory Project 2014-4 ~ Pharmacy Compounding. He noted the receipt of one question for clarification, but no comments or testimony on the proposed rule. The members approved the interim guidance provided by staff. Mr. McKay then moved,

Resolved, on consideration of the public comments and testimony,

and in the absence of any need for revision of the proposal as originally published, we authorize the Executive Director to prepare and submit the required report for the legislative oversight committee upon the instruction of the President, and in the absence of any further intervention, to publish the original proposal as a Final Rule.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay then directed the members to the summary of the comments and testimony offered during the October 30 public hearing concerning Regulatory Project 2014-5 ~ Prescriptions. He noted that no further comments had been received on this proposal; he then moved,

Resolved, on consideration of the absence of any public comments or testimony, and in the absence of any need for further revision of the proposal as originally published, we authorize the Executive Director to prepare and submit the required report for the legislative oversight committee upon the instruction of the President, and in the absence of any further intervention, to publish the previously revised proposal as a Final Rule.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay then directed the members to the summary of the comments and testimony offered during the October 30 public hearing concerning Regulatory Project 2014-6 ~ Special Event Pharmacy Permit. He noted no comments or testimony had been offered for the proposed rule; he then moved,

Resolved, on consideration of the absence of any public comments or testimony, and in the absence of any need for revision of the original proposal as published, we authorize the Executive Director to prepare and submit the required report for the legislative oversight committee upon the instruction of the President, and in the absence of any further intervention, to publish the original proposal as a Final Rule.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay then directed the members to a copy of Regulatory Proposal 2015-B ~ Dispenser Reporting to Prescription Monitoring Program (PMP) & Drugs of Concern (Draft #1). He reminded the members of Act 472 of the 2014 Legislature, which amended the deadline by which dispensers of controlled substance prescriptions are required to submit those prescription transactions to the PMP database. He also reminded the members the drug product tramadol had been classified as a 'drug of concern' in this state and was recently placed in Schedule IV of the federal list of controlled substances. He then indicated the regulatory proposal amended the Board's PMP rule to comply with the recent legislative act as well as the federal scheduling action. On behalf of the committee, he then moved,

Resolved, to approve Regulatory Proposal 2015-B ~ Dispenser Reporting to PMP & Drugs of Concern (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to

authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay then directed the members to a copy of Regulatory Proposal 2015-C ~ Expiration Date of Schedule II Prescriptions (Draft #2). He reminded the members of Act 865 of the 2014 Legislature, which reduced the expiration date of Schedule II prescriptions from six months to ninety days. He then indicated the regulatory proposal amended the Board's controlled substances rule to match the new law. On behalf of the committee, he then moved,

Resolved, to approve Regulatory Proposal 2015-C ~ Expiration Date of Schedule II Prescriptions (Draft #2), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve any acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

In addition to approving the two regulatory proposals during their last meeting, the committee members also voted to return three previously assigned topics back to the Board with no action. In particular, with respect to

- *Foreign pharmacy interns*, the committee discussed the concept at several meetings and determined that a policy enabling some type of temporary credentialing for foreign pharmacy interns would be a better approach than a formal rule. The President directed staff to prepare a policy for the Board's consideration.
- *Prohibition of physician ownership of pharmacies*, the committee believed that the absence of any statutory language addressing the ownership of pharmacies would defeat any proposed rule. The members requested staff to refer the underlying concern to the La. Board of Medical Examiners.
- *Disposition of dispensed prescription medications from central fill pharmacy*, the members believed that Wal-Mart Pharmacies had changed their policies and procedures to address the Board's current rules, and therefore no amendments to the rules were necessary. The members requested the Board's compliance officers to monitor the relevant pharmacies for compliance with the current rules.

Finally, Mr. McKay concluded his report with appreciation to the other committee members for their ongoing efforts as well as for the staff support.

I. Executive Committee

Mr. Aron informed the members the committee had met the previous day to consider the matters on their posted agenda. He noted the committee reviewed several resolutions and proposed policies prepared by the staff and had voted to recommend the approval of all of them. He indicated Mr. McKay was prepared to offer the recommendations on behalf of the committee. Mr. McKay then moved,

Resolved, to approve the Bank Box Access Resolution for Whitney

National Bank.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve the Resolution for Professional Legal Services for Ms. Celia R. Cangelosi for Fiscal Year 2014-2015.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve the Resolution for Professional Legal Services for Mr. E. Wade Shows for Fiscal Year 2014-2015.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve the proposed revision to Board Policy No. I.A.2 – Declaratory Statements and Advisory Opinions.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve the proposed new policy, Board Policy No. II.I.4 – Ebola Virus Disease.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Aron completed his report with appreciation to his fellow officers for their ongoing efforts.

At this point, Mr. Aron declared a luncheon recess. It was noted the members recessed at 11:50 am and then reconvened in open session at 12:40 pm. He then continued with the sequence of the posted agenda.

11. Staff Reports

J. Assistant Executive Director

Mr. Aron called upon Mr. Fontenot for the report. He presented the quarterly report for the Prescription Monitoring Program, noting several metrics cumulative through September 2014. The program database now holds just over 78 million prescription transactions dating back to 2009, averaging approximately 1.1 million new transactions per month. The number of prescribers and dispensers authorized to access the database continues to increase, fueled by the recent approval of delegates for those prescribers and dispensers. The number of queries by the prescribers and dispensers continues to rise, totaling just under 4.5 million since the program's inception, the daily average for the third quarter of this year was 4,435 queries per day.

He reminded the members about the 2009 change in the PMP law that authorized the Board to issue waivers to the duty to report data to the program. He then directed the members to a list of 12 pharmacies requesting such a waiver. Mr. Pitre moved,

Resolved, to authorize the issuance of PMP reporting waivers to:

- > PHY.002217-IR – Teche Action Clinic Pharmacy;
- > PHY.005322-NR – Walgreen Mail Service (FL);
- > PHY.006068-NR – FarmVet.com (TN);
- > PHY.006930-NR – Walgreens Call Center (FL);
- > PHY.006944-NU – Cardinal Health – West Monroe (LA);

- > PHY.006950-NR – Leedstone (MN);
 - > PHY.006952-NR – Praxis Rx (FL);
 - > PHY.006959-NR – Pharmaceutical Specialties Express (GA);
 - > PHY.006962-NR – Pet’s Choice Pharmacy (KS);
 - > PHY.006963-NR – Panther Specialty Pharmacy (PA);
 - > PHY.006981-HOS – Promise Hospital of Baton Rouge (LA); and
 - > PHY.006984-HOS – Promise Hospital of Ascension (LA)
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Fontenot indicated the completion of his report.

K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet then presented the following files to the members for their consideration of the staff’s recommendations.

Lakyn Hope Manuel (CPT.009959) Mr. Pitre moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$250 plus administrative costs.

Colin Michael Browder (CPT.010907) Mr. Moore moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, issued a permanent prohibition on the acceptance of any future application for the reinstatement of the certificate or for any other credential issued by the Board.

Bonnie Irene Sherman (CPT.011152) Mr. Burch moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$250 plus administrative costs.

Cassandra Leticia Rochelle Thomas (CPT.006932) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$250 plus administrative costs.

Nicole Graham Russo (CPT.009361) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$250 plus administrative costs.

Jennifer Violet Gibson (CPT.010456) Ms. Milano moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary

surrender of the certificate, resulting in the active suspension of the certificate for an indefinite period of time, effective November 5, 2014.

Myrna Lynn Williams (PST.013793) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the license, resulting in the active suspension of the license for an indefinite period of time, effective September 2, 2014.

Jerry Samuel Adkins (PST.014585) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the license, resulting in the active suspension of the license for an indefinite period of time, effective October 24, 2014.

Sara Lynn Henning (CPT.009568) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the certificate, resulting in the active suspension of the certificate for an indefinite period of time, effective October 30, 2014.

Gregg Spaulding Hunter (CDS.029158-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the summary suspension of his medical license by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective May 30, 2014.

Joseph John Mogan (CDS.024766-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his medical license to the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective August 1, 2014.

James Buell Denney (CDS.007103-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the summary suspension of his medical license by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective July 29, 2014.

Milton Randolph Eichmann (CDS.013713-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his medical license to the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective November 13, 2014.

Fiaz Afzal (CDS.025015-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the suspension of his medical license by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective November 1, 2014.

Zahid Imran (CDS.024368-MD) Mr. McKay moved to suspend the medical license for an indefinite period of time, based on the voluntary surrender of his medical license to the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective September 30, 2014.

Gregory Alphonse Redmann (CDS.026642-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the summary suspension of his medical license by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective August 20, 2014.

Cecil William Lovell, Jr. (CDS.003648-MD) Mr. McKay moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his medical license to the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective September 15, 2014.

Finally, Mr. Finalet indicated the conclusion of his report.

L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
 - Census Reports – Credentials & Compliance Divisions
 - Production Reports – Credentials Division
 - Exceptions Report
- Examinations
 - MPJE
 - NAPLEX
 - PARE
 - PTCB
- Operations
 - Credentials Division

Compliance Division
Administrative Division

- State Activities
 - Dept. of Health & Hospitals
 - La. State Board of Medical Examiners
- National Activities
 - National Association of Boards of Pharmacy (NABP)
 - NABP-AACP District 6 Annual Meeting
 - MALTAGON
 - U.S. Drug Enforcement Administration (DEA)
 - U.S. National Transportation Safety Board (NTSB)
- International Activities
 - International Pharmaceutical Federation (FIP)

12. Announcements

Mr. Aron directed the members to the announcements in their meeting binder, noting especially the tentative meeting dates for the Board in Calendar Year 2015.

13. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the meeting at 1:30 p.m.

Respectfully submitted,

Brian A. Bond
Secretary



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

Interim Report Fiscal Year 2014-2015

February 25, 2015

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
FY 2014-2015
Statement of Assets, Liabilities, Equity

FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014
---------------------------	---------------------------

ASSETS

> Current Assets			
* Cash			
General Operations			
Whitney Bank	160,352		160,433
Iberia Bank	829,409		1,097,374
Hurricane Relief Fund - Whitney Bank	83,137		83,180
Reserve Funds			
General Account	1,504,183		1,517,523
OPEB Account	<u>985,716</u>		<u>1,041,664</u>
* <i>Total Cash</i>	<i>3,562,797</i>		<i>3,900,174</i>
<i>Total Current Assets</i>	<i>3,562,797</i>		<i>3,900,174</i>
> Fixed Assets			
Land: Lot 5-A, Towne Center Business Park	709,080		709,080
Land: Lot 1-A-2, Leonard Place Subdivision	295,860		295,860
Office Building - 3388 Brentwood Drive	1,052,255		1,057,861
Office Equipment	195,598		214,496
Furniture	152,750		152,750
Software: Licensure & Website	408,560		408,560
Accumulated Depreciation	<u>(675,066)</u>		<u>(716,775)</u>
<i>Total Fixed Assets</i>	<i>2,139,037</i>		<i>2,121,832</i>
<u><i>TOTAL ASSETS</i></u>	<u><i>5,701,834</i></u>		<u><i>6,022,006</i></u>

LIABILITIES

> Current Liabilities			
Accrued salaries and benefits	72,047		0
Unemployment taxes payable	26		19
State taxes withheld	3,098		4,769
State retirement withheld	0		0
Accounts payable	3,536		0
Interest payable	5,338		0
Compensated absences (ST)	56,065		56,065
Building Loan @ Iberia Bank (ST)	<u>75,795</u>		<u>75,795</u>
<i>Total Current Liabilities</i>	<i>215,905</i>		<i>136,648</i>
> Long Term Liabilities			
Compensated absences (LT)	63,228		63,228
Building Loan @ Iberia Bank (LT)	885,109		448,223
Other Post Employment Benefits (OPEB) Payable	<u>1,016,868</u>		<u>1,016,868</u>
<i>Total Long Term Liabilities</i>	<i>1,965,205</i>		<i>1,528,319</i>
<u><i>TOTAL LIABILITIES</i></u>	<u><i>2,181,110</i></u>		<u><i>1,664,967</i></u>

Louisiana Board of Pharmacy
FY 2014-2015
Statement of Assets, Liabilities, Equity

FY 13-14	FY 14-15
Q4 06/30/2014	Q2 12/31/2014

EQUITY

Fund Balance at End of Prior Fiscal Year	1,872,264	1,747,956
Fund Balance - designated	174,954	174,954
Invested in Fixed Assets	1,178,132	1,597,814
Net Income/Loss	<u>295,374</u>	<u>836,315</u>
<i>TOTAL EQUITY</i>	<i>3,520,724</i>	<i>4,357,039</i>
<i><u>TOTAL LIABILITIES & EQUITY</u></i>	<i><u>5,701,834</u></i>	<i><u>6,022,006</u></i>

Louisiana Board of Pharmacy
 FY 2014-2015
 Statement of Revenue, Expenses, and Budget Performance

	Revenue		
	FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014	FY 14-15 Budget (A#1)
<i>Licenses & Permits</i>			
Pharmacist Renewals	755,775	742,925	755,000
New Pharmacist Licensing Fee	164,400	67,200	161,000
Technician Renewals	312,350	9,000	312,000
Technician Candidate Registrations	37,375	17,725	35,000
Lapsed Credential Fees	57,000	21,400	50,000
Student Registrations	3,070	1,920	3,000
Permits - Pharmacies	264,200	264,475	260,000
Permits - CDS	437,860	184,540	440,000
Permits - Emergency Drug Kits	12,525	1,350	12,500
Permits - Automated Medication Systems	17,700	4,350	18,000
Permits - Durable Medical Equipment	68,975	73,975	70,000
<i>Examinations</i>			
Reciprocity	47,700	29,100	45,000
Technicians	61,300	27,200	63,000
<i>Penalties</i>			
Licenses and Certificates	8,187	2,937	8,000
Permits	11,473	6,818	11,000
<i>Administrative Fees</i>			
Documents: Copies and Certification Fees	8,820	2,592	7,500
Duplicate Credentials	3,665	3,245	4,000
Silver Certificates	400	400	500
Original Certificates	9,750	5,550	10,000
NSF Fees	425	250	500
Handling & Mailing Fees	170	179	0
<i>Sale of Goods & Services</i>			
Law Books	5,095	1,265	6,000
Official Lists of Licensees	6,750	4,500	6,000
USCPSC Inspection Fee	1,650	2,400	2,000
<i>Enforcement Actions</i>			
Hearing Fees	22,000	11,250	24,000
Fines	215,000	471,275	250,000
Investigative Costs	39,198	15,560	40,000
<i>Prescription Monitoring Program</i>			
Assessments	462,825	193,425	465,000
Grants	0	0	0
<i>Miscellaneous</i>			
	820	220	1,000
TOTAL REVENUE	3,036,458	2,167,026	3,060,000

Louisiana Board of Pharmacy
 FY 2014-2015
 Statement of Revenue, Expenses, and Budget Performance

		Expenses		
		FY 13-14	FY 14-15	FY 14-15
		Q4 06/30/2014	Q2 12/31/2014	Budget (A#1)
<i>Operations</i>	Rentals - Office & Equipment	2,952	6,703	18,000
	Equipment Maintenance	2,681	2,180	4,000
	Telephone	15,629	9,466	15,000
	Printing	56,235	14,032	25,000
	Postage	51,628	25,092	45,000
	Civil Service Assessment	4,236	6,074	6,100
	Office Insurance (ORM)	6,272	7,112	7,500
	Dues & Subscriptions	20,354	8,451	23,000
	Office Supply Expenses	17,630	8,772	20,000
	Financial Service Charges	52,466	35,045	50,000
	Depreciation of Fixed Assets	141,772	53,508	141,000
	Interest Payments on Building Loan	63,000	25,036	63,000
	Office Meeting Expenses	47	126	500
	Utilities	10,655	4,482	10,000
	Miscellaneous	0	0	0
<i>Acquisitions</i>		345	929	52,500
<i>Personal Services</i>	Salaries	1,193,177	613,826	1,334,100
	Payroll Taxes (FICA + FUTA)	21,330	10,665	27,100
	Retirement Contributions	371,283	226,908	494,000
	Health Insurance (SEGBP)	119,974	63,012	160,200
	Other Post Employment Benefits (OPEB)	91,464	0	91,500
	Board Member Per Diem	27,900	14,100	31,000
<i>Professional Services</i>	Accounting	23,961	13,937	25,000
	Legal	35,908	5,946	30,000
	Information Systems	97,303	79,787	98,000
	Property Management	16,375	10,088	35,000
	Temp. Labor	20,354	8,519	20,000
	Prescription Monitoring Program	195,791	38,900	80,000
<i>Staff Expenses</i>	ED - Travel	1,178	83	10,000
	GC - Travel	12	4,198	10,000
	AED - Travel	1,964	138	10,000
	CO - Travel	3,912	1,792	7,000
	CO - Rental Cars & Fuel	15,522	7,551	17,500
	CO - Education	7,079	3,513	15,000
	House Staff - Travel	0	199	1,000
	Mileage	15,491	6,850	20,000
<i>Board Expenses</i>	Meeting Expenses	13,637	6,144	15,000
	Committee Expenses	6,460	2,239	8,000
	Conventions	14,829	14,131	15,000
	Mileage	12,268	5,240	15,000
	President's Expenses	10,946	5,784	10,000
TOTAL EXPENSES		2,764,020	1,350,558	3,060,000

Louisiana Board of Pharmacy
 FY 2014-2015
 Summary of Income Fund Balance Changes

Summary

	FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014	FY 14-15 Budget (A#1)
Income Statement			
Total Revenue	3,036,458	2,167,026	2,817,000
Total Expenses	2,764,020	1,350,558	2,817,000
Net Ordinary Income	272,438	816,468	0
Other Income & Expenses			
Investment	22,936	19,590	0
Disposl of assets	0	257	0
Net Income	295,374	836,315	0

	FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014	FY 14-15 Budget (A#1)
Fund Balance			
Beginning Fund Balance	3,225,350	3,520,724	3,520,724
Total Income	3,059,394	2,186,873	3,060,000
Total Expenses	2,764,020	1,350,558	3,060,000
Ending Fund Balance	3,520,724	4,357,039	3,520,724
Reservations of Fund Balance	2,162,000	2,102,000	2,102,000
Unreserved Fund Balance	1,358,724	2,255,039	1,418,724

Notes on Reservation of Fund Balance

FY 13-14	Other Post-Employment Benefits Payable	929,700
	Debt Service Payable	1,032,300
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	<i>TOTAL</i>	<i>2,162,000</i>

FY 14-15	Other Post Employment Benefits Payable	1,017,000
	Debt Service Payable	885,000
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	<i>TOTAL</i>	<i>2,102,000</i>

Louisiana Board of Pharmacy
FY 2014-2015
Schedule A - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity	FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014
ASSETS		
Current Assets		
Hancock Bank - Checking Account	<u>83,137</u>	<u>83,180</u>
<u>TOTAL ASSETS</u>	<u>83,137</u>	<u>83,180</u>
LIABILITIES		
Current Liabilities	0	0
EQUITY		
Retained Earnings	82,970	83,137
Net Income	<u>167</u>	<u>43</u>
<u>TOTAL LIABILITIES & EQUITY</u>	<u>83,137</u>	<u>83,180</u>
Statement of Receipts & Disbursements		
	FY 13-14 Q4 06/30/2014	FY 14-15 Q2 12/31/2014
RECEIPTS		
FEMA - Funds for payment of claims	8,920,812	8,920,812
FEMA - Administrative allowance	81,103	81,103
Pharmacies - reversal of claims	430,138	430,138
Interest income	<u>22,062</u>	<u>22,105</u>
<u>TOTAL RECEIPTS</u>	<u>9,454,115</u>	<u>9,454,158</u>
DISBURSEMENTS		
Claims paid to pharmacies	8,920,812	8,920,812
Reversed claim funds returned	430,138	430,138
Reversed administrative allowance returned	7,338	7,338
Interest earned on reversed admin. allowance returned	<u>12,690</u>	<u>12,690</u>
<u>TOTAL DISBURSEMENTS</u>	<u>9,370,978</u>	<u>9,370,978</u>
FUND BALANCE	<u>83,137</u>	<u>83,180</u>

Note: These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

Louisiana Board of Pharmacy
FY 2014-2015
Summary of Board Actions

Date	Action
11/5/2013	Original Budget - Finance Committee Approval
11/6/2013	Original Budget - Board Approval
8/5/2014	Budget Amendment #1 - Finance Committee Approval
8/6/2014	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
	Acceptance of Final Report

Account Number: H5E-049797
 Statement Period: 12/01/2014 - 12/31/2014

LOUISIANA BOARD OF PHARMACY
 3388 BRENTWOOD DR
 BATON ROUGE LA 70809 - 1700


Your Account Executive:
 JOSEPH BARRECA, JR.
 (504) 310-7364

Valuation at a Glance

	This Period
Beginning Account Value	\$1,517,586.63
Dividends/Interest	10,165.12
Change in Account Value	-10,565.63
Ending Account Value	\$1,517,186.12
Estimated Annual Income	\$1,989.01

Asset Allocation

	This Period	% Allocation
Cash, Money Funds, and Bank Deposits	99,863.14	7%
Fixed Income	1,417,322.98	93%
Account Total (Pie Chart)	\$1,517,186.12	100%



Client Service Information

Your Account Executive: X57

JOSEPH BARRECA, JR.
IBERIA FINANCIAL SERVICES
2900 RIDGELAKE DRIVE
METAIRIE LA 70002-4923

Contact Information

Telephone Number: (504) 310-7364

Your Account Information

Tax Lot Default Disposition Method

Default Method for Mutual Funds: AVERAGE COST (USING FIRST IN FIRST OUT)
Default Method for Stocks in a Dividend Reinvestment Plan: FIRST IN FIRST OUT

Default Method for all Other Securities: FIRST IN FIRST OUT

Bond Amortization Elections:

Treat all interest as original issue discount (OID): No
Amortize premium on taxable bonds based on Constant Yield Method: Yes
Accrual market discount method for all other bond types: Ratable Method
Include market discount in income annually: No

Copies of Statement Sent

KOLDER, CHAMPAGNE, SLAVEN & CO

At your request copies of this statement have been sent to the above.

Electronic Delivery

You are currently enrolled to receive the following account communications via electronic delivery:

Statements and Reports
Trade Confirmations
Tax Documents
Notifications

Please log in to your account to make any changes to your electronic delivery preferences.

E-mail notifications are delivered to the following e-mail address(es):
k#####@pharmacy.la.gov

The above e-mail address is partially masked for your security. Please log into your account to review the full e-mail address.



Not Guaranteed by the Bank. Not FDIC Insured. Not a Deposit.

Statement Period: 12/01/2014 - 12/31/2014

Activity Summary (All amounts shown are in base currency)

	This Period	Year-to-Date	Debits	This Period	Year-to-Date
Credits			Securities		
Securities Bought	0.00	0.00	Securities Bought	0.00	-1,185,012.00
Securities Sold	0.00	80,706.00	Securities Sold	0.00	0.00
Total Securities	\$0.00	\$80,706.00	Total Securities	\$0.00	-\$1,185,012.00
Dividends and Interest	\$10,165.12	\$11,065.03	Dividends and Interest	\$0.00	\$0.00
Distributions	\$88,000.00	\$88,000.00	Distributions	\$0.00	\$0.00
Cash			Cash		
Deposits	0.00	1,000,000.00	Deposits	0.00	0.00
Total Cash	\$0.00	\$1,000,000.00	Total Cash	\$0.00	\$0.00
Total Credits	\$98,165.12	\$1,179,771.03	Total Debits	\$0.00	-\$1,185,012.00

Transactions in Date Sequence

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	Currency	
12/01/14	BOND INTEREST RECEIVED 45083AAV4	10000 IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 RD 11/14 PD 11/29/14				192.20	USD	
12/12/14	BOND INTEREST RECEIVED 69506YB00	243000 PACIFIC WESTN BK LOS ANGELES CALIF CTF DEP ACT/365 0.400% 11/12/15 B/E DTD 11/12/14 RD 11/27 PD 12/12/14				79.89	USD	
12/29/14	BOND INTEREST RECEIVED 90521AH50	88000 UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 RD 12/28 PD 12/29/14				9,892.96	USD	
12/29/14	SECURITY REDEEMED 90521AH50	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 ACCOUNT REDEMPTION	-88,000,000			88,000.00	USD	
12/31/14	MONEY MARKET FUND INCOME RECEIVED 370990228	GENERAL MNY MKT CL B				0.07	USD	
Total Value of Transactions						\$0.00	\$98,165.12	USD

The price and quantity displayed may have been rounded.

Portfolio Holdings

Description	Quantity	Opening Balance	Closing Balance	Accrued Income	Income This Year	30-Day Yield
Cash, Money Funds, and Bank Deposits 7.00% of Portfolio						
Money Market						
GENERAL MINY MKT FUND CL B	99,863.140	1,698.02	99,863.14	0.00	45.01	0.01%
Total Money Market		\$1,698.02	\$99,863.14	\$0.00	\$45.01	
Total Cash, Money Funds, and Bank Deposits		\$1,698.02	\$99,863.14	\$0.00	\$45.01	

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income 93.00% of Portfolio (In Maturity Date Sequence)						
Certificates of Deposit						
PACIFIC WESTN BK LOS ANGELES CALIF CTF	243,000.000	99.8350	242,599.05	50.60	972.00	0.40%
DEP ACT/365 0.400% 11/12/15 B/E						
DTD 11/12/14 1ST CPN DTE 12/12/14						
CPN PMT MONTHLY ON 12						
Security Identifier: 69506YBD0						
PEOPLES UTD BK BRIDGEPORT CT CTF	243,000.000	99.8350	242,599.05	130.49	972.00	0.40%
DEP ACT/365 0.400% 11/12/15 B/E						
DTD 11/12/14 1ST CPN DTE 11/12/15						
INTEREST PAYABLE AT MATURITY						
Security Identifier: 71270QKA3						
UNION BK N A SAN FRANCISCO CALIF CTF	88,000.000	124.0000	109,120.00	0.00		
DEP ACT/365 0.000% 12/30/15 B/E						
DTD 12/30/11 INTEREST PAYABLE						
AT MATURITY						
Security Identifier: 90521AHP6						
IBERIABANK LAFAYETTE LA CTF DEP ACT/365	10,000.000	102.1620	10,216.20	0.00		
0.000% 05/31/16 B/E DTD 05/31/11						
1ST CPN DTE 11/29/11 CPN PMT SEMI ANNUAL						
ON MAY 31 AND NOV 31						
Security Identifier: 45083AAV4						
BANK OF THE WEST INSTL CTF DEP	89,000.000	95.9730	86,305.97	0.00		
PROGRAM BOOK ENTRY INSTL CTF DEP						
0.000% 12/28/16 B/E DTD 12/28/11						
1ST CPN DTE 12/28/12 CPN PMT ANNUALLY						
ON DEC 28						
Security Identifier: 06426XC12						

Statement Period: 12/01/2014 - 12/31/2014

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 1ST CPN DTE 07/30/14 CPN PMT ANNUALLY ON JUL 30 Security Identifier: 06740AAA41	5,000,000	103.0800	5,154.00	0.00		
BMO HARRIS BK NATL ASSN CHICAGO ILL CTF DEP ACT/365 ANNUAL LKD CD 0.000% 01/31/19 B/E DTD 01/30/14 1ST CPN DTE 01/30/15 CPN PMT ANNUALLY ON JAN 30 Security Identifier: 05573JMN1	250,000,000	101.1240	252,810.00	0.00		
JPMORGAN CHASE BK NA COLUMBUS OH CTF DEP CTF DEP LKD J P MORGAN ETF EFFICIENT 0.000% 01/31/19 B/E DTD 01/31/14 INTEREST PAYABLE AT MATURITY Security Identifier: 48125TDG7	125,000,000	98.4500	123,062.50	0.00		
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 01/31/19 B/E DTD 01/31/14 Security Identifier: 90521AQG6	74,000,000	99.9500	73,963.00	0.00		
HSEC BK USA N A MC LEAN VA CTF DEP ACT/365 INCOME OPPTY CD INDUSTRY TITANS 0.000% 03/04/20 B/E DTD 03/04/13 1ST CPN DTE 03/04/14 CPN PMT ANNUALLY ON MAR 04 Security Identifier: 40434AHV4	250,000,000	97.1700	242,925.00	0.00		
Total Certificates of Deposit:	1,377,000,000		\$1,388,754.77	\$181.09	\$1,944.00	

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
U.S. Treasury Securities						
UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10	25,000,000	104.9530	28,568.21	156.26		
Moody Rating AAA Security Identifier: 912828NM8 Factor: 1.08880000 Effective Date: 12/31/14 Current Face Value: 27,220,000						
Total U.S. Treasury Securities:	25,000,000		\$28,568.21	\$156.26		
Total Current Face Value:	27,220,000					
Total Fixed Income:	1,402,000,000		\$1,417,322.98	\$337.35	\$1,944.00	
Total Portfolio Holdings						
			Market Value	Accrued Interest	Estimated Annual Income	
			\$1,517,186.12	\$337.35	\$1,989.01	

6 The Current Face value represents the outstanding principal balance of the underlying security. The Current Face value is determined by multiplying the current factor times the original face amount of the security. Factors may change over time and are obtained from sources we believe to be reliable.

Portfolio Holdings Disclosures

Pricing

This section includes the net market value of the securities in your account on a settlement date basis, including short positions, at the close of the statement period. The market prices, unless otherwise noted, have been obtained from independent vendor services, which we believe to be reliable. Market prices do not constitute a bid or an offer, and may differ from the actual sale price. Securities for which a price is not available are marked "N/A" and are omitted from the Total.

THE AS OF PRICE DATE ONLY APPEARS WHEN THE PRICE DATE DOES NOT EQUAL THE STATEMENT DATE.

Estimated Annual Figures

The estimated annual income (EAI) and estimated annual yield (EAY) figures are estimates and for informational purposes only. These figures are not considered to be a forecast or guarantee of future results. These figures are computed using information from providers believed to be reliable; however, no assurance can be made as to the accuracy. Since interest and dividend rates are subject to change at any time, and may be affected by current and future economic, political, and business conditions, they should not be relied on for making investment, trading, or tax decisions. These figures assume that the position quantities, interest and dividend rates, and prices remain constant. A capital gain or return of principal may be included in the figures for certain securities, thereby overstating them. Refer to www.pershing.com/business_continuity.html for specific details as to formulas used to calculate the figures. Accrued interest represents interest earned but not yet received.

Reinvestment

The dollar amount of Mutual Fund distributions, Money Market Fund dividend income, Bank Deposit interest income, or dividends for other securities shown on your statement may have been reinvested. You will not receive confirmation of these reinvestments. Upon written request to your financial institution, information pertaining to these transactions, including the time of execution and the name of the person from whom your security was purchased, may be obtained. In dividend reinvestment transactions, Pershing acts as your agent and receives payment for order flow.

Option Disclosure

Information with respect to commissions and other charges incurred in connection with the execution of option transactions has been included in confirmations previously furnished to you. A summary of this information is available to you promptly upon your written request directed to your introducing firm. In order to assist your introducing firm in maintaining current background and financial information concerning your option accounts, please promptly advise them in writing of any material change in your investment objectives or financial situation. Expiring options which are valuable are exercised automatically pursuant

Statement Period: 12/01/2014 - 12/31/2014

Portfolio Holdings Disclosures (continued)

Option Disclosure (continued)
 to the exercise by exception procedure of the Options Clearing Corporation. Additional information regarding this procedure is available upon written request to your introducing firm.

Certificates of Deposit

Please be advised that the secondary market for CDs is generally illiquid; the actual value of CDs may be different from their purchase price; and a significant loss of principal could result if your CDs are sold prior to maturity. In the event that the CDs listed above do not indicate a market valuation, an accurate market value could not be determined. In the event that a price is listed above for your CDs, Pershing has obtained a price from sources deemed to be reliable or has priced your CDs using a matrix formula. Prices are estimates and the actual value you may obtain for your CD may be different if you elect to sell your CD in the secondary market.

Foreign Currency Transactions

Pershing may execute foreign currency transactions as principal for your account. Pershing may automatically convert foreign currency to or from U.S. dollars for dividends and similar corporate action transactions unless you instruct your financial organization otherwise. Pershing's currency conversion rate will not exceed the highest interbank conversion rate identified from customary banking sources on the conversion date or the prior business day, increased by up to 1%, unless a particular rate is required by applicable law. Your financial organization may also increase the currency conversion rate. This conversion rate may differ from rates in effect on the date you executed a transaction, incurred a charge, or received a credit. Transactions converted by agents (such as depositories) will be billed at the rates such agents use.

Proxy Vote

Securities not fully paid for in your margin account may be lent by Pershing to itself or others in accordance with the terms outlined in the Margin Agreement. The right to vote your shares held on margin may be reduced by the amount of shares on loan. The Proxy Voting Instruction Form sent to you may reflect a smaller number of shares entitled to vote than the number of shares in your margin account.

Money Market Fund Detail

Date	Activity Type	Description	Amount	Balance
Sweep Money Market Fund				
GENERAL MNY MKT FUND CL B				
Account Number: 0000671452 Current Yield: 0.01% Activity Ending: 12/31/14				
11/29/14	Operating Balance		1,698.02	1,698.02
12/02/14	Deposit		192.20	1,890.22
12/15/14	Deposit		79.89	1,970.11
12/30/14	Deposit	MONEY FUND PURCHASE	97,892.96	99,863.07
12/31/14	Deposit	MONEY FUND PURCHASE	0.07	99,863.14
12/31/14	Closing Balance	INCOME REINVEST		\$99,863.14
Total All Money Market Funds				\$99,863.14

Messages

Although a money market mutual fund seeks to preserve the value of your investment at \$1 per share, it is possible to lose money by investing in a money market mutual fund. Shares of a money market mutual fund or the balance of a bank deposit product held in your brokerage account may be liquidated upon request with the proceeds credited to your brokerage account. Please see the money market mutual fund's prospectus or the bank deposit product's disclosure document or contact your advisor for additional information.

Messages (continued)

Pershing's Impartial Lottery Process: Partial Calls

Information about Pershing's impartial lottery process can be found on pershing.com/business_continuity. You may also request a printed copy of this information by calling (888) 367-2563, option 3 then option 5.

When a security is subject to a partial redemption, pursuant to FINRA Rule 4340, Pershing must have procedures in place that are designed to treat clients fairly in accordance with an impartial lottery process.

When an issuer initiates a partial call of securities, the depository holding such securities (typically, the Depository Trust Clearing and Corporation, or DTCC) conducts an impartial, computerized lottery using an incremental random number technique to determine the allocation of called securities to participants for which it holds securities on deposit (including Pershing). Because DTC's lottery is random and impartial, participants may or may not receive an allocation of securities selected for redemption.

When Pershing is notified that it received an allocation of called securities, Pershing conducts a similar, computer-generated random lottery. The lottery determines the accounts that will be selected and the number of securities in the account that will be redeemed. Allocations are based on the number of trading units held in the account. The probability of any trading unit held by an account being selected as called in a partial call is proportional to the total number of trading units held through Pershing.

Once the lottery is complete, Pershing notifies introducing broker-dealers whose introduced accounts have received an allocation. Securities registered in the client's name, either in transit or held in custody, are excluded from the Pershing lottery process.

Pershing initiates the lottery process by identifying the accounts holding the called security, the total par value of the called securities held, and the trading unit of the security.

Example (unit of trade = \$25,000):

Client Account	Par Value	Number of Trading Units
ABC-123234	\$100,000	4
DEF-325465	\$75,000	3
EDR-567433	\$150,000	6
EGT-876574	\$50,000	2
EGT-888345	\$25,000	1
FRT-435234	\$25,000	1
FRT-658797	\$75,000	3

•

In brief, the allocation process involves the following steps:

- The number of trading units held in each account is identified.
- A sequential number is assigned to each trading unit (e.g., account EDR-567433 would be assigned six numbers).

Statement Period: 12/01/2014 - 12/31/2014

Messages (continued)

- * A random number is generated that will result in one of these trading units being the first unit in the selection process.
 - * Thereafter, the trading units participating in the allocation are based on an incremental random number technique until the number of trading units allocated to Pershing is exhausted.
- Additional Information**
- * The allocation of called securities is not made on a pro-rata basis. Therefore, it is possible that a client may receive a full or partial redemption of shares held. Conversely, it is also possible that a client may not have any securities selected for redemption at all.
 - * When a partial call is deemed favorable to the holders of the called security, Pershing will exclude certain accounts from the lottery. Excluded accounts will include Pershing's proprietary and employee accounts, as well as proprietary and employee accounts of introducing broker-dealers (if Pershing carries and clears those accounts). No allocation will be made to these proprietary and employee accounts until all other client positions at Pershing in such securities have been called. When a partial call is deemed unfavorable to holders of the called security, Pershing will not exclude any accounts from the lottery.
 - * If the partial call is made at a price above the current market price as captured in Pershing's price reporting system, Pershing will generally categorize the partial call as one that is favorable to the holders of such security. If the partial call is made at a price that is equal to or below the current market price of the security as captured in Pershing's price reporting system, Pershing will generally categorize that call as one that is unfavorable to holders of the security.
 - * Clients have the right to withdraw uncalled, fully paid securities from Pershing at any time prior to the cutoff date and time established by the issuer, transfer agent and/or depository with respect to the partial call. Clients also have the right to withdraw excess margin securities, provided that the client account is not subject to restriction under Regulation T or that such withdrawal will not cause an under-margined condition.

Cash Not Yet Received

Security	Record Date	Payable Date	Quantity Held	Rate	Dividend Option	Amount of Payment
Interest PACIFIC WESTN BK LOS ANGELES CALIF CTF DEP ACT/365	12/28/14	01/12/15	243,000,000	0.000340	Cash	82.55
Total Cash Not Yet Received						\$82.55

Assets shown here are not reflected in your account. This information has been received from sources we believe to be reliable. Pershing does not guarantee the accuracy of the information.

Important Information and Disclosures

The Role of Pershing

- Pershing carries your account as clearing broker pursuant to a clearing agreement with your financial institution. Pershing may accept from your financial institution without inquiry or investigation (i) orders for the purchase and sale of securities and other property and (ii) any other instructions concerning your account. Pershing is not responsible or liable for any acts or omissions of your financial institution or its employees and it does not supervise them. Pershing provides no investment advice nor does it assess the suitability of any transaction or order. Pershing acts as the agent of your financial institution and you agree that you will not hold Pershing or any person controlling or under common control with it liable for any investment losses incurred by you.
- Pershing performs several key functions at the direction of your financial institution. It acts as custodian for funds and securities you may deposit with it directly or through your financial institution or that it receives as the result of securities transactions it processes.
- Your financial institution is responsible for adherence to the securities laws, regulations and rules which apply to it regarding its own operations and the supervision of your account, its sales representatives and other personnel. Your financial institution is also responsible for approving the opening of accounts and obtaining account documents; the acceptance and, in certain instances, execution of securities orders; the assessment of the suitability of those transactions, where applicable; the rendering of investment advice, if any, to you and in general, for the ongoing relationship that it has with you.
- Inquiries concerning the positions and balances in your account may be directed to the Pershing Customer Service Department at (201) 413-3333. All other inquiries regarding your account or activity should be directed to your financial institution. Your financial organization's contact information can be found on the first page of this statement.
- For a description of other functions performed by Pershing please consult the Disclosure Statement provided to you upon the opening of your account. This notice is not meant as a definitive enumeration of every possible circumstance, but as a general disclosure. If you have any questions regarding this notice or if you would like additional copies of the Disclosure Statement, please contact your financial institution.
- Pershing is a member of the Securities Investor Protection Corporation (SIPCSM). Please note that SIPC does not protect against loss due to market fluctuation. In addition to SIPC protection, Pershing provides coverage in excess of SIPC limits. For more detailed information please visit: www.pershing.com/strength_stability.html.
- This statement will be deemed conclusive. You are advised to report any inaccuracy or discrepancy (including unauthorized trading) promptly, but no later than ten days after receipt of this statement, to your financial organization and Pershing. Please be advised that any oral communication should be re-confirmed in writing to further protect your rights, including your rights under the Securities Investor Protection Act.
- Your financial organization's contact information can be found on the first page of this statement. Pershing's contact information is as follows: **Pershing LLC, Legal Department, One Pershing Plaza, Jersey City, New Jersey 07309; (201) 413-3330.** Errors and Omissions excepted.

Important Arbitration Disclosures

- All parties to this agreement are giving up the right to sue each other in court, including the right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed.
- Arbitration awards are generally final and binding; a party's ability to have a court reverse or modify an arbitration award is very limited.
- The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings.
- The arbitrators do not have to explain the reason(s) for their award, unless, in an eligible case, a joint request for an explained decision has been submitted by all parties to the panel at least 20 days prior to the first scheduled hearing date.
- The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.
- The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court.
- The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this agreement.

Important Arbitration Agreement

Any controversy between you and Pershing LLC shall be submitted to arbitration before the Financial Industry Regulatory Authority. No person shall bring a putative or certified class action to arbitration, nor seek to enforce any predispute arbitration agreement against any person who has initiated in court a putative class action, who is a member of a putative class who has not opted out of the class with respect to any claims encompassed by the putative class action until: (i) the class certification is denied; (ii) the class is decertified; or (iii) the client is excluded from the class by the court. Such forbearance to enforce an agreement to arbitrate shall not constitute a waiver of any rights under this agreement except to the extent stated herein. The laws of the State of New York govern.

Pershing's contact information is as follows: **Pershing LLC, Legal Department, One Pershing Plaza, Jersey City, New Jersey 07309; (201) 413-3330.**

TERMS AND CONDITIONS

TRANSACTIONS

- ALL ORDERS AND TRANSACTIONS SHALL BE SOLELY FOR YOUR ACCOUNT AND RISK SHALL BE SUBJECT TO THE CONSTITUTION, RULES, REGULATIONS, CUSTOMS, USAGES, RULINGS AND INTERPRETATIONS OF THE EXCHANGE OR MARKET AND THE CLEARING FACILITY. IF ANY, WHERE THE TRANSACTIONS ARE EXECUTED AND/OR SETTLED, OR IF APPLICABLE, OF THE FINANCIAL INDUSTRY REGULATORY AUTHORITY AND TO ALL APPLICABLE LAWS AND REGULATIONS.
- TITLE TO SECURITIES SOLD TO YOU, WHERE PERSHING HAS ACTED AS PRINCIPAL, SHALL REMAIN WITH PERSHING UNTIL THE ENTIRE PURCHASE PRICE IS RECEIVED OR UNTIL THE SETTLEMENT DATE, WHICHEVER IS LATER.
- YOU MAY HAVE RECEIVED CONFIRMATIONS FOR TRANSACTIONS WHICH DO NOT APPEAR ON YOUR STATEMENT. IF SO, THE TRANSACTIONS WILL APPEAR ON YOUR NEXT PERIODIC STATEMENT. SUCH TRANSACTIONS MUST BE CONSIDERED BY YOU WHEN COMPUTING THE VALUE OF YOUR ACCOUNT. THIS IS ESPECIALLY TRUE IF YOU HAVE WRITTEN OPTIONS WHICH HAVE BEEN EXERCISED.

FREE CREDIT BALANCES: ANY FREE CREDIT BALANCE CARRIED FOR ON PERSHING'S BOOKS OF RECORD, ARE NOT SEGREGATED AND MAY BE USED IN THE CONDUCT OF ITS BUSINESS.

DEBIT BALANCES: INTEREST CHARGED ON DEBIT BALANCES IN YOUR ACCOUNT APPEARS ON THE STATEMENT. THE RATE OF INTEREST AND PERIOD COVERED ARE INDICATED. THE RATE MAY CHANGE FROM TIME TO TIME DUE TO FLUCTUATIONS IN MONEY RATES OR OTHER REASONS. INTEREST IS COMPUTED AS DESCRIBED IN MATERIAL PREVIOUSLY FURNISHED TO YOU. PLEASE CONTACT YOUR FINANCIAL INSTITUTION IF YOU DESIRE ADDITIONAL COPIES.

MARGIN INFORMATION: IF YOU MAINTAIN A MARGIN ACCOUNT, THIS IS A COMBINED STATEMENT OF YOUR GENERAL ACCOUNT AND A SPECIAL MEMORANDUM ACCOUNT MAINTAINED FOR YOU UNDER REGULATION T OF THE BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM. THE PERMANENT RECORD OF THE SEPARATE ACCOUNT AS REQUIRED BY REGULATION T IS AVAILABLE FOR YOUR INSPECTION UPON REQUEST.

TAX INFORMATION

- AFTER YEAR END, PERSHING IS REQUIRED TO PROVIDE TAX INFORMATION TO THE INTERNAL REVENUE SERVICE AND OTHER GOVERNMENTAL AUTHORITIES. AT THAT TIME PERSHING WILL PROVIDE THAT INFORMATION ON THE ANNUAL TAX INFORMATION STATEMENT TO YOU; USE THAT STATEMENT TO PREPARE YOUR TAX FILINGS. THE TAX STATEMENT ALSO INCLUDES OTHER USEFUL INFORMATION TO ASSIST IN ACCUMULATING THE DATA TO PREPARE YOUR TAX RETURNS.
- DIVIDENDS, INTEREST AND OTHER DISTRIBUTIONS SHOWN ON THIS STATEMENT WERE CLASSIFIED AS TAXABLE OR NON-TAXABLE BASED ON CERTAIN INFORMATION KNOWN AS OF THE DISTRIBUTION DATE. THIS CLASSIFICATION IS SUBJECT TO CHANGE AND IS SOLELY INTENDED FOR USE AS GENERAL INFORMATION.
- PERSHING DOES NOT PROVIDE TAX, INVESTMENT OR LEGAL ADVISORY SERVICES AND NO ONE ASSOCIATED WITH PERSHING IS AUTHORIZED TO RENDER SUCH ADVICE. DO NOT RELY UPON ANY SUCH ADVICE, IF GIVEN. INVESTORS ARE ENCOURAGED TO CONSULT THEIR TAX ADVISORS TO DETERMINE THE APPROPRIATE TAX TREATMENT OF THEIR BUSINESS.

GENERAL INFORMATION

- WHENEVER YOU ARE INDEBTED TO PERSHING LLC ("PERSHING") FOR ANY AMOUNT, ALL SECURITIES HELD BY IT FOR YOU IN ANY ACCOUNT IN WHICH YOU HAVE ANY INTEREST SHALL SECURE ALL YOUR LIABILITIES TO PERSHING, AND PERSHING MAY IN ITS DISCRETION AT ANY TIME, WITHOUT TENDER, DEMAND OR NOTICE TO YOU, CLOSE OR REDUCE ANY OR ALL OF YOUR ACCOUNTS BY PUBLIC OR PRIVATE SALE OR PURCHASE OR BOTH OF ALL OR ANY SECURITIES CARRIED IN SUCH ACCOUNTS; ANY BALANCE REMAINING DUE PERSHING TO BE PROMPTLY PAID BY YOU.
- WHENEVER YOU ARE INDEBTED TO PERSHING FOR ANY AMOUNT, ALL SECURITIES CARRIED FOR YOUR ACCOUNT ARE OR MAY BE, WITHOUT FURTHER NOTICE TO YOU, LOANED OR PLEDGED BY PERSHING, EITHER SEPARATELY OR UNDER CIRCUMSTANCES WHICH WILL PERMIT THE COMMINGLING THEREOF, WITH OTHER SECURITIES FOR ANY AMOUNT LESS THAN, EQUAL TO OR GREATER THAN YOUR LIABILITIES TO PERSHING, BUT NOT UNDER CIRCUMSTANCES FOR AN AMOUNT PROHIBITED BY LAW.
- PERSHING MAY TRADE FOR ITS OWN ACCOUNT AS A MARKET MAKER, SPECIALIST, ODD LOT DEALER, BLOCK POSITIONER, ARBITRAGEUR OR INVESTOR. CONSEQUENTLY, AT THE TIME OF ANY TRANSACTION YOU MAY MAKE, PERSHING MAY HAVE A POSITION IN SUCH SECURITIES, WHICH POSITION MAY BE PARTIALLY OR COMPLETELY HEDGED.
- IF AVERAGE PRICE TRANSACTION IS INDICATED ON THE FRONT OF THIS STATEMENT YOUR FINANCIAL INSTITUTION OR PERSHING MAY HAVE ACTED AS PRINCIPAL, AGENT OR BOTH. DETAILS AVAILABLE UPON REQUEST.
- A FINANCIAL STATEMENT OF PERSHING IS AVAILABLE FOR YOUR PERSONAL INSPECTION AT PERSHING'S OFFICES. A COPY OF IT WILL BE MAILED UPON YOUR WRITTEN REQUEST OR YOU CAN VIEW IT ONLINE AT WWW.PERSHING.COM.
- FOR BUSINESS CONTINUITY AND ADDITIONAL DISCLOSURES: WWW.PERSHING.COM/BUSINESS_CONTINUITY.HTML
- THIS STATEMENT SHOULD BE RETAINED FOR YOUR RECORDS.

PAYMENT FOR ORDER FLOW AND ORDER ROUTING POLICIES DISCLOSURES (REGULATION NMS—RULE 607(A)(1)-(2))

IF ANY OF THE ABOVE TERMS AND CONDITIONS ARE UNACCEPTABLE TO YOU, PLEASE NOTIFY PERSHING IMMEDIATELY IN WRITING BY CERTIFIED MAIL TO ONE PERSHING PLAZA, JERSEY CITY, NJ 07389, ATTN: LEGAL DEPT

PERSHING SENDS CERTAIN EQUITY ORDERS TO EXCHANGES, ELECTRONIC COMMUNICATION NETWORKS, OR BROKER-DEALERS DURING NORMAL BUSINESS HOURS AND DURING EXTENDED TRADING SESSIONS. CERTAIN OF THESE VENUES PROVIDE PAYMENTS TO PERSHING OR CHARGE ACCESS FEES TO PERSHING DEPENDING UPON THE CHARACTERISTICS OF THE ORDER AND ANY SUBSEQUENT EXECUTION. THE DETAILS OF THESE PAYMENTS AND FEES ARE AVAILABLE UPON WRITTEN REQUEST. PERSHING RECEIVES PAYMENTS FOR DIRECTING LISTED OPTIONS ORDER FLOW TO CERTAIN OPTION EXCHANGES. IN ADDITION, PERSHING ROUTES CERTAIN EQUITY AND OPTION ORDERS TO ITS AFFILIATE, BNY MELLON CAPITAL MARKETS, LLC, FOR EXECUTION AS PRINCIPAL. COMPENSATION IS GENERALLY IN THE FORM OF A PER OPTION CONTRACT CASH PAYMENT.

BEST EXECUTION: NOTWITHSTANDING THE PREVIOUS PARAGRAPH REGARDING PAYMENT FOR ORDER FLOW, PERSHING SELECTS CERTAIN MARKET CENTERS TO PROVIDE EXECUTION OF OVER-THE-COUNTER AND EXCHANGE LISTED SECURITIES TRANSACTIONS WHICH AGREE TO ACCEPT ORDERS, TRANSMITTED ELECTRONICALLY UP TO A SPECIFIED SIZE, AND TO EXECUTE THEM AT OR BETTER THAN THE NATIONAL BEST BID OR OFFER (NBBO) ON CERTAIN LARGER ORDERS, OR IF THE DESIGNATED MARKET CENTERS DO NOT MAKE A MARKET IN THE SUBJECT SECURITY, PERSHING DIRECTLY CONTACTS MARKET CENTERS TO OBTAIN AN EXECUTION. THE DESIGNATED MARKET CENTERS TO WHICH ORDERS ARE AUTOMATICALLY ROUTED ARE SELECTED BASED ON THE CONSISTENT HIGH QUALITY OF THEIR EXECUTIONS IN ONE OR MORE MARKET SEGMENTS AND THEIR ABILITY TO PROVIDE OPPORTUNITIES FOR EXECUTIONS AT PRICES SUPERIOR TO THE NBBO. PERSHING ALSO REGULARLY REVIEWS REPORTS FOR QUALITY OF EXECUTION PURPOSES.

WRAP ACCOUNT CUSTOMERS WHO ELECTED NOT TO RECEIVE IMMEDIATE CONFIRMATION OF TRANSACTIONS
THE FOLLOWING TERMS AND CONDITIONS ARE APPLICABLE ONLY IF YOUR ACCOUNT IS AN INVESTMENT ADVISORY ACCOUNT AND THE TRANSACTION CONFIRMATIONS ARE NOT SENT TO YOU (SENT ONLY TO YOUR FIDUCIARY) PURSUANT TO YOUR INSTRUCTION:

WRAP ACCOUNT TRANSACTIONS

- THE FOLLOWING INFORMATION WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR FINANCIAL INSTITUTION ("INTRODUCING FIRM") WITH RESPECT TO ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU: (THE MARKET UPON WHICH ANY TRANSACTION WAS EXECUTED; THE TIME OF DAY THAT ANY TRANSACTION WAS EXECUTED; THE NAME OF THE PERSON FROM WHOM ANY SECURITY WAS PURCHASED OR TO WHOM SUCH SECURITY WAS SOLD; THE SOURCE AND AMOUNT OF OTHER COMMISSIONS RECEIVED IN CONNECTION WITH ANY TRANSACTION; AND A COPY OF THE TRANSACTION CONFIRMATION).
 - YOUR INTRODUCING FIRM EFFECTED EACH TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU AS YOUR AGENT.
 - IN CONNECTION WITH EACH EQUITY SECURITY AND CERTAIN OTHER SECURITIES SOLD, YOUR INTRODUCING FIRM CHARGES TO YOU, AND REMITS TO A REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE, A "TRANS. FEE." PERSHING CALCULATES THIS FEE BASED ON AMOUNTS PAID BY YOUR INTRODUCING FIRM TO THE APPLICABLE REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE. THIS, IN TURN, IS BASED ON THE VALUE OF THE APPLICABLE SECURITIES SOLD. TO DETERMINE THE EXACT AMOUNT OF THIS FEE WITH RESPECT TO ANY TRANSACTION, PLEASE CONTACT YOUR INTRODUCING FIRM.
 - IF ANY TRANSACTION INVOLVES AN ASSET-BACKED SECURITY, INCLUDING A MUNICIPAL COLLATERALIZED MORTGAGE OBLIGATION, WHICH REPRESENTS AN INTEREST IN OR IS SECURED BY A POOL OF RECEIVABLES OR OTHER FINANCIAL ASSETS THAT ARE SUBJECT CONTINUOUSLY TO PREPAYMENT, THEN THE ACTUAL YIELD OF SUCH SECURITY MAY VARY ACCORDING TO THE RATE AT WHICH THE UNDERLYING RECEIVABLES OR OTHER FINANCIAL ASSETS ARE PREPAID. INFORMATION CONCERNING THE FACTORS THAT AFFECT YIELD (INCLUDING AT A MINIMUM ESTIMATED YIELD, WEIGHTED AVERAGE LIFE, AND THE PREPAYMENT ASSUMPTIONS OF UNDERLYING YIELD) WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR INTRODUCING FIRM.
- WRAP ACCOUNT ORDER FLOW:** YOUR INTRODUCING FIRM DOES NOT RECEIVE ANY PAYMENT FOR ORDER FLOW FOR ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU.
- WRAP ACCOUNT CALL FEATURES:** CALL FEATURES MAY EXIST FOR SECURITIES. CALL FEATURES FOR FIXED INCOME SECURITIES MAY AFFECT YIELD. COMPLETE INFORMATION WILL BE PROVIDED UPON REQUEST.
- WRAP ACCOUNT RATINGS:** THE RATINGS THAT APPEAR IN THE DESCRIPTION OF SOME FIXED INCOME SECURITIES HAVE BEEN OBTAINED FROM RATINGS SERVICES WHICH PERSHING BELIEVES TO BE RELIABLE; HOWEVER, PERSHING CANNOT GUARANTEE THEIR ACCURACY. SECURITIES FOR WHICH A RATING IS NOT AVAILABLE ARE MARKED "UNRATED".

Account Number: HSE-077160
 Statement Period: 12/01/2014 - 12/31/2014

Valuation at a Glance

	This Period
Beginning Account Value	\$1,043,186.39
Dividends/Interest	42.66
Change in Account Value	-2,098.46
Ending Account Value	\$1,041,130.59
Estimated Annual Income	\$5,379.52

LA BD OF PHARMACY OPEB RES ACT
 3388 BRENTWOOD DRIVE
 BATON ROUGE LA 70809-1700

Your Account Executive:
 JOSEPH BARRECA, JR.
 (504) 310-7364

Asset Allocation

	This Period	% Allocation
Cash, Money Funds, and Bank Deposits	3,224.39	1% Please review your allocation
Fixed Income	1,037,906.20	99%
Account Total	\$1,041,130.59	100%

Client Service Information

Your Account Executive: X57
 JOSEPH BARRECA, JR.
 IBERIA FINANCIAL SERVICES
 2900 RIDGELAKE DRIVE
 METAIRIE LA 70002-4923

Contact Information

Telephone Number: (504) 310-7364

Your Account Information

Tax Lot Default Disposition Method

Default Method for Mutual Funds: AVERAGE COST (USING FIRST IN FIRST OUT)
 Default Method for Stocks in a Dividend Reinvestment Plan: FIRST IN FIRST OUT
 Default Method for all Other Securities: FIRST IN FIRST OUT

Bond Amortization Elections:

Treat all interest as original issue discount (OID): No
 Amortize premium on taxable bonds based on Constant Yield Method: Yes
 Accrual market discount method for all other bond types: Ratable Method
 Include market discount in income annually: No

Copies of Statement Sent

KODLER, CHAMPAGNE, SLAVEN & CO

All your request copies of this statement have been sent to the above.

Electronic Delivery

You are currently enrolled to receive the following account communications via electronic delivery:
 Statements and Reports
 Trade Confirmations
 Tax Documents
 Notifications

Please log in to your account to make any changes to your electronic delivery preferences.

E-mail notifications are delivered to the following e-mail address(es):
 k#####@pharmacy.la.gov
 The above e-mail address is partially masked for your security. Please log
 into your account to review the full e-mail address.

Activity Summary (All amounts shown are in base currency)

	This Period	Year-to-Date		This Period	Year-to-Date
Credits			Debits		
Securities Bought	0.00	0.00	Securities Bought	0.00	-173,002.00
Total Securities	\$0.00	\$0.00	Total Securities	\$0.00	-\$173,002.00
Dividends and Interest	\$42.66	\$6,226.39	Dividends and Interest	\$0.00	\$0.00
Distributions	\$0.00	\$120,000.00	Distributions	\$0.00	\$0.00
Cash			Cash		
Deposits	0.00	50,000.00	Deposits	0.00	0.00
Total Cash	\$0.00	\$50,000.00	Total Cash	\$0.00	\$0.00
Total Credits	\$42.66	\$176,226.39	Total Debits	\$0.00	-\$173,002.00

Statement Period: 12/01/2014 - 12/31/2014

Transactions in Date Sequence

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	Currency
12/12/14	BOND INTEREST RECEIVED 14147VEEZ	173000 CARDINAL BK MCLEAN VA CTF DEP ACT/365 0.300% 11/12/15 B/E DTD 11/12/14 RD 11/27 PD 12/12/14				42.66	USD
Total Value of Transactions					\$0.00	\$42.66	USD

The price and quantity displayed may have been rounded.

Portfolio Holdings

Cash, Money Funds, and Bank Deposits 1.00% of Portfolio

Description	Quantity	Opening Balance	Closing Balance	Accrued Income	Income This Year	30-Day Yield
Money Market						
FEDERATED CAPITAL RESERVES	3,224.390	3,181.73	3,224.39	0.00	0.52	0.00%
Total Money Market		\$3,181.73	\$3,224.39	\$0.00	\$0.52	
Total Cash, Money Funds, and Bank Deposits		\$3,181.73	\$3,224.39	\$0.00	\$0.52	

Fixed Income 99.00% of Portfolio (In Maturity Date Sequence)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Certificates of Deposit						
ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.000% 05/26/15 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 020050F57	120,000.000	100.2850	120,342.00	124.93	1,200.00	0.99%
CARDINAL BK MCLEAN VA CTF DEP ACT/365 0.300% 11/12/15 B/E DTD 11/12/14 1ST CPN DTE 12/12/14 CPN PMT MONTHLY ON 12 Security Identifier: 14147VEEZ	173,000.000	99.7500	172,567.50	27.02	519.00	0.30%

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 1.250% 05/23/16 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 2546718G4	120,000,000	100.8380	121,005.60	156.16	1,500.00	1.23%
GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 1.800% 05/23/17 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 38143ASV8	120,000,000	101.2410	121,489.20	224.88	2,160.00	1.77%
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD PERFORM OF A BSKT 0.000% 05/30/17 B/E DTD 05/31/12 1ST CPN DTE 05/31/13 CPN PMT ANNUALLY ON MAY 31 Security Identifier: 06740ATS8	83,000,000	93.4800	77,588.40	0.00		
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 0.000% 04/27/18 B/E DTD 04/30/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 27 Security Identifier: 06740AVS2	160,000,000	93.1800	149,088.00	0.00		
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 04/30/18 B/E DTD 04/29/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 29 Security Identifier: 06426XGL8	155,000,000	97.4600	151,063.00	0.00		
JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 ACT/365 AT-MATURITY 0.000% 07/31/18 B/E DTD 07/31/13 Security Identifier: 48124JS41	125,000,000	99.8100	124,762.50	0.00		
Total Certificates of Deposit:	1,056,000,000		\$1,037,906.20	\$532.99	\$5,379.00	
Total Fixed Income:	1,056,000,000		\$1,037,906.20	\$532.99	\$5,379.00	
Total Portfolio Holdings						
			Market Value	Accrued Interest	Estimated Annual Income	
			\$1,041,130.59	\$532.99	\$5,379.52	

Statement Period: 12/01/2014 - 12/31/2014

Portfolio Holdings Disclosures

Pricing

This section includes the net market value of the securities in your account on a settlement date basis, including short positions, at the close of the statement period. The market prices, unless otherwise noted, have been obtained from independent vendor services, which we believe to be reliable. Market prices do not constitute a bid or an offer, and may differ from the actual sale price. Securities for which a price is not available are marked "N/A" and are omitted from the Total.

THE AS OF PRICE DATE ONLY APPEARS WHEN THE PRICE DATE DOES NOT EQUAL THE STATEMENT DATE.

Estimated Annual Figures

The estimated annual income (EAI) and estimated annual yield (EAY) figures are estimates and for informational purposes only. These figures are not considered to be a forecast or guarantee of future results. These figures are computed using information from providers believed to be reliable; however, no assurance can be made as to the accuracy. Since interest and dividend rates are subject to change at any time, and may be affected by current and future economic, political, and business conditions, they should not be relied on for making investment, trading, or tax decisions. These figures assume that the position quantities, interest and dividend rates, and prices remain constant. A capital gain or return of principal may be included in the figures for certain securities, thereby overstating them. Refer to www.pershing.com/business_continuity.html for specific details as to formulas used to calculate the figures. Accrued interest represents interest earned but not yet received.

Reinvestment

The dollar amount of Mutual Fund distributions, Money Market Fund dividend income, Bank Deposit interest income, or dividends for other securities shown on your statement may have been reinvested. You will not receive confirmation of these reinvestments. Upon written request to your financial institution, information pertaining to these transactions, including the time of execution and the name of the person from whom your security was purchased, may be obtained. In dividend reinvestment transactions, Pershing acts as your agent and receives payment for order flow.

Option Disclosure

Information with respect to commissions and other charges incurred in connection with the execution of option transactions has been included in confirmations previously furnished to you. A summary of this information is available to you promptly upon your written request directed to your introducing firm. In order to assist your introducing firm in maintaining current background and financial information concerning your option accounts, please promptly advise them in writing of any material change in your investment objectives or financial situation. Expiring options which are valuable are exercised automatically pursuant to the exercise by exception procedure of the Options Clearing Corporation. Additional information regarding this procedure is available upon written request to your introducing firm.

Certificates of Deposit

Please be advised that the secondary market for CDs is generally illiquid; the actual value of CDs may be different from their purchase price; and a significant loss of principal could result if your CDs are sold prior to maturity. In the event that the CDs listed above do not indicate a market valuation, an accurate market value could not be determined. In the event that a price is listed above for your CDs, Pershing has obtained a price from sources deemed to be reliable or has priced your CDs using a matrix formula. Prices are estimates and the actual value you may obtain for your CD may be different if you elect to sell your CD in the secondary market.

Foreign Currency Transactions

Pershing may execute foreign currency transactions as principal for your account. Pershing may automatically convert foreign currency to or from U.S. dollars for dividends and similar corporate action transactions unless you instruct your financial organization otherwise. Pershing's currency conversion rate will not exceed the highest interbank conversion rate identified from customary banking sources on the conversion date or the prior business day, increased by up to 1%, unless a particular rate is required by applicable law. Your financial organization may also increase the currency conversion rate. This conversion rate may differ from rates in effect on the date you executed a transaction, incurred a charge, or received a credit. Transactions converted by agents (such as depositories) will be billed at the rates such agents use.

Proxy Vote

Securities not fully paid for in your margin account may be lent by Pershing to itself or others in accordance with the terms outlined in the Margin Agreement. The right to vote your shares held on margin may be reduced by the amount of shares on loan. The Proxy Voting Instruction Form sent to you may reflect a smaller number of shares entitled to vote than the number of shares in your margin account.

Money Market Fund Detail

Date	Activity Type	Description	Amount	Balance
Sweep Money Market Fund				
FEDERATED CAPITAL RESERVES				
Account Number: 0002529992 Current Yield: 0.00% Activity Ending: 12/31/14				
11/29/14	Opening Balance		3,181.73	3,181.73
12/15/14	Deposit	MONEY FUND PURCHASE	42.66	3,224.39
12/31/14	Closing Balance			\$3,224.39
Total All Money Market Funds				

Messages

Although a money market mutual fund seeks to preserve the value of your investment at \$1 per share, it is possible to lose money by investing in a money market mutual fund. Shares of a money market mutual fund or the balance of a bank deposit product held in your brokerage account may be liquidated upon request with the proceeds credited to your brokerage account. Please see the money market mutual fund's prospectus or the bank deposit product's disclosure document or contact your advisor for additional information.

Pershing's Impartial Lottery Process: Partial Calls

Information about Pershing's impartial lottery process can be found on pershing.com/business_continuity. You may also request a printed copy of this information by calling (888) 367-2563, option 3 then option 5.

When a security is subject to a partial redemption, pursuant to FINRA Rule 4340, Pershing must have procedures in place that are designed to treat clients fairly in accordance with an impartial lottery process.

When an issuer initiates a partial call of securities, the depository holding such securities (typically, the Depository Trust Clearing and Corporation, or DTCC) conducts an impartial, computerized lottery using an incremental random number technique to determine the allocation of called securities to participants for which it holds securities on deposit (including Pershing). Because DTC's lottery is random and impartial, participants may or may not receive an allocation of securities selected for redemption.

When Pershing is notified that it received an allocation of called securities, Pershing conducts a similar, computer-generated random lottery. The lottery determines the accounts that will be selected and the number of securities in the account that will be redeemed. Allocations are based on the number of trading units held in the account. The probability of any trading unit held by an account being selected as called in a partial call is proportional to the total number of trading units held through Pershing.

Once the lottery is complete, Pershing notifies introducing broker-dealers whose introduced accounts have received an allocation. Securities registered in the client's name, either in transit or held in custody, are excluded from the Pershing lottery process.

Pershing initiates the lottery process by identifying the accounts holding the called security, the total par value of the called securities held, and the trading unit of the security.

Example (unit of trade = \$25,000):

Client Account	Par Value	Number of Trading Units
ABC-123234	\$100,000	4
DEF-325465	\$75,000	3
EDR-567433	\$150,000	6
EGT-876574	\$50,000	2

Statement Period: 12/01/2014 - 12/31/2014

Messages (continued)

EGT-888345	\$25,000	1
FRT-435234	\$25,000	1
FRT-658797	\$75,000	3

In brief, the allocation process involves the following steps:

- The number of trading units held in each account is identified.
- A sequential number is assigned to each trading unit (e.g., account EDR-567433 would be assigned six numbers).
- A random number is generated that will result in one of these trading units being the first unit in the selection process.
- Thereafter, the trading units participating in the allocation are based on an incremental random number technique until the number of trading units allocated to Pershing is exhausted.

Additional Information

- The allocation of called securities is not made on a pro-rata basis. Therefore, it is possible that a client may receive a full or partial redemption of shares held. Conversely, it is also possible that a client may not have any securities selected for redemption at all.
- When a partial call is deemed favorable to the holders of the called security, Pershing will exclude certain accounts from the lottery. Excluded accounts will include Pershing's proprietary and employee accounts, as well as proprietary and employee accounts of introducing broker-dealers (if Pershing carries and clears those accounts). No allocation will be made to these proprietary and employee accounts until all other client positions at Pershing in such securities have been called. When a partial call is deemed unfavorable to holders of the called security, Pershing will not exclude any accounts from the lottery.
- If the partial call is made at a price above the current market price as captured in Pershing's price reporting system, Pershing will generally categorize the partial call as one that is favorable to the holders of such security. If the partial call is made at a price that is equal to or below the current market price of the security as captured in Pershing's price reporting system, Pershing will generally categorize that call as one that is unfavorable to holders of the security.
- Clients have the right to withdraw uncalled, fully paid securities from Pershing at any time prior to the cutoff date and time established by the issuer, transfer agent and/or depository with respect to the partial call. Clients also have the right to withdraw excess margin securities, provided that the client account is not subject to restriction under Regulation T or that such withdrawal will not cause an under-margined condition.

Cash Not Yet Received

Security	Record Date	Payable Date	Quantity Held	Rate	Dividend Option	Amount of Payment
Interest CARDINAL BK MCLEAN VA CTF DEP ACT/365 0.300% 11/12/15 B/E	12/28/14	01/12/15	173,000,000	0.000255	Cash	44.08
Total Cash Not Yet Received						\$44.08

Assets shown here are not reflected in your account. This information has been received from sources we believe to be reliable. Pershing does not guarantee the accuracy of the information.

Important Information and Disclosures

The Role of Pershing

- Pershing carries your account as clearing broker pursuant to a clearing agreement with your financial institution. Pershing may accept from your financial institution without inquiry or investigation (i) orders for the purchase and sale of securities and other property and (ii) any other instructions concerning your account. Pershing is not responsible or liable for any acts or omissions of your financial institution or its employees and it does not supervise them. Pershing provides no investment advice nor does it assess the suitability of any transaction or order. Pershing acts as the agent of your financial institution and you agree that you will not hold Pershing or any person controlling or under common control with it liable for any investment losses incurred by you.
- Pershing performs several key functions at the direction of your financial institution. It acts as custodian for funds and securities you may deposit with it directly or through your financial institution or that it receives as the result of securities transactions it processes.
- Your financial institution is responsible for adherence to the securities laws, regulations and rules which apply to it regarding its own operations and the supervision of your account, its sales representatives and other personnel. Your financial institution is also responsible for approving the opening of accounts and obtaining account documents; the acceptance and, in certain instances, execution of securities orders; the assessment of the suitability of those transactions, where applicable; the rendering of investment advice, if any, to you and in general, for the ongoing relationship that it has with you.
- Inquiries concerning the positions and balances in your account may be directed to the Pershing Customer Service Department at (201) 413-3333. All other inquiries regarding your account or activity should be directed to your financial institution. Your financial organization's contact information can be found on the first page of this statement.
- For a description of other functions performed by Pershing please consult the Disclosure Statement provided to you upon the opening of your account. This notice is not meant as a definitive enumeration of every possible circumstance, but as a general disclosure. If you have any questions regarding this notice or if you would like additional copies of the Disclosure Statement, please contact your financial institution.
- Pershing is a member of the Securities Investor Protection Corporation (SIPC). Please note that SIPC does not protect against loss due to market fluctuation. In addition to SIPC protection, Pershing provides coverage in excess of SIPC limits. For more detailed information please visit: www.pershing.com/strength.html.
- This statement will be deemed conclusive. You are advised to report any inaccuracy or discrepancy (including unauthorized trading) promptly, but no later than ten days after receipt of this statement, to your financial organization and Pershing. Please be advised that any oral communication should be re-confirmed in writing to further protect your rights, including your rights under the Securities Investor Protection Act.
- Your financial organization's contact information can be found on the first page of this statement. Pershing's contact information is as follows: **Pershing LLC, Legal Department, One Pershing Plaza, Jersey City, New Jersey 07399; (201) 413-3330**. Errors and Omissions excepted.

Important Arbitration Disclosures

- All parties to this agreement are giving up the right to sue each other in court, including the right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed.
- Arbitration awards are generally final and binding; a party's ability to have a court reverse or modify an arbitration award is very limited.
- The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings.
- The arbitrators do not have to explain the reason(s) for their award, unless, in an eligible case, a joint request for an explained decision has been submitted by all parties to the panel at least 20 days prior to the first scheduled hearing date.
- The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.
- The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court.
- The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this agreement.

Important Arbitration Agreement

Any controversy between you and Pershing LLC shall be submitted to arbitration before the Financial Industry Regulatory Authority. No person shall bring a putative or certified class action to arbitration, nor seek to enforce any predispute arbitration agreement against any person who has initiated in court a putative class action, who is a member of a putative class who has not opted out of the class with respect to any

Statement Period: 12/01/2014 - 12/31/2014

Important Information and Disclosures (continued)

Important Arbitration Agreement (continued)

claims encompassed by the putative class action until; (I) the class certification is denied; (II) the class is decertified; or (III) the client is excluded from the class by the court. Such forbearance to enforce an agreement to arbitrate shall not constitute a waiver of any rights under this agreement except to the extent stated herein. The laws of the State of New York govern.

Pershing's contact information is as follows: Pershing LLC, Legal Department, One Pershing Plaza, Jersey City, New Jersey 07399; (201) 413-3330.

TERMS AND CONDITIONS

TRANSACTIONS

- ALL ORDERS AND TRANSACTIONS SHALL BE SOLELY FOR YOUR ACCOUNT AND RISK SHALL BE SUBJECT TO THE CONSTITUTION, RULES, REGULATIONS, CUSTOMS, USAGES, RULINGS AND INTERPRETATIONS OF THE EXCHANGE OR MARKET AND THE CLEARING FACILITY, IF ANY, WHERE THE TRANSACTIONS ARE EXECUTED AND/OR SETTLED, OR IF APPLICABLE, OF THE FINANCIAL INDUSTRY REGULATORY AUTHORITY AND TO ALL APPLICABLE LAWS AND REGULATIONS.

- TITLE TO SECURITIES SOLD TO YOU, WHERE PERSHING HAS ACTED AS PRINCIPAL, SHALL REMAIN WITH PERSHING UNTIL THE ENTIRE PURCHASE PRICE IS RECEIVED OR UNTIL THE SETTLEMENT DATE, WHICHEVER IS LATER.
- YOU MAY HAVE RECEIVED CONFIRMATIONS FOR TRANSACTIONS WHICH DO NOT APPEAR ON YOUR STATEMENT. IF SO, THE TRANSACTIONS WILL APPEAR ON YOUR NEXT PERIODIC STATEMENT. SUCH TRANSACTIONS MUST BE CONSIDERED BY YOU WHEN COMPUTING THE VALUE OF YOUR ACCOUNT. THIS IS ESPECIALLY TRUE IF YOU HAVE WRITTEN OPTIONS WHICH HAVE BEEN EXERCISED.

FREE CREDIT BALANCES: ANY FREE CREDIT BALANCE CARRIED FOR YOUR ACCOUNT REPRESENTS FUNDS PAYABLE UPON DEMAND WHICH, ALTHOUGH PROPERLY ACCOUNTED FOR ON PERSHING'S BOOKS OF RECORD, ARE NOT SEGREGATED AND MAY BE USED IN THE CONDUCT OF ITS BUSINESS.

DEBIT BALANCES: INTEREST CHARGED ON DEBIT BALANCES IN YOUR ACCOUNT APPEARS ON THE STATEMENT. THE RATE OF INTEREST AND PERIOD COVERED ARE INDICATED. THE RATE MAY CHANGE FROM TIME TO TIME DUE TO FLUCTUATIONS IN MONEY RATES OR OTHER REASONS. INTEREST IS COMPUTED AS DESCRIBED IN MATERIAL PREVIOUSLY FURNISHED TO YOU. PLEASE CONTACT YOUR FINANCIAL INSTITUTION IF YOU DESIRE ADDITIONAL COPIES.

MARGIN INFORMATION: IF YOU MAINTAIN A MARGIN ACCOUNT, THIS IS A COMBINED STATEMENT OF YOUR GENERAL ACCOUNT AND A SPECIAL MEMORANDUM ACCOUNT MAINTAINED FOR YOU UNDER REGULATION T OF THE BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM. THE PERMANENT RECORD OF THE SEPARATE ACCOUNT AS REQUIRED BY REGULATION T IS AVAILABLE FOR YOUR INSPECTION UPON REQUEST.

TAX INFORMATION

- AFTER YEAR END, PERSHING IS REQUIRED TO PROVIDE TAX INFORMATION TO THE INTERNAL REVENUE SERVICE AND OTHER GOVERNMENTAL AUTHORITIES. AT THAT TIME PERSHING WILL PROVIDE THAT INFORMATION ON THE ANNUAL TAX INFORMATION STATEMENT TO YOU; USE THAT STATEMENT TO PREPARE YOUR TAX FILINGS. THE TAX STATEMENT ALSO INCLUDES OTHER USEFUL INFORMATION TO ASSIST IN ACCUMULATING THE DATA TO PREPARE YOUR TAX RETURNS.
- DIVIDENDS, INTEREST AND OTHER DISTRIBUTIONS SHOWN ON THIS STATEMENT WERE CLASSIFIED AS TAXABLE OR NON-TAXABLE BASED ON CERTAIN INFORMATION KNOWN AS OF THE DISTRIBUTION DATE. THIS CLASSIFICATION IS SUBJECT TO CHANGE AND IS SOLELY INTENDED FOR USE AS GENERAL INFORMATION.
- PERSHING DOES NOT PROVIDE TAX, INVESTMENT OR LEGAL ADVISORY SERVICES AND NO ONE ASSOCIATED WITH PERSHING IS AUTHORIZED TO RENDER SUCH ADVICE. DO NOT RELY UPON ANY SUCH ADVICE, IF GIVEN. INVESTORS ARE ENCOURAGED TO CONSULT THEIR TAX ADVISORS TO DETERMINE THE APPROPRIATE TAX TREATMENT OF THEIR BUSINESS.

GENERAL INFORMATION

- WHENEVER YOU ARE INDEBTED TO PERSHING LLC (PERSHING) FOR ANY AMOUNT, ALL SECURITIES HELD BY IT FOR YOU IN ANY ACCOUNT IN WHICH YOU HAVE ANY INTEREST SHALL SECURE ALL YOUR LIABILITIES TO PERSHING, AND PERSHING MAY IN ITS DISCRETION AT ANY TIME, WITHOUT TENDER, DEMAND OR NOTICE TO YOU, CLOSE OR REDUCE ANY OR ALL OF YOUR ACCOUNTS BY PUBLIC OR PRIVATE SALE OR PURCHASE OR BOTH OF ALL OR ANY SECURITIES CARRIED IN SUCH ACCOUNTS; ANY BALANCE REMAINING DUE PERSHING TO BE PROMPTLY PAID BY YOU.
- WHENEVER YOU ARE INDEBTED TO PERSHING FOR ANY AMOUNT, ALL SECURITIES CARRIED FOR YOUR ACCOUNT ARE OR MAY BE, WITHOUT FURTHER NOTICE TO YOU, LOANED OR PLEDGED BY PERSHING, EITHER SEPARATELY OR UNDER CIRCUMSTANCES WHICH WILL PERMIT THE COMMINGLING THEREOF, WITH OTHER SECURITIES FOR ANY AMOUNT LESS THAN, EQUAL TO OR GREATER THAN YOUR LIABILITIES TO PERSHING, BUT NOT UNDER CIRCUMSTANCES FOR AN AMOUNT PROHIBITED BY LAW.
- PERSHING MAY TRADE FOR ITS OWN ACCOUNT AS A MARKET MAKER, SPECIALIST, ODD LOT DEALER, BLOCK POSITIONER, ARBITRAGEUR OR INVESTOR. CONSEQUENTLY, AT THE TIME OF ANY TRANSACTION YOU MAY MAKE, PERSHING MAY HAVE A POSITION IN SUCH SECURITIES, WHICH POSITION MAY BE PARTIALLY OR COMPLETELY HEDGED.
- IF AVERAGE PRICE TRANSACTION IS INDICATED ON THE FRONT OF THIS STATEMENT YOUR FINANCIAL INSTITUTION OR PERSHING MAY HAVE ACTED AS PRINCIPAL, AGENT OR BOTH. DETAILS AVAILABLE UPON REQUEST.
- A FINANCIAL STATEMENT OF PERSHING IS AVAILABLE FOR YOUR PERSONAL INSPECTION AT PERSHING'S OFFICES. A COPY OF IT WILL BE MAILED UPON YOUR WRITTEN REQUEST OR YOU CAN VIEW IT ONLINE AT WWW.PERSHING.COM.
- FOR BUSINESS CONTINUITY AND ADDITIONAL DISCLOSURES: WWW.PERSHING.COM/BUSINESS_CONTINUITY.HTML
- THIS STATEMENT SHOULD BE RETAINED FOR YOUR RECORDS.

PAYMENT FOR ORDER FLOW AND ORDER ROUTING POLICIES DISCLOSURES (REGULATION NMS—RULE 607(A)(1)-(2))

IF ANY OF THE ABOVE TERMS AND CONDITIONS ARE UNACCEPTABLE TO YOU, PLEASE NOTIFY PERSHING IMMEDIATELY IN WRITING BY CERTIFIED MAIL TO ONE PERSHING PLAZA, JERSEY CITY, NJ 07389, ATTN: LEGAL DEPT

PERSHING SENDS CERTAIN EQUITY ORDERS TO EXCHANGES, ELECTRONIC COMMUNICATION NETWORKS, OR BROKER-DEALERS DURING NORMAL BUSINESS HOURS AND DURING EXTENDED TRADING SESSIONS. CERTAIN OF THESE VENUES PROVIDE PAYMENTS TO PERSHING OR CHARGE ACCESS FEES TO PERSHING DEPENDING UPON THE CHARACTERISTICS OF THE ORDER AND ANY SUBSEQUENT EXECUTION. THE DETAILS OF THESE PAYMENTS AND FEES ARE AVAILABLE UPON WRITTEN REQUEST. PERSHING RECEIVES PAYMENTS FOR DIRECTING LISTED OPTIONS ORDER FLOW TO CERTAIN OPTION EXCHANGES. IN ADDITION, PERSHING ROUTES CERTAIN EQUITY AND OPTION ORDERS TO ITS AFFILIATE, BNY MELLON CAPITAL MARKETS, LLC, FOR EXECUTION AS PRINCIPAL. COMPENSATION IS GENERALLY IN THE FORM OF A PER OPTION CONTRACT CASH PAYMENT.

BEST EXECUTION: NOTWITHSTANDING THE PREVIOUS PARAGRAPH REGARDING PAYMENT FOR ORDER FLOW, PERSHING SELECTS CERTAIN MARKET CENTERS TO PROVIDE EXECUTION OF OVER-THE-COUNTER AND EXCHANGE-LISTED SECURITIES TRANSACTIONS WHICH AGREE TO ACCEPT ORDERS, TRANSMITTED ELECTRONICALLY UP TO A SPECIFIED SIZE, AND TO EXECUTE THEM AT OR BETTER THAN THE NATIONAL BEST BID OR OFFER (NBBO), ON CERTAIN LARGER ORDERS, OR IF THE DESIGNATED MARKET CENTERS DO NOT MAKE A MARKET IN THE SUBJECT SECURITY, PERSHING DIRECTLY CONTACTS MARKET CENTERS TO OBTAIN AN EXECUTION. THE DESIGNATED MARKET CENTERS TO WHICH ORDERS ARE AUTOMATICALLY ROUTED ARE SELECTED BASED ON THE CONSISTENT HIGH QUALITY OF THEIR EXECUTIONS IN ONE OR MORE MARKET SEGMENTS AND THEIR ABILITY TO PROVIDE OPPORTUNITIES FOR EXECUTIONS AT PRICES SUPERIOR TO THE NBBO. PERSHING ALSO REGULARLY REVIEWS REPORTS FOR QUALITY OF EXECUTION PURPOSES.

WRAP ACCOUNT CUSTOMERS WHO ELECTED NOT TO RECEIVE IMMEDIATE CONFIRMATION OF TRANSACTIONS

THE FOLLOWING TERMS AND CONDITIONS ARE APPLICABLE ONLY IF YOUR ACCOUNT IS AN INVESTMENT ADVISORY ACCOUNT AND THE TRANSACTION CONFIRMATIONS ARE NOT SENT TO YOU (SENT ONLY TO YOUR FIDUCIARY) PURSUANT TO YOUR INSTRUCTION:

WRAP ACCOUNT TRANSACTIONS

- THE FOLLOWING INFORMATION WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR FINANCIAL INSTITUTION (INTRODUCING FIRM) WITH RESPECT TO ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU: THE MARKET UPON WHICH ANY TRANSACTION WAS EXECUTED; THE TIME OF DAY THAT ANY TRANSACTION WAS EXECUTED; THE NAME OF THE PERSON FROM WHOM ANY SECURITY WAS PURCHASED OR TO WHOM SUCH SECURITY WAS SOLD; THE SOURCE AND AMOUNT OF OTHER COMMISSIONS RECEIVED IN CONNECTION WITH ANY TRANSACTION; AND A COPY OF THE TRANSACTION CONFIRMATION.
- YOUR INTRODUCING FIRM EFFECTED EACH TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU AS YOUR AGENT.
- IN CONNECTION WITH EACH EQUITY SECURITY AND CERTAIN OTHER SECURITIES SOLD, YOUR INTRODUCING FIRM CHARGES TO YOU, AND REMITS TO A REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE, A "TRANS-FEE." PERSHING CALCULATES THIS FEE BASED ON AMOUNTS PAID BY YOUR INTRODUCING FIRM TO THE APPLICABLE REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE. THIS, IN TURN, IS BASED ON THE VALUE OF THE APPLICABLE SECURITIES SOLD. TO DETERMINE THE EXACT AMOUNT OF THIS FEE WITH RESPECT TO ANY TRANSACTION, PLEASE CONTACT YOUR INTRODUCING FIRM.
- IF ANY TRANSACTION INVOLVES AN ASSET-BACKED SECURITY, INCLUDING A MUNICIPAL COLLATERALIZED MORTGAGE OBLIGATION, WHICH REPRESENTS AN INTEREST IN OR IS SECURED BY A POOL OF RECEIVABLES OR OTHER FINANCIAL ASSETS THAT ARE SUBJECT CONTINUOUSLY TO PREPAYMENT, THEN THE ACTUAL YIELD OF SUCH SECURITY MAY VARY ACCORDING TO THE RATE AT WHICH THE UNDERLYING RECEIVABLES OR OTHER FINANCIAL ASSETS ARE PREPAID. INFORMATION CONCERNING THE FACTORS THAT AFFECT YIELD (INCLUDING AT A MINIMUM ESTIMATED YIELD, WEIGHTED AVERAGE LIFE, AND THE PREPAYMENT ASSUMPTIONS OF UNDERLYING YIELD) WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR INTRODUCING FIRM.

WRAP ACCOUNT ORDER FLOW: YOUR INTRODUCING FIRM DOES NOT RECEIVE ANY PAYMENT FOR ORDER FLOW FOR ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU.

WRAP ACCOUNT CALL FEATURES: CALL FEATURES MAY EXIST FOR SECURITIES. CALL FEATURES FOR FIXED INCOME SECURITIES MAY AFFECT YIELD. COMPLETE INFORMATION WILL BE PROVIDED UPON REQUEST.

WRAP ACCOUNT RATINGS: THE RATINGS THAT APPEAR IN THE DESCRIPTION OF SOME FIXED INCOME SECURITIES HAVE BEEN OBTAINED FROM RATINGS SERVICES WHICH PERSHING BELIEVES TO BE RELIABLE; HOWEVER, PERSHING CANNOT GUARANTEE THEIR ACCURACY. SECURITIES FOR WHICH A RATING IS NOT AVAILABLE ARE MARKED "UNRATED."



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Application Review Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reciprocity Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reciprocity Committee has been ordered and called for 8:30 a.m. on Wednesday, February 25, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 12-28-2014

- A. Call to Order
- B. Quorum Call
- C. Call for Additional Agenda Items & Adoption of Agenda
- D. Opportunity for Public Comment
- E. Consideration of Applications
 - 1. Brandee Cecelia Lam (FL)
- F. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Violations Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Impairment Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Tuesday, February 24, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-05-2015

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Review of Docket
 - A. *For Acceptance of Voluntary Surrenders of Credentials*
 - i. Case No. 14-0391 ~ PST.015640 – Richard Jeffrey Gaude
 - B. *Petitions For Reinstatement of Suspended Credentials*
 - i. Case No. 15-0011 ~ PST.018065 – Matthew Marston Lane
 - C. *Petitions for Modification of Previous Orders*
 - i. Case No. 15-0025 ~ PST.011704 – Steve John Soteropulos
 - D. *Applications for a Credential*
 - i. Case No. 14-0374 ~ PST.A – Melissa Kay Sherer
 - ii. Case No. 14-0375 ~ PST.A – Lenard Neil Shaw
 - E. *Appearances for Informal Conference*
 - i. Case No. 14-0392 ~ PST.016310 – Joseph Percy Ricard, Jr.
 - F. *Appearances for Guidance*
6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reinstatement Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ Email: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reinstatement Committee has been ordered and called for 9:00 a.m. on Tuesday, February 24, 2015 in the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-13-2015

1. Call to Order
 2. Quorum Call
 3. Call for Additional Agenda Items & Adoption of Agenda
 4. Opportunity for Public Comment
 5. Consideration of Applications
 - A. *Petitions for Reinstatement (suspended + lapsed > 5 years + chair's discretion)*
 - i. Case No. 14-0268 ~ PST.016284 – Charles Jude Mitchell, Jr.
 - ii. Case No. 15-0030 ~ PST.013542 – Thadrian Marquis Johnson
 - iii. Case No. 15-0027 ~ CPT.006044 – Kelly Elizabeth Reinhardt
 - iv. Case No. 15-0028 ~ CDS.042068 – Starns Pharmacy
 - B. *Petitions for Modification of Previous Orders*
 - C. *Petitions for Return of Inactive Licenses to Active Status*
- [Note: Appearances are not required for the remaining applicants.]**
- D. *CDS Petitions for Reinstatement (lapsed > 5 years, appearance not required)*
 - i. CDS.030091.DPM – Dannie J. Scoot
 - ii. CDS.028760.MD – Henri Joseph Roca
 - iii. CDS.036142.PA – Carson Shetley Holtzclaw
 - iv. CDS.020203.DVM – Cherie Bridges Messina
 - v. CDS.029843.DVM – Leslie Birke
 - vi. PHY.004459.NR – Express Scripts
 - vii. PHY.004570.NR – Express Scripts
 - E. *Reinstatement of CDS Licenses Previously Suspended Secondary to Action by Another Agency*
 - i. CDS.023751.MD – Barbara Noguchi
 - ii. CDS.039898.MD – Rafael O. Robledo

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

iii. CDS.026648.MD – Randy L. Lavespere

F. Discretionary Approvals by Committee Chair (lapsed > 1 year)

- i. CPT.004270 – Dana Lynn Barras
- ii. CDS.01877.MD – Jimmy Joe Morrison
- iii. CDS.015222.DDS – Patrick Mark Crawford
- iv. CDS.040506.MD – Elizabeth Jeanne- Anne Waller
- v. CDS.022280.DVM – James Rollie Norris
- vi. CDS.035084.MD – Hall R. Howard
- vii. CDS.039973.MP – Rafael S. Salas
- viii. CDS.028762.MD – Patricia Shearer
- ix. CDS.029771.DDS – Leah Veuleman Byles
- x. CDS.033997.DVM – Elysse A. Orchard
- xi. CDS.035457.MD – La'nasha C. Tanner
- xii. CDS.037117.MD – Ashish Udhrain
- xiii. CDS.040993.DDS – David M. Glass
- xiv. CPT.009449 – Amanda Gayle Punched
- xv. CPT.007984 – Shellene Lee Moseley
- xvi. PST.019586 – Catherine Elise Anthan
- xvii. CPT.005407 – Dawn Colette Ducote
- xviii. CDS.035382.MD – Anil Minocha
- xix. CDS.042429.MD – Erin Simmers
- xx. CDS.034030.DVM – Christian Michael Charlton
- xxi. CDS.024659.MD – Michael Lamar Brown
- xxii. CDS.020897.MD – Charles Ray Stephens
- xxiii. CDS.041180.DVM – Haylie A. Hendershot
- xxiv. CDS.41033.APN – Judith Lynn Turpen
- xxv. CDS.037588.APN – Lisa Denise Robertson-Poitier
- xxvi. PST.019820 – Erin Marie Spahn
- xxvii. CDS.021778.MD – David Caletri
- xxviii. CDS.020151.DVM – Gary Charles Simon
- xxix. CDS.42155.MD – David Emile Moll
- xxx. CDS.041261.PA – Charles Kock
- xxxi. CDS.030559.DPM – Michael Richard Kaye
- xxxii. CPT.001812 – Loretta Lynn Richardson
- xxxiii. CPT.009235 – Shaunquel Michelle Dubose
- xxxiv. PHY.006262.NR – Express Scripts
- xxxv. CDS.025771.MD – David Charles Vajnar

G. Staff Approvals by Board Policy (lapsed < 1 year)

- i. DME.000439 – Synergy Medical
- ii. CDS.041177.MD – Lawrence Dwayne Counts
- iii. CDS.018917.MD – Jonathan Arlen Roundtree
- iv. CDS.026665.MD – Tracy Leigh LeGros
- v. CDS.017843.MD – Mark Dal Corso
- vi. CDS.039820.APN – Margaret S. Evans
- vii. CDS.041041.DDS – Daniel D. Choi
- viii. EDK.007090 – Many Healthcare
- ix. DME.000485 - WI Medical
- x. CPT.005464 – Brandon Rowlett Sims
- xi. CPT.010169 – Shantoria Latrice Britton

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xii. CDS.042447.MD – James W. Erwin
- xiii. CDS.038350.APN – Andrea D. Plauche
- xiv. CDS.036960.MD – Sarika Sharad Gunda
- xv. CDS.043600.APN – Michaelyn Brabham
- xvi. CDS.042104.DVM – Jennifer E. Bruno
- xvii. CDS.043804.RES – Pradeep Garg, Ph. D.
- xviii. CDS.018861.MD – Catherine McClelland McCormick
- xix. CPT.009208 – Karl Logan Hinton
- xx. CPT.006831 – Rosanne Karen Downey-Halliday
- xxi. CDS.022940.DVM – Kathryn Turkey Hartline
- xxii. CDS.033836.OD – Trever J. Mitchell
- xxiii. CDS.042316.DDS – Daniel Joseph Cassis
- xxiv. CDS.042353.DDS – Matthew B. Brady
- xxv. CDS.009334.DDS – John Stephen Picou
- xxvi. CDS.032525.MD – Scott Alan Walls
- xxvii. CDS.012863.MD – Erin T. O’Sullivan
- xxviii. CDS.024337.MD – Wilfrido R. Castaneda
- xxix. CDS.028352.DVM – Cristen G. Mitchell
- xxx. CDS.038375.DVM – Emelie Schlatre McLellan
- xxxi. CDS.042123.APN – Yolanda R. Mornay
- xxxii. CDS.015793.DVM – Wayne E. Blust
- xxxiii. CDS.037079.MD – Trevor C. Richard
- xxxiv. CDS.020096.DVM – Craig Joseph Guidry
- xxxv. CDS.041894.APN – Angela Marie Bradley-Byers
- xxxvi. CDS.022218.DDS – Cynthia Marie Ramkelawan
- xxxvii. CDS.031548.DVM – Elizabeth A. Kergosien
- xxxviii. CDS.035705.MD – Dean D. Aubin
- xxxix. CDS.043943.APN – Tanya Lucille Romanowski
- xl. CDS.024895.MD – Lily Yang
- xli. CDS.027389.MD – Deirdre O’Boyle Hooper
- xlii. CDS.042263.DDS – Elise M. Trahant
- xliii. CDS.042382.DVM – Joshua Randolph Franklin
- xliv. CDS.037189.MD – Minh Quos Mai
- xlv. CDS.043613.APN – Tracy Renee Harris
- xlvi. CDS.043824.DVM – Stephanie Jones Thomas
- xlvii. CDS.008660.DDS – John McHugh Smith
- xlviii. DME.000411 – Hanger Prosthetics & Orthotics
- xlix. DME.000417 - Hanger Prosthetics & Orthotics
 - I. DME.000415 - Hanger Prosthetics & Orthotics
 - li. DME.000412 - Hanger Prosthetics & Orthotics
 - lii. DME.000409 - Hanger Prosthetics & Orthotics
 - liii. DME.000408 - Hanger Prosthetics & Orthotics
- liv. CPT.011323 – Davetta Monique Brisco-Winfield
- lv. CDS.031926.DVM – Michael Ryan Guidry
- lvi. CDS.039914.DVM – Christopher P. Algero
- lvii. CDS.024090.MD – Abida Banu Butler
- lviii. CDS.035039.DVM – Rosanne Krupa Peters
- lix. CDS.043908.DVM – Julie Anne Wheeler
- lx. CDS.037340.RES – Karen Briski Sylvester
- lxi. CDS.032989.OD – Phillip L. Carney, Jr.
- lxii. CDS.021465.MD – Raga Malaty

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- lxiii. CDS.040477.MD – John B. Green
- lxiv. CDS.035017.MD – Sean Kristofer Troxclair
- lxv. CDS.029299.MD – Ian Ross Gardner
- lxvi. CDS.033575.DPM – Nicklya Harris-Ray
- lxvii. CDS.020134.MD – Robert Maddox
- lxviii. CDS.043840.MD – Joshua Rai Clark
- lxix. CDS.024917.MD – James David Hammond
- lxx. CDS.020461.DDS – Annette D. Theriot
- lxxi. CDS.030929.MD – Lynn James Groome
- lxxii. CDS.019396.DVM – Drew Francis Le Compte
- lxxiii. AMS.010372 – Walgreen Pharmacy
- lxxiv. CDS.037078.MD – Genesa Natalie Garofalo Kreisler
- lxxv. CDS.039803.DDS – Martha Jane Sandel Herrington
- lxxvi. CDS.033391.MD – Ginger Auer Black
- lxxvii. CDS.037279.APN – Delana M. Martinez
- lxxviii. CDS.024998.MD – John Kelvin Jackson
- lxxix. CDS.037322.RES – Bruce A. Bunnell
- lxxx. CDS.044021.MD – Mignonne Beaudoin Morrell
- lxxxi. CDS.018827.MD – Alan Michael Robson
- lxxxii. CDS.017448.MD – Michael Keith Butler
- lxxxiii. CDS.036186.APN – Anita T. Crutchfield
- lxxxiv. CDS.043711.MD – Leslie Palmer Lee
- lxxxv. CDS.018955.DVM – Laura Barnes McElroy
- lxxxvi. CDS.030960.MD – Bryam Wayne Barrett
- lxxxvii. CDS.040469.MD – Benjamin Wade Wilkerson
- lxxxviii. CDS.018662.DVM – Daniel Patrick Brennan
- lxxxix. CDS.041165.MD – Gina L. Dean
 - xc. CDS.043920.APN – Kelly Kathleen Horton
 - xc. CDS.026403.MD – Kenny James Cole
 - xcii. CDS.039817.MD – Geetika Dembla
 - xciii. CDS.028330.MD – Patrick Paul McCaslin
 - xciv. CDS.034086.APN – Camille Thompson Wise
 - xcv. CDS.006297.MD – Robert Keene Fell
 - xcvi. CDS.030340.MD – Paul Milner Lessig
 - xcvii. CDS.028390.DVM – Jeanna Johnston Scully
 - xcviii. CDS.018919.DDS – Victor Edward Babin, III
 - xcix. CDS.043832.MD – Paul Randall Lillich
 - c. CDS.043710-MD – Maasumeh Shirin Sabbaghian
 - ci. CPT.008322-MD – India Nicole Wright
 - cii. CPT.002763 – Christie Elizabeth Madere
 - ciii. CDS.014110.DDS – Edgardo Louis Rabel
 - civ. CDS.020731.MD - Robert Michael Anderson
 - cv. CDS.035853.MD – Jo Anne Pine
 - cvi. CDS.019403.MD – Barrett J. Day
 - cvii. CDS.036127.APN – Laurie Stine Finger
 - cviii. CDS043260.MD - Michael Christopher Blancaneaux
 - cix. CDS.014118.DDS – John S. Dupont, Jr.
 - cx. CDS.041012.APN - Jocelyn S. Beasley
 - cx. CDS.037353.APN – Roxane Minet
 - cxii. CDS.026468.MD 0 John Henry Smith, III
 - cxiii. CPT.010030 – Amber Shiree Wells

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- cxiv. DME.00300 - Byram Healthcare Centers
- cxv. CDS.06070.DVM - Bronk B. McDaniel
- cxvi. CDS.044081.APN - Kayla Riche' Fung
- cxvii. CDS.037265.PA - Christina F. Tyson
- cxviii. CDS.042207.MD - Kelly Marie Johnson
- cxix. CDS.03297.MD – Robert Theus Crotty
- cxx. CDS.040414.PA - Beretta Craft-Coffman
- cxxi. CDS.040236.MD - Claus Brandigi
- cxxii. CDS.035084.MD – Hall Renfro Howard
- cxxiii. CDS.041228.DDS - Thomas R. Leach, Jr.
- cxxiv. CDS.032888.HOS - Sterlington Rehabilitation Hospital at Bastrop
- cxxv. CDS.030628.HOS - Greenbrier Hospital
- cxxvi. CPT.001753 – Barbara Verret Broussard

6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Tripartite Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Regulation Revision Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Summary of Testimony & Public Comments
re
Regulatory Project 2015-1 ~ Dispenser Reporting to Prescription Monitoring Program
at
January 28, 2015 Public Hearing

There were no comments received prior to or during the public hearing.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Summary of Testimony & Public Comments
re
Regulatory Project 2015-2 ~ Expiration Date of Schedule II Prescriptions
at
January 28, 2015 Public Hearing

There were no comments received prior to or during the public hearing.

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 12. Automated Medication Systems

§1217. Stocking and Restocking; Electronic Product Verification

- A. ...
- B. ...
- C. Electronic Product Verification.
 - 1. A bar code verification, electronic verification, or similar verification process may be utilized to assure the correct selection of drugs to be placed into an automated medication system.
 - 2. The use of a bar code, electronic, or similar verification process shall require an initial quality assurance validation followed by ongoing quality assurance reviews at intervals no greater than 90 days since the previous review, all conducted by a pharmacist.
 - 3. When a bar code verification, electronic verification, or similar verification process is utilized as specified in this Paragraph and in the absence of any human intervention in the product selection process, the stocking and restocking functions in systems located either on-site or off-site may be performed by a pharmacy technician without the necessity of direct pharmacist supervision, or in the alternative, by a licensed health care practitioner trained and authorized by the pharmacist in-charge.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271 (June 2000) effective July 1, 2000, amended LR

Chapter 15. Hospital Pharmacy

§1509. Drug Distribution Control

- A. ...
- B. Automated Medication Systems. A hospital pharmacy may use one or more automated medication systems in compliance with the provisions of Chapter 12 – Automated Medication Systems of the board’s rules.
 - 1. When the pharmacy uses an electronic product verification process as described in §1217 of the board’s rules, and in the absence of any subsequent human intervention in the automated drug product selection process, the pharmacist-in-charge may elect to forego manual checks of drug products selected in that manner, provided however, that such election by the pharmacist-in-charge shall require an initial quality assurance validation followed by an ongoing quality assurance reviews at intervals no greater than 90 days since the previous review, all conducted by a pharmacist.
 - 2. The pharmacist-in-charge remains accountable to the board for the accuracy of all drug distribution activities.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

53 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2093
54 (October 2003), effective January 1, 2004, amended LR
55
56 ...
57

1 HLS 15-
2 Regular Session, 2015
3 House / Senate Bill No.
4 By Representative / Senator

5
6 PUBLIC RECORDS: Provides relative to the exemption for certain records maintained by the
7 Louisiana Board of Pharmacy.

8
9 AN ACT

10
11 To amend and reenact R.S. 44:4(35), relative to the exemption for certain records maintained by
12 the Louisiana Board of Pharmacy.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 44:4(35) is hereby amended and reenacted to read as follows:

15 §4. Applicability

16 This Chapter shall not apply:

17 ...

18 (35) To any records, writings, accounts, letters, exhibits, pictures, drawings, charts, or
19 photographs, or copies or memoranda thereof, in any report of examinations or
20 evaluations or in any other information or data in the custody of the Louisiana
21 Board of Pharmacy concerning the fitness of any person to receive, or continue to
22 hold, a license, permit, certificate, or registration to practice or assist in the
23 practice of pharmacy, or conduct any activities as authorized by a controlled
24 dangerous substance license, or relative to prescription department security

25 information. However, any final determination made by the board and any legal
26 grounds upon which such action is based, relative to the fitness of any person to
27 receive or continue to hold a license, permit, certificate, or registration to practice
28 or assist in the practice of pharmacy, or conduct any activities authorized by a
29 controlled dangerous substance license shall be a public record.

1 HLS 15-
 2 Regular Session, 2015
 3 House / Senate Bill No. _____
 4 By Representative / Senator _____
 5

6 CONTROLLED SUBSTANCES: Re-schedules hydrocodone combination products from
 7 Schedule III to Schedule II, and adds suvorexant and tramadol to Schedule IV.
 8

9 AN ACT

10

11 To amend and reenact R.S. 40:964, relative to the composition of various schedules of controlled
 12 substances.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:

15 §964. Composition of schedules

16 * * *

17 Schedule III

18 * * *

19 D. Limited Narcotic Drugs

20 Unless specifically excepted or unless listed in another schedule:

21 (1) Any material, compound, mixture, or preparation containing limited
 22 quantities of any of the following narcotic drugs, or any salts
 23 thereof:

24 * * *

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

(c) ~~Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters, or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium~~ Repealed.

(d) ~~Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters, or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts such as acetaminophen or ibuprofen~~ Repealed.

* * *

Schedule IV

* * *

A. Narcotic Drugs

* * *

(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)

* * *

B. Depressants

* * *

(45.5) Suvorexant

* * *

1 HLS 15-
2 Regular Session, 2015
3 House / Senate Bill No.
4 By Representative / Senator

5
6 CONTROLLED SUBSTANCES: Provides relative to the access and disclosure of prescription
7 monitoring information within a secure interstate data exchange system.

8
9 AN ACT

10
11 To amend and reenact R.S. 40:1007, relative to access to prescription monitoring information.

12
13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:1007 is hereby amended and reenacted to read as follows:

15 A. Except as provided in Subsections C, D, E, F, G, H, and I of this Section,
16 prescription monitoring information submitted to the board shall be protected health
17 information, not subject to public or open records law, including but not limited to
18 R.S. 44:1 et seq., and not subject to disclosure. Prescription monitoring information
19 shall not be available for civil subpoena from the board, nor shall such information be
20 disclosed, discoverable, or compelled to be produced in any civil proceeding nor shall
21 such records be deemed admissible as evidence in any civil proceeding for any
22 reason. Notwithstanding this provision, law enforcement and professional licensing,
23 certification, and regulatory agencies may utilize prescription monitoring information
24 in the course of any investigational and subsequent criminal and administrative

25 proceedings, but only in accordance with federal and state law and the requirements
26 of this Part.

27 B – F. ...

28 G. The board may provide prescription monitoring information in response to queries
29 from prescription monitoring programs located in other states, through its
30 participation in a secure interstate data exchange system, and the information may be
31 used by those programs in a manner consistent with this Section. ~~However, the~~
32 ~~board shall not provide prescription monitoring information to prescription~~
33 ~~monitoring programs located in other states unless the laws of the state receiving the~~
34 ~~information provide at a minimum both of the following:~~

35 (1) ~~That the prescription monitoring information is protected health information, not~~
36 ~~subject to the Public Records Law, and not subject to disclosure.~~

37 (2) ~~That the prescription monitoring information shall not be subject to civil~~
38 ~~subpoena, nor shall such information be disclosed, discoverable, or compelled to~~
39 ~~be produced in any civil proceeding, nor shall such records be deemed admissible~~
40 ~~as evidence in any civil proceeding for any reason~~

41 H – J. ...

42



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Executive Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

PROPOSED CONTRACTS / AGREEMENTS
Fiscal Year 2015-2016

Contractor	Service	2011/2012 Terms	2012/2013 Terms	2013/2014 Terms	2014/2015 Terms	2015/2016 Terms	Changes to prior FY	Contract Received
Celia Cangelosi	Legal	\$195/hr maximum \$80,000	\$195/hr maximum \$80,000	\$195/hr maximum \$80,000	\$195/hr maximum \$80,000	\$225/hr maximum \$80,000	Yes	Yes
E. Wade Shows	Legal	\$175/hr maximum \$40,000	\$175/hr maximum \$40,000	\$175/hr maximum \$40,000	\$175/hr maximum \$40,000	\$225/hr maximum \$40,000	Yes	Yes
Kolder, Champagne, Slaven	CPA	\$65/hr - prepare bank reconciliations, journal entries, financial statements	\$65/hr - prepare bank reconciliations, journal entries, financial statements	\$70/hr - prepare bank reconciliations, journal entries, financial statements	\$75/hr - prepare bank reconciliations, journal entries, financial statements	\$75/hr - prepare bank reconciliations, journal entries, financial statements	No	
		\$130/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$130/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$130/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$145/hr - review bank reconciliations, adjusting journal entries, and financial statements	\$160/hr - review bank reconciliations, adjusting journal entries, and financial statements	Yes	
		\$150/hr - oversight and final approval of accounting work	\$150/hr - oversight and final approval of accounting work	\$180/hr - oversight and final approval of accounting work	\$180/hr - oversight and final approval of accounting work	\$180/hr - oversight and final approval of accounting work	No	
		maximum \$22,500	maximum \$22,500	maximum \$22,500	maximum \$22,500	maximum \$22,500	No	
NexLearn (Formerly Portico)	Web-based Learning Programs	\$5/course/user \$65/hr: data input \$110/hr: development spec. \$125/hr: other services Maximum \$20,000	\$5/course/user \$65/hr: data input \$110/hr: development spec. \$125/hr: other services Maximum \$20,000	Maximum \$20,000	Will not be renewed. To be dropped on/around 03/01/14	Will not be renewed.	N/A	N/A
Optimum (HID 07/01/10 - 02/28/14)	PMP (Rx Hosting)	\$110,500	\$110,500	To go through renewal process		\$76,100	No	
Essential Solutions	IT Support	\$1,500 / month maximum \$25,000	\$2,000/mo (July -Dec) \$2,200/mo (Jan-June)	\$2,500/mo (July -June)	\$2,500/mo (July -June)	\$2,500/mo (July -June)	No	
Iron Data (Formerly CAVU)	Database	\$52,951	\$52,951	\$55,346 (includes 40 hrs of deployment services).	\$57,600 (plus additional for software upgrade)	\$60,600 (plus additional for software upgrade)	No	

To be sent to DHH / Contracts & Procurement Department

New contract terms



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



RESOLUTION

The following Motion and Resolution was offered by _____ who moved for its adoption, and seconded by _____ at the February 25, 2015 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as the Board's prosecutor, and further, there is a need for an attorney experienced in administrative law to provide prosecutorial services during its administrative hearings, and further, to provide additional representation when the Board's decisions are appealed to the judiciary, and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law; and

WHEREAS, the Board has worked with **Celia R. Cangelosi** in the same capacity for over fifteen years, providing the experience as prosecuting attorney, with additional experience in representing the Board's interests in the 19th Judicial District Court, the First Circuit Court of Appeals; and the Louisiana Supreme Court; and

WHEREAS, the Board's proposed contract with **Celia R. Cangelosi** specifies an hourly rate of two hundred twenty five dollars (\$225) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed eighty thousand dollars (\$80,000) for Fiscal Year 2015-2016; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect on July 1, 2015.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **Celia R. Cangelosi** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS: ___
NAYS: ___
ABSENT: ___
NOT VOTING: ___

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 25th day of February 2015.

I, Carl W. Aron, President of the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held February 25, 2015, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 25th day of February, 2015.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



RESOLUTION

The following Motion and Resolution was offered by _____ who moved for its adoption, and seconded by _____ at the February 25, 2015 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as an advisor to the Board's Hearing Officer, and further, there is a need for an attorney experienced in administrative law to provide advisory services to the Board's Hearing Officer during its administrative hearings, or to serve as the Hearing Officer; and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law, as well as other professional legal services as may be requested by the Board from time to time; and

WHEREAS, the Board has worked with **Shows, Cali & Walsh, LLP** in the same capacity for over ten years, where they have provided advisory services to the Board's Hearing Officer as well as serving as the Hearing Officer from time to time; and further, they represented the Board and its staff during a suit against the Board during 2013; and

WHEREAS, the Board's proposed contract with **Shows, Cali & Walsh, LLP** specifies an hourly rate of two hundred twenty-five (\$225) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed forty thousand dollars (\$40,000) for Fiscal Year 2015-2016; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect on July 1, 2015.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **Shows, Cali & Walsh, LLP** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS: —
NAYS: —
ABSENT: —
NOT VOTING: —

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 25th day of February, 2015.

I, Carl W. Aron, President of the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held February 25, 2015, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 25th day of February, 2015.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



MEMORANDUM

To: Board Members
From: Malcolm Broussard
Date: February 25, 2015
Re: Proposal for Board Approval of Pharmacy Law Update CE

During my early years with the Board, part of my duties included delivering pharmacy law updates to local and state pharmacy membership organizations. I worked with the sponsoring organizations to obtain ACPE accreditation for those presentations so that the participants could also use those CE presentations for licensure renewal purposes.

ACPE changed their standards for CE providers in 2009, and one of those changes related to the method of assessing learning outcomes for CE presentations. In particular, direct questions became a requirement. Previous to that time, we had been able to use some other methods of assessing learning outcomes. The challenge that presented to me relates to one of my other duties for the Board, which is maintaining the item bank for the MPJE-Louisiana examination. I am responsible for reviewing the questions to ensure their continuing accuracy, and I am also responsible for writing new test questions. The signed agreement I have with NABP for that responsibility includes an exclusivity clause – I can only write pharmacy law test questions intended for public use for NABP and only for use with the MPJE-Louisiana test. Since that change in the ACPE standards, I am no longer able to obtain ACPE accreditation for pharmacy law update CE presentations. I advised the different organizations that I was always open to delivering the same presentations without ACPE accreditation but there has been no interest.

Given the passage of time and the number of changes in both pharmacy laws and rules since that time, I believe the Board may wish to consider taking advantage of an option that currently exists in its CE rules. In particular, the CE rules require CE used for re-licensure purposes to be ACPE-accredited or Board-approved. We have rarely allowed Board-approved CE – in fact, the only time we have allowed it so far is for those Louisiana-licensed pharmacists who live and practice in another state, and the board of pharmacy in that state has approved CE that is not accredited by ACPE for re-licensure purposes in that state. We have said we would recognize that CE for re-licensure purposes in this state. To date, the Louisiana Board has not approved any CE, primarily because there are no approval criteria, policies, or procedures for that purpose.

I am prepared to develop a pharmacy law update CE presentation for your approval, and then deliver that CE presentation to pharmacists and technicians at different locations around the state. By selecting locations that would allow our use for no fee, we can avoid having to charge a fee for the presentations. My plan is to advertise the event by email to pharmacists and technicians in a certain geographic area, require their electronic pre-registration with a minimal amount of information, and have a staff member with me on-site for check-in purposes. After the event, we could send their participation data to CPE Monitor at NABP, and then acknowledge their participation by email, along with a reminder that the CE, though not accredited by ACPE was approved by the Board and is suitable for re-licensure purposes in this state.

I have developed a program entitled Louisiana Pharmacy Law Update for 2015 and now seek your approval of this program as suitable for re-licensure purposes in Louisiana. The program will include a discussion of the pharmacy-related laws adopted by the 2014 Legislature as well as a discussion of the rules promulgated by the Board during 2014 and any other new rules adopted in this year. My plan is for 90 minutes of structured comments and 30 minutes of question/answer or other open discussion. It is possible that I could adjust that ratio of structured vs open discussion based on individual meeting dynamics, but I would still look for a total of two hours. I am seeking your approval of this presentation and respectfully suggest a credit of two hours via live presentation.

In the event you deem it appropriate, I have a suggested motion for your consideration.

Resolved, to approve the continuing education presentation entitled Louisiana Pharmacy Law Update for 2015 as delivered by the Executive Director, and further, to award participants two hours of credit for the live presentation, and further, to approve the presentation for re-licensure purposes in this state.

LOUISIANA BOARD OF PHARMACY



Corporate Travel Card Policy

February 25, 2015

Board of Pharmacy
Corporate Travel Card Policy

Travel Card Program Policy Statement

1. This policy covers the Travel card program (T-card) and establishes minimum standards possession and use. Travel Card is a tool used to assist in the management of purchasing, payment, and accounting. Travel Card is a Visa card issued by Bank of America for the State of Louisiana. This card will enable employees to purchase items with the convenience of a credit card, while providing management with a means of maintaining control over those purchases. The use of this card will improve efficiency and effectiveness by reducing costs associated with processing purchases and payments and will allow for the receipt of goods on a timely basis.
2. The Louisiana Board of Pharmacy allows a maximum Single Purchase Limit (SPL) of up to \$5,000. Multiple purchases may be made with the T-Card for contract purchases, each day, up to but not exceeding \$5,000 per contract. The board has safeguards in place to ensure that purchases from contract vendors are for each contract's specific approved contract items.
3. Purchases should never be artificially divided to avoid the Travel Card policy limits or placed on different cards within the Section/Unit.
4. Current Purchasing Policies, Rules and Regulations, Louisiana Statutes, Executive Orders and/or State Travel Card Policy, as well as the Board's Travel Policy must always be followed during the use of the Travel Card. Copies of State of Louisiana Travel Card Purchasing Card Policy, Rules and Regulations, LA Statutes and Executive Orders may be viewed/obtained from the State Purchasing Website at www.doa.louisiana.gov/ops/traveloffice.htm.
5. All program participants, i.e. program administrators, cardholder, CBA, administrators and cardholder approvers are required to complete an online certification class, annually, receiving a passing grade of at least 90 in order to receive a new t-card, a renewal t-card, remain as CBA administrator or remain as a cardholder approver. These certifications will be developed and updated, as necessary, by the Office of State Purchasing and Travel and the agency will be notified as soon as they are approved. All program participants will be given ample time to obtain this certification once notified. Note: The certification class for the CBA administrator would be the same as a cardholder's certification.

A cardholder's approver must be a supervisor of the cardholder which would be at least one level higher than the cardholder. The approver must be the most logical supervisor which would be most familiar with the business case and appropriate business needs for the cardholder's transactions.

To allow for proper and complete program audits, all program participants, including public post secondary, will be mandated to implement WORKS Workflow, which is an online system through Bank of America. The system captures transactions; Workflow requires both cardholders and cardholder approver's electronic signatures, along with the ability to maintain receipts and backup supporting documentation in one central location through the scanning feature which is also being mandated, therefore, assisting with audits and reviews. The system allows for an additional level of approvals, beyond the cardholder and approver. Another function of Workflow allows accounting information to be coded by the cardholder for each transaction. The accounting function is mandated

for ISIS/LaGov interfaced agencies which would ultimately be interfaced to the ISIS and LaGov systems. For all other agencies/post secondary/board/commissions, which are not ISIS/LaGov, interfaced agencies, although it is still mandated for the agency to utilize Workflow including scanning capabilities, the agency will not be required to interface with any accounting system.

Agency program participation requires annual review of the agency's program conducted by the agency's internal audit section.

All receipt and supporting documentation must be scanned and tied to the applicable transaction and not as one image for all transactions.

6. The Department Head will be responsible for designating Agency T-Card/CBA Program Administrators and for notifying the Office of State Purchasing and Travel of any changes.

DECLARED EMERGENCY USE

In the event the Governor declares a state of emergency, the T-Card may be changed to allow higher limits and opening of certain MCC codes for essential employees who are cardholders that would be active during an emergency situation and not for ALL cardholders. An emergency profile must be created in WORKS which shall not exceed the following limits, without prior approval from Office of State Purchasing and Travel: SPL (single purchase limit) \$25,000, Travel and Rest MCC Groups may be removed if determined to be necessary for group accommodations however, the Cash MCC Group must remain attached to the profile at all times, as the use of cash is never allowed, even during emergency situations.

Higher limits do NOT eliminate the need to follow emergency procurement rules, policies, procedures and/or executive orders.

DEFINITIONS

1. Approver - individual within the agency who is responsible for verifying that all charges against the cardholder's account are authorized and supported by adequate documentation. This may or may not be the cardholder's direct supervisor.
2. CBA (Controlled Billed Account) – a credit account issued in an agency's name (no plastic cards issued). These accounts are direct liabilities of the State and are paid by each agency. CBA Accounts are controlled through an authorized approver(s) to provide means to purchase any allowed transactions/services allowed in the current State Liability Travel Card and CBA Policy. Please realize that although other travel related charges are now allowed on the CBA account, the traveler needs to ensure that the actual "plastic" is not necessary, as there is no plastic issued for a CBA Account.
3. Cardholder - employee whose name appears on the card and who is accountable for all charges made with the card.
4. Cardholder Agreement Form - an agreement signed by the cardholder, prior to being issued a Travel Card, which verifies that the cardholder has read and understands the policies and procedures of the Louisiana Board of Pharmacy, and agrees to comply with them.
5. Cardholder Enrollment Form - a form containing pertinent information on a cardholder necessary for statement and information mailing purposes, contact information, daily/monthly spending limits and budgetary controls. The form must be submitted by the cardholder to the Program Administrator for completion and approval.
6. Credit Card - a Visa card issued by Bank of America for State of Louisiana for the purpose of making authorized purchases on behalf of the Louisiana Board of Pharmacy.
7. Cycle – the period of time between billings. For example the State of LA t-Card closing period ends at midnight the 8th of each month.
8. Cycle Limit – maximum spending (dollar) limit a T-Card/CBA is authorized to charge in a cycle. These limits should reflect the individual's purchasing patterns. These are preventative controls and, as such, should be used judiciously.
9. Denied Item - a purchase that has been determined by the Supervisor/Reviewer as a non work related purchase and not acceptable for payment. This item must be returned for a credit memo or must if not returnable, employee must reimburse the Department. Continued purchases of this type will result in disciplinary action.
10. Disputed Item – any transaction that was double charged; charged an inaccurate amount, or charged without corresponding good or services by the individual cardholder.
11. Electronic Fund Transfer (EFT) – an electronic exchange or transfer of money from one amount to another, either within the same financial institution or across multiple institutions.
12. Electronic Signature – an electronic sound, symbol or process attached to or logically associated with a record or executed or adopted by a person with the intent to sign the record.
13. Fraud – any transaction, intentionally made that was not authorized by the cardholder or not for Official State Business.
14. Incidental Expense – if travel expenses have been approved, these are expenses incurred while traveling on official state business which are not allowed on the state liability purchasing card. Incidentals include but are not limited to, meals; fees and tips to porters, baggage carriers, bellhops, hotel maids; transportation between places of lodging/airport such as taxi; phone calls and any other expense not allowed in the State Liability Travel Card and CBA Policy.
- 15.

DEFINITIONS (continued)

16. INTELLILINK – Visa’s web-based auditing tool which is used to assist with monitoring and managing the agency’s card program usage to ensure that card use conforms to all policies and procedures.
17. ISIS – State of Louisiana’s integrated system used for accounting, financing, purchasing, and contracting functions.
18. LaGov – State of Louisiana’s newest integrated system used for accounting, financing, logistics, human resources, travel and data warehouse storage and reporting.
19. MCC Code (Merchant Category Code) – a standard code the credit card industry used to categorize merchants based on the type of goods or services provided by the merchant. A merchant is assigned an MCC by the acquiring bank.
20. Merchant Category Code Group (MCCG) – a defined group of merchant category codes. MCCGs are used to control whether or not cardholders can make purchases from particular types of merchants.
21. Merchant – a business or other organization that may provide goods or services to a customer.
22. Billing Statement of Account - a listing of all transactions charged to the cardholder’s account through the end of the monthly billing cycle. This statement is sent by the bank, directly to the cardholder, on a monthly basis for reconciliation purposes. This is not a bill. The cardholder must reconcile this statement upon receipt and forward it to the Approver to accompany transaction documentation at the time of review and approval.
23. Monthly Spending Limit - a dollar limit assigned to the cardholder for the total of all charges made during the monthly billing cycle.
24. PPM 49 (Policy Procedure Memorandum 49) – the state’s general travel regulations. These regulations apply to all state departments, boards and commissions created by the legislature or executive order and operating from funds appropriated, dedicated, or self sustaining; federal funds, or funds generated from any other source.
<http://doa.louisiana.gov/osp/travel/travelpolicy/2013-2014travelguide.pdf>
25. Program Administrator - liaison between the cardholder, Agency Travel Card Administrator, State Program Administrator and Bank of America. Provides support and assistance to all agencies, processes new card applications and changes to cardholder information, provides training and maintains policies and procedures. Maintains user login id and passwords for all agency users. Maintains hierarchal structure for all agency roles.
26. Single Purchase Limit (SPL) – the maximum spending (dollar) limit a T-Card is authorized to charge in a single transaction. The SPL limit may be up to \$5,000; however, this limit should reflect the individual’s purchasing patterns. These are preventative controls and, as such, should be used judiciously. Purchases shall not be split with the intent of and for the purpose of evading the T-Card single purchase limit set for cardholders.
27. T-Card – a credit card account issued in an employee’s name. This account is a direct liability of the State and is paid by each agency.
28. Billing Cycle Purchase Log - Printed from WORKS to document the online reconciliation process for purchases/services charged during the billing cycle. The Billing Cycle Purchase Log is printed and filed with the billing statement and the transaction documentation obtained from the merchant.
29. Transaction – a single purchase. A credit also constitutes a transaction.

DEFINITIONS (continued)

30. Transaction Documentation – all documents pertaining to a transaction, both paper and electronic. The documentation is also used for reconciliation at the end of the billing cycle and is to be retained with the monthly reconciliation documentation for review and audit purposes. Examples of transaction documentation include, but are not limited to: itemized purchase receipts/invoices (with complete item descriptions, not generic such as “general merchandise), receiving documents, credits, disputes, and written approvals. If travel has been approved, documentation should also contain airline exceptions, justifications, approvals, travel authorization, travel expense, etc.
31. WORKS – Bank of America’s web-based system used for program maintenance, card/CBA issuing/suspension/cancellation and reporting.
32. WORKS Workflow – Bank of America’s online system that includes user profiles and transaction workflow. For ISIS and LaGov interfaced agencies, transactions are coded and interfaced to the ISIS/LaGov systems for payment monthly.

Cardholder Enrollment

1. A Cardholder Enrollment Form be completed and signed by the Executive Director for each prospective cardholder. The Executive Director is responsible for assigning cardholder's spending limits per transaction and per monthly cycle which limits the number of transactions allowed for the cardholder. The form should be sent to:
Executive Director
Louisiana Board of Pharmacy
3388 Brentwood
Baton Rouge, LA 70809
mbroussard@pharmacy.la.gov
2. When the Program Administrator receives the new card from the bank, the cardholder will be contacted for training. The prospective cardholder must attend a training session before receiving and using the credit card.
3. Credit cards are not transferable. Use by anyone other than the cardholder is prohibited. The only person authorized to use the card is the person whose name appears on the face of the card. A transaction can only be signed by the cardholder. A receipt may be signed by someone other than the cardholder if it is being used as a delivery receipt for a phone order. In this case the receipt should be signed "Received By" followed by the employee's name accepting the delivery.
4. The Program Administrator must be notified immediately of a cardholder's termination. The cardholder is responsible for return of the credit card to the Program Administrator upon termination of employment. Cardholders who transfer to a new position in the same agency and require the use of the card as part of their new duties must complete a Cardholder Enrollment Form and submit the form to the Program Administrator indicating "Change" on the form.
5. If the card is lost, stolen, or damaged, the cardholder must immediately notify Bank of America at 1-888-449-2273 and the Program Administrator at (225) 925-7771 after reporting the incident to the bank. If the card is located after reported lost or stolen, it must be destroyed.
6. Whenever any information contained on the Cardholder Enrollment Form changes, the changes must be submitted to the Program Administrator on the form with "Change" checked on the form.
7. The cardholder shall submit through their chain of command a Cardholder Enrollment Form indicating "Change" if use of the card has changed and lower or higher limits are necessary.

Supervisor/Approver Responsibilities

1. Obtain annual approver certification through the State's online certification training program in which a passing grade of at least 90 must be obtained.
2. Obtain agency program training and sign an Approver Agreement Form, annually, with originals given to agency program administrator along with approver receiving a copy.
3. Obtain, review and understand the state and agency policies and all applicable rules, regulations, policies, procedures, guidelines, statutes, executive orders and PPM49, if applicable.
4. Keep well informed of program updates as sent from agency program administrators or anyone associated with the State Liability T-Card Program.
5. Ensure that a log is completed by each cardholder, that the log corresponds with the monthly billing statement and that the log and statement are signed by both approver and the cardholder.
6. Always submit approvals with all necessary documentation including complete line item descriptions where generic description is on receipts such as "general merchandise" (both paper and electronic) in a timely manner.
7. Ensure that supporting documentation, including the signed log or approved electronic log and signed statement, by both approver and the cardholder, along with any findings and justifications are sent to the agency's fiscal office for review, where the documentation will be maintained in one central location, in accordance with the state's requirements and the agency's policy.
8. Immediately report any fraud or misuse, whether actual, suspected or personal charges to the agency program administrator, as well as, agency head and other personnel/agencies as required. An approver will participate in any disciplinary actions which may be deemed appropriate, if necessary.
9. Notify an agency program administrator, immediately, upon separation, change in department/section or during extended leave for any cardholders in which you are the approver.
10. Complete an exit review, with the cardholder, of the cardholder's transactions, supporting documentation and receipts, as well as, obtaining necessary signatures prior to departure.
11. Ensure that the T-Card is obtained from the employee upon separation or change in department/section and return card to agency program administrator. Ensure that agency program administrator makes necessary changes to cancel the card and to remove approver as the employee's approver and/or employee from the list of cardholders for which approver is responsible.
12. Ensure that either approver or the cardholder notifies the agency program administrator if card is lost, stolen or has fraudulent charges. Ensure the cardholder immediately notifies the bank as well.
13. Review, at a minimum annually, all cardholders which approver is designated as an approver along with profile limits to ensure appropriate utilization of the card and program intent. This will ensure that all cardholders limits, MCC Codes, etc., are working properly for the cardholder. If limits or codes are not allowing the cardholder to perform his duties, then approver should contact the agency program administrator to make necessary adjustments.
14. Ensure that cardholder is never a final approver of his own monthly transactions.
15. Ensure each transaction, to the best of approver's knowledge:

- Has an appropriate business purpose, fits the cardholder's business needs, and is audited including a review of all supporting documentation.
 - Is in compliance with all current purchasing rules and regulations, statutes, executive orders, policies and PPM49, if applicable.
 - Is in compliance with the board's policy and the State Liability Travel Card and CBA Policy, if applicable.
 - Does not include state tax, as this program is state tax exempt.
 - Includes all required and complete documentation, including a detailed receipt, supporting the transaction and all documentation is scanned into Workflow and tied to the appropriate transactions.
 - Is not a duplication of personal request and/or reimbursements, if for travel related expenses.
 - Has been verified to ensure that each transaction has a receipt and the receipt's date, supporting documentation and documentation dates, along with the log dates, correspond with known business needs or trip allowances and dates, if applicable and travel has been approved, along with program cycle dates (which begin the 8th of one month and ends the 9th of the following month).
 - Has been coded properly for payments as outlined in the agency policy and procedures and as required in Workflow for ISIS and LaGov interfaced agencies.
16. Secure all assigned WORKS application User IDs and passwords. Never share User ID and passwords and/or leave the work area while logged into the system or leave log-in information lying in an unsecure area.
17. Ensure Ebay, Paypal, Amazon, etc are tied to business accounts and are legitimate state business related purchases.
18. Understand that failure to properly fulfill responsibilities as a T-Card approver could result, at a minimum, in the following:
- Written counseling which would be placed in employee file for a minimum of 12 months.
 - Consultation with agency program administrators, and possibly head of agency and internal audit section.
 - Disciplinary actions, up to and including termination of employment.
 - Legal actions, as allowed by the fullest extent of the law.

A. Audit Reports

State Purchasing has created a list of reports created for agencies to use for monthly audit requirements of this program through WORKS and Intellilink. Some reports are required to be generated and reviewed at least once a month, while others have been created and designed as added value to assist in policy compliance. Although all of the reports are not required monthly, agencies are strongly encouraged to determine which of the reports are of the most value to them and should consider rotating them, at a minimum every other month.

When running these reports, it is the agency's responsibility to not only review the data gathered, but to make certain that transactions are for a business purpose and have a legitimate business need for the cardholder. In the event that a transaction is being investigated, the cardholder must explain and justify the transaction being questioned.

Supervisor/Approver Responsibilities (continued)

Based on the cardholder's explanation, the agency should address the situation accordingly.

All documentation/findings/replies, resulting from the monthly audit of T-card transactions, are to be centrally located and readily available for any internal or external audits that may occur. Most reports are available through VISA Intellilink. Intellilink's data is available for a 27 rotating month period. If an agency requires documentation retention for more than 27 months, it is the responsibility of the agency to obtain and archive the transaction data accordingly.

Monthly certification that the above procedures have been conducted must be submitted to the Office of State Travel. The certification will indicate that agency personnel administering the T-card program have generated the required reports, all requirements listed in the policy have been completed, and necessary findings have been investigated, documented and handled appropriately.

In addition, reports shall be used as a tool to assist the agency program administrator/agency with determining which cardholders may need a refresher training course, re-certification of the state's online training, counseling, cancellation of card, due to inaccuracies, etc., as well as, to determine possible changes to cardholder's limits, profiles, and MCC groups.

When WORKS Workflow implementation has been completed, a Billing Cycle Purchase Log report will be available for print. It is an un-editable, PDF, formatted report. The WORKS Workflow system data is generated at the time of report request with the most current signoff information with the date and time stamp of the approval captured in the audit tracking along with all documentation which has been scanned to support T-Card transactions and tied to the appropriate transaction. Always ensure that the correct cycle period/dates are entered when printing the log report. Cycle dates for the program begin on the 8th of one month and ends on the 9th of the following month.

Once an agency has implemented WORKS Workflow, there are additional reports that can be created to give cardholder approvers, accountants, agency program administrators, auditors, and management information to monitor the compliance of their cardholders and staff. Data is available electronically within WORKS Workflow for up to 3 years. If an agency requires documentation retention for more than 3 years, it is the responsibility of the agency to obtain and archive the transaction data annually.

Cardholder Responsibilities

1. Use T-Card for official state business only. No personal use. T-Card is limited to the person whose name is embossed on the card. The T-Card shall not be used to pay for another or loaned to another person to pay for official or non-official business expenses.
2. Attend required agency training and sign a State Corporate Liability Cardholder Agreement Form, annually, acknowledging cardholder's responsibilities prior to receiving the card.
3. Obtain annual cardholder certification through the State's online certification training program receiving a passing grade of at least 90 to possess or continue to possess a State of Louisiana T-Card.
4. Never include the full T-Card account number in emails, fax, reports, memos, etc. If an account number is necessary, only the use of the last four or eight digits of the account number is allowed.
5. Secure assigned WORKS application User IDs. Never share User ID and password and/or leave work area while logged into the system or leave log-in information lying in an unsecure area.
6. Recognize that the T-Card is the property of the State of Louisiana and the cardholder is responsible for the physical security and control of the T-Card and its appropriate use. The Cardholder is also responsible for maintaining the security of card data such as the account number, the expiration date, and the card verification value (CVV), the 3-digit security code located on the back of the card.
7. Never send a copy of the T-Card if requested by a merchant. If this is required for payment, then the cardholder must use another form of payment other than the State Liability T-Card.
8. Never use an individual T-Card for personal, non-business expenses for any reason.
9. Never pay taxes on purchases with this card, since it is a state liability. See Section 6.
10. Never, under any circumstances, use the T-Card to access or attempt to access cash.
11. Never accept cash in lieu of a credit to the T-Card account.
12. Never use T-Card for gift cards/gift certificates, without prior approval from the Office of State Purchasing and Travel, as they are considered cash and taxable.
13. Never use T-Cards to avoid procurement or payment procedures.
14. Never use the T-Card for the purchase of alcohol, food, travel expense transactions or entertainment services. The only exceptions are vehicle rentals.
15. Never use T-Card for fuel or vehicle maintenance if agency is part of the Fuel Card and Maintenance Program.
16. Submit all required transaction documentation (both paper and un-editable electronic format), special approvals, etc., timely. Remember, every transaction must have a receipt with a full description, not a generic description such as "general merchandise" or item should be fully documented/described elsewhere (both paper and un-editable electronic format). Failure to do so should result in cancellation of T-Card. All paper supporting documentation, including the signed log or approved electronic log and signed memo statement, along with any findings and justifications is to be scanned into Workflow and tied to each applicable transaction. All mentioned above, will be sent to the supervisor/approver for required audit and signatures, and forwarded to the agency's fiscal office for review and file maintenance.

Cardholder Responsibilities (continued)

17. **NEVER MAKE A PAYMENT DIRECTLY TO THE BANK** in the event that an unauthorized charge is placed on the individual's state corporate liability T-Card. Making a payment directly to the bank will cause the monthly statement billing file to be out of balance, and the agency will have to determine the cause. Ultimately, it will be determined that a personal payment was made. In order to avoid this situation, report any unauthorized charges to the agency's program administrator immediately, along with decision on how the funds will be reimbursed back to the agency.
18. Notify the agency's program administrator if fraudulent charges are noticed, as the card may need to be cancelled and another card issued.
19. Notify the agency's program administrator if use of a card has changed and lower or higher limits are necessary.
20. Responsible for requesting additional training if the use of the online Works system proves to be difficult to master
21. Agrees to reimbursement of unauthorized charges by personal check or payroll deduction.
22. Makes purchases for which the cardholder has been authorized to spend and does not exceed their single transaction limit.
23. Card declines due to exceeding monthly or single transaction limit may result in cancellation of the card. (See Card Misuse section).
24. Online accounts such as Ebay, Paypal, Amazon, etc must have a standalone business account or registration and must not be combined with an individual's personal account.
25. Cardholder's business email address must match the cardholder's name.

Making a Purchase

Merchants Category Codes (MCC) have been developed and built into the card. These codes authorize the types of goods and/or services for which individual cards may be used (i.e. office supplies). A list of Merchants Category Codes is furnished to cardholders. Included in the list are prohibited and restricted codes. Cardholders are prohibited from attempting to purchase from the prohibited or restricted merchants unless the Department has obtained prior approval from the Office of State Purchasing and Travel.

LBP – Louisiana Board of Pharmacy purchasing procedures will remain the same. Procedures for making card purchases:

1. Obtain necessary approvals to purchase through proper chain of command.
2. When making purchases in person, the cardholder must sign the charge receipt and retain the customer copy or proper documentation of the purchase. Cardholder should be certain that the total amount of the purchase (including shipping, handling, postage, freight, etc.) does not exceed the card's single transaction dollar limit.
3. State sales tax should not be charged on card purchases.
4. When making a purchase other than in person (e.g. via telephone, computer, mail order, etc.), the cardholder should give the vendor the account number and tax exempt number (both of which are embossed on the card) and direct the vendor to include the following on the shipping label or packing slip.
 - Cardholder name and telephone number
 - Department name
 - Complete delivery address
 - VISA purchase
5. For items such as subscriptions and registrations, where the vendor does not normally generate a receipt or packing slip, a copy of the ordering document may be used. Acceptable documentation must include a line description and line item pricing for the purchase or the item will not be reimbursed.
6. The cardholder must maintain a file of transactions including document purchase type (telephone, computer, mail order, etc.) to facilitate monthly reconciliation. The cardholder will be solely responsible for reconciling his statement with the database.
7. In the event the Central Warehouse receives a shipment on behalf of the cardholder, Central Warehouse personnel will notify the cardholder of receipt. The cardholder will be responsible for retaining all documentation (shipping labels, packing slips, etc.) related to the purchase.
8. The cardholder will maintain a permanent file of all supporting documentation for card purchases, in accordance with state laws. The documentation is subject to review by LBP, the Legislative Auditor and other duly authorized auditors. The file must be maintained for a period of 3 years. If the purchase is for a grant funded project, the cardholder is responsible for ensuring the documentation is maintained for the appropriate required retention schedule.

Making a Purchase (continued)

Merchandise Returns & Exchanges

1. The cardholder is responsible for contacting the merchant when merchandise purchased with the card is not acceptable (incorrect, damaged, defective, etc.) and arranging for the return for credit or exchange.
2. If the merchandise is to be exchanged, the cardholder is responsible for returning the merchandise to the merchant and obtaining a replacement as soon as possible. Documentation of the resolution of the exchange is to be retained with the support documentation of that purchase.
3. If the merchandise is returned in person, the cardholder is responsible for obtaining a credit receipt from the merchant and retaining the receipt with the support documentation. If the merchandise is shipped back to the supplier, prepare the package according to supplier instructions and retain shipping documents until supplier issues a credit or exchanges merchandise. Supplier must issue credit to the card. Receiving cash or checks to resolve a credit is prohibited.

State Corporate Business Account (CBA) Requirements/Guidelines

1. All CBA transactions must be in accordance with PPM49 guidelines, State Liability Travel Card and CBA Policy, Purchasing Policies, Rules and Regulations, Board policy, Louisiana Statutes and/or Executive Orders.
2. The purpose of a CBA is to provide a tool for agencies to purchase airfare, conference registrations and assist with payment of high dollar travel expenses only, as per current State Liability Travel Card and CBA Policy. Please realize that although other travel related charges are now allowed on the CBA account, the traveler should be aware that there is no plastic issued for a CBA to ensure that this will not impair his travel plans.
3. The account(s) are issued in the name of the agency and the agency program administrator is the primary point of contact for administering the accounts. The agency may designate an administrator/authorizer per account. Each administrator has the same duties, obligations and responsibilities as a cardholder. The contract travel agency must be notified of authorizers for each CBA account.
4. CBA account(s) shall have an overall card cycle limit determined by the agency. These limits should reflect the agency's travel patterns. Therefore, these limits must be judiciously established by the agency and adhered to accordingly. The agency Program Administrator may establish a new or additional CBA account through Bank of America's on-line system, WORKS.
5. The CBA accounts are the direct liability of the State. Each agency is responsible for ensuring all accounts are paid timely and in full each month with ONE electronic funds transfer (EFT) to Bank of America.
6. CBA accounts do not allow issuance of a plastic card. These are referred to as ghost accounts. If it is determined that personal or other unauthorized charges are occurring on the CBA account, appropriate steps, up to and including dismissal, shall be taken to resolve the misuse/abuse of the account.
7. The full CBA account number shall never be included in emails, fax, reports, memos, etc. If an account number is necessary, only the use of the last four or eight digits of the account number is allowed.
8. All persons with approval for use of travel on their T-Card shall follow the Statewide Travel card policy and procedures and PPM49.

Reconciliation

Agency procedures and controls are in place for prompt payment, reconciliation and cost distribution of charges and credits. Post audits of cardholder transactions will be performed to monitor the number and dollar amount of purchases made; vendor used, and detailed transaction information to properly allocate the cost.

1. The paper billing statements from Bank of America will be mailed directly to each cardholder at the business address. The cardholder must reconcile purchases made during the billing cycle by matching the billing statement to the online transaction log in WORKS, along with the cardholder's supporting documentation (receipts). The documentation (receipts) will be reviewed and certified by the cardholder as received OR reported as a disputed item if the receipt does not match the transaction online information. The cardholder shall allocate the expense to the appropriate budget categories and sign off electronically in WORKS on each transaction by the 8th of the month. This information will be queued for supervisory review and approval.
 - If a charge or credit does not appear on the statement within 60 days after the original charge or credit was made, the cardholder must notify the Program Administrator.
 - Incorrect charges are disputed online in the WORKS system.
2. The Approver must review the information in WORKS, along with the documentation submitted by the cardholder. Approver must verify that acceptable documentation exists (including line item description, price and coding) to support each purchase and/or credit, verify that purchases are for official state business, and that purchases comply with appropriate rules and regulations. The Approver shall approve the log by signing off in WORKS to certify his review and approval. A cardholder shall not, and cannot, approve his own monthly purchasing log in WORKS. The WORKS transaction log must be reviewed and approved (signed off) by the Approver for the previous billing cycle by the 11th of the month.

Once approved and returned to the cardholder, the cardholder shall print a copy of the Billing Cycle Purchase Log to file with the billing statement and transaction documentation. This log will document the electronic approvals and coding in addition to the electronic approvals tracked within WORKS online system.

Note: If the Approver determines that personal or unauthorized charges are made on the card, the transaction is "flagged" in WORKS, which returns it to the cardholder, with a comment, for resolution. If repeated issues occur, appropriate steps shall be taken to resolve the misuse/abuse of the card. When an unapproved item was purchased and it is discovered during review, the item should be returned for a credit memo. If the item is nonrefundable, the employee must reimburse the Department for this purchase.

Reconciliation (continued)

3. If a cardholder's transactions are not signed off timely, the card balance will not be fully refreshed to the full monthly credit limit until all transactions are completed (signed-off) for all previous cycles.
4. All supporting documentation, including the signed log or approved electronic log and signed memo statement, by both cardholder and approver, along with any findings and justifications, must then be forwarded to the agency's fiscal office for review and maintenance of the file. Once all approvals and audits by cardholder approvers have been obtained and forwarded to the agency's fiscal office, the agency's fiscal office must review receipts in the program journal vouchers to correct any necessary coding changes.

Card Misuse

1. **Fraud Purchase** – any use of the T-card/CBA which is determined to be an intentional attempt to defraud the state for personal gain or for the personal gain of others.

An employee suspected of having misused the T-Card/CBA with the intent to defraud the state will be subjected to an investigation. Should the investigation result in findings which show that the actions of the employee have caused impairment to state service, and should those findings be sufficient to support such action, the employee will be subject to disciplinary action. The nature of the disciplinary action will be at the discretion of the Entity's Appointing Authority and will be based on the investigation findings and the record of the employee. Any such investigation and ensuing action shall be reported to the Legislative Auditor, the Office of Inspector General and the Director of the Office of State Purchasing and Travel.

2. **Non-Approved Purchase** – a purchase made by a State cardholder for whom payment by the state is unapproved. A non-approved purchase differs from a fraud purchase in that it is a non-intentional misuse of the T-card/CBA with no intent to deceive that agency for personal gain or for the personal gain of others.

A non-approved purchase is generally the result of a miscommunication between a supervisor and the cardholder. A non-approved purchase could occur when the cardholder mistakenly uses the T-card/CBA rather than a personal card.

When a non-approved purchase occurs, the cardholder should be counseled to use more care in handling of the T-card/CBA. The counseling should be in writing and maintained in the employee's file for no longer than one year unless another incident occurs. The employee shall pay for the item purchased inappropriately. Should another incident of a non-approved purchase occur within a twelve (12) month period, the appointing authority should consider revocation of the T-card/CBA.

3. **Same Vendor/Same Day (Split Purchasing)** – A split purchase occurs when a cardholder purchases like commodities within a limited time frame, while exceeding the single purchase limit set for cardholder. Purchases shall not be artificially divided to avoid the single purchase limit (SPL) or procurement procedures.
4. **Merchant Forced Transaction**-Commercial cards are accepted by a variety of merchants that process transactions only if approved by the issuing bank thereby abiding by the card controls in place. Merchant transactions are processed using one of the 2 steps as follows:
 1. Merchants process transactions against card controls (MCC, limits, expiration date, etc.) and, if approved, receive an authorization number.
 2. Merchants submit the transactions for payment from the bank.
 3. In rare instances, merchants will circumvent the authorization process and only perform step 2. This means that the merchant didn't process the transaction against the card controls and therefore did not receive an authorization number.

Card Misuse (continued)

4. If this happens, the merchant has forfeited all dispute rights and the transaction can be disputed and unless the merchant can provide a valid authorization number, the dispute will be resolved in the cardholders favor.

5. Card and WORKS User ID/Password Security

Each cardholder, CBA administrator, agency program administrator, auditor, cardholder approver, etc is responsible for the security of their card, User ID(s) and password(s), and therefore should:

- Never display their card account number, WORKS and WORKS Workflow User ID numbers and passwords around their work area
- Never share User IDs and passwords and/or leave work area while logged into the system or leave log-in information lying in an unsecure area
- Never give his or her card account number, User IDs or passwords to someone else
- Never email the full account numbers or User IDs numbers or passwords under any circumstances

Consequences of Card Misuse

- Suspension/cancellation of card
- Written counseling which would be placed in employee file for a minimum of 12 months
- Consultation with agency program administrators, and possibly head of agency and internal audit section
- Disciplinary actions, up to and including termination of employment.
- Legal actions, as allowed by the fullest extent of the law.

Sales Tax

1. LA state sales tax should not be charged on card purchases.
2. In the event state sales tax is charged and a credit is warranted, it will be the cardholder's responsibility to have the vendor (not Bank of America) issue a credit to the cardholder's account.
3. It is State Policy not to pay LA sales tax; however, the Agencies may exempt cardholders from obtaining a credit from the vendor for the state sales tax charges of \$25.00 or less. If a cardholder continually allows taxes of \$ 25.00 or less to be charged to the card, corrective measures must be taken. It is the Agency's responsibility to monitor these sales tax transactions to ensure corrective action is taken against repeat offenders.
4. See current State Liability Travel card and CBA Policy for travel exemptions

Documentation

1. Ensure that documentation is adequate and sufficient to adhere to current purchasing policies, rules, regulations, statutes, executive orders, State Travel Card and CBA Policy, for recording of expenditures in the State/Agency accounting system and the State Liability Travel card and CBA Policy and PPM49, if applicable. The agency must ensure that all supporting documentation along with receipts are scanned and attached to each corresponding transaction. Agencies should ensure that immediate supervisors/approvers are verifying and ensuring that these controls are being met and that transactions are appropriate, accurate, have a business case and business need for the purchase, all receipt dates and other supporting documentation dates are applicable with known need or business travel, if applicable, and approved. Documentation of approval must be accomplished electronically online by signing off on the transaction. Approval by the approver certifies that the documentation is acceptable for each transaction, that it was for official state business, that it is in compliance with appropriate rules and regulations, etc., as mentioned above and that it has been reviewed and is approved.
2. Documentation is required for all purchases and credits. For items purchased over the counter, the cardholder should obtain the customer copy of the receipt. When ordering by telephone, fax, or computer, the cardholder must obtain a packing list or similar document. For items such as registrations, where the vendor does not normally generate a receipt or packing slip, a copy of the ordering document may be used. Acceptable documentation must include a line description, with full description not a generic "general merchandise" description, and line item pricing for the purchase. Electronic receipts are allowed if they are un-editable and are maintained in compliance with the agency retention policy.
3. For internet purchases, the print out of the order confirmation showing the details, or the printout of the order details, or the shipping document if it shows what was purchased, the quantity and the price paid suffice for the itemized receipts.
4. The agency cardholder approvers will forward all supporting documentation along with invoices, receipts and signed paper or approved electronic log, by both cardholder and approver, and signed statement, by both cardholder and approver, and any findings and justifications to the agency's fiscal office for review and for maintenance of the files in accordance with record retention laws. This file must be centrally located in the agency's fiscal office and will be subject to review by the Office of State Purchasing and Travel, the Louisiana Legislative Auditors Office and any other duly authorized auditor.
5. All system entries and scanned supporting documentation, when utilizing Workflow and electronic approvals are maintained electronically within the WORKS Workflow online system for up to 3 years. If an agency requires documentation retention for more than 3 years, it is the responsibility of the agency to obtain and archive the transaction data annually. If the purchase is for a grant funded project, the cardholder is responsible for ensuring the documentation is maintained for the appropriate, required retention schedule.

Dispute Resolution

The cardholder's first recourse is to contact the merchant to try and resolve problems regarding disputed items, charges or quality.

1. If the merchant agrees the error has been made, he will credit the cardholder's account. The credit will appear on the next monthly billing statement. The cardholder should check the next statement for the credit.
2. If the problem with the vendor is not resolved, notice of the dispute must be communicated to bank within 60 days from the billing close date (5th of each month) to:

Bank of America-Commercial Card Service Operation
P.O. Box 53142
Phoenix, AZ 85072-3142
Phone (800) 352-4027 Fax (888) 678-6046

A copy of the dispute form should be faxed to the Program Administrator at (225) 925-6510.

3. The transaction will be paid; therefore, it is important for the cardholder to mark the online WORKS transaction as "DISPUTED." The cardholder should retain a copy of the disputed documentation and verify receipt of the credit on future statements.
4. All disputes will be resolved by Bank of America within 180 days.

Fraudulent Charge

In the event of a fraudulent charge, the cardholder shall complete the following steps:

- Contact the Bank of America's Security Division at (877) 451-4602. Sign and return the affidavit provided by Bank of America. Notify the Travel Card Program Administrator (225) 925-6498 of the fraudulent charge. Submit a copy of the fraudulent charge affidavit to the Travel Card Program Administrator. Indicate the fraudulent charge in the comment section of the transaction during online reconciliation in WORKS.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Assistant Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Prescription Monitoring Program


Board Meeting
February 25, 2015

Joe Fontenot, R.Ph. Assistant Executive Director
Danielle C. Meadors, Administrative Assistant

Number of Eligible Transactions Reported to the PMP

Total Reported as of
December 31, 2014


81,093,677




Prescriber & Pharmacist Access

(as of December 31, 2014)

Prescribers – Total
Authorized 5,575




Pharmacists – Total
Authorized 3,184



Combined totals – 8,759

Prescriber & Pharmacist Queries – 2014

Overall Query total = 1,430,248



Prescriber & Pharmacist Queries


(01/01/2009 through 12/31/2014)

Overall Query total = 4,957,625



Board and Regulatory Agencies

Profile Views by Boards & Regulatory Agencies Total = 8,469
(01/01/2009 through 12/31/2014)



Law Enforcement Access and Requests

Number of Law Enforcement
Requests Processed = **6,018**
(01/01/2009 through 12/31/2014)

2009	2010	2011	2012	2013	2014
680	889	1,230	845	1,150	1,224

Requests for Exemption from PMP Reporting February 25, 2015

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
7015	HOS	Acadia General Hospital		Yes	Crowley	LA
7045	NR	American Homecare Federation	Specialty Pharmacy	Yes	Enfield	CT
6888	NR	AnovoRx Group	Specialty Pharmacy	Yes	Memphis	TN
6898	NR	Arriva Pharmacy		Yes	Lakeland	FL
6970	HOS	Brentwood Hospital	Inpatient Hospital Pharmacy	Yes	Shreveport	LA
7062	NRN	Cardinal Health 414		No	Indianapolis	IN
6015	IR	Carmichael's LTC of Crowley		Yes	Crowley	LA
6051	IR	Carmichael's Pharmacy IHP		Yes	Lake Charles	LA
6244	HOS	Christus Schumpert Medical Center Pharmacy	Inpatient Hospital Pharmacy	Yes	Shreveport	LA
6840	NR	Complete Medical Homecare	Diabetic Pharmacy	Yes	Lenexa	KS
6842	IR	HaloCare Specialty Therapeutics	Specialty Pharmacy	Yes	Denham Springs	LA
6692	HOS	Louisiana Continuing Care Hospital	Inpatient Hospital Pharmacy	Yes	Marrero	LA
3996	HOS	Madison Parish Hospital Pharmacy	Inpatient Hospital Pharmacy	Yes	Tallulah	LA
5105	CH	NW LA Interfaith Pharmacy	Charitable Pharmacy	No	Shreveport	LA
7028	NR	Onco360		Yes	Buffalo	NY
6853	HOS	Our Lady of the Angels Hospital	Inpatient Hospital Pharmacy	Yes	Bogalusa	LA
6854	IR	Our Lady of the Angels Hospital Outpatient Phy		Yes	Bogalusa	LA
6484	IR	Restore Rx	Specialty Pharmacy	Yes	Brunswick	TN
5967	HOS	Specialty Hospital of Winnfield	Inpatient Hospital Pharmacy	Yes	Winnfield	LA
6331	HOS	St. Martin Hospital Pharmacy	Inpatient Hospital Pharmacy	Yes	Breaux Bridge	LA
6932	HOS	University Health Conway	Inpatient Hospital Pharmacy	Yes	Monroe	LA
6192	HOS	Winn Parish Medical Center Pharmacy	Inpatient Hospital Pharmacy	Yes	Winnfield	LA

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

WAIVER TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS CONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy's request for a waiver to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of hospital inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this waiver and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.

Danielle Clausen

From: Roteff, James <jamesr@lgh.org>
Sent: Wednesday, December 24, 2014 10:09 AM
To: Danielle Clausen
Subject: PMP

Danielle, I would like to request to be exempt from reporting to PMP. As of June 1 2014 American Legion Hospital was bought out by Lafayette General Health. At that time our reporting software was removed because we were no longer self insured and no further prescriptions were filled. Currently we are Acadia General Hospital permit# PHY.007015-HOS and do not fill any type of retail prescriptions at all. Thanks.

James Roteff P.D., M.B.A.
Director of Pharmacy
Acadia General Hospital
1305 Crowley-Rayne Hwy
Crowley, La. 70526
Tele: 337-788-6536 Fax: 337-788-6533

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited.

Danielle Clausen

From: Joe Fontenot
Sent: Thursday, January 22, 2015 5:04 PM
To: Danielle Clausen
Subject: FW: PDMP Reporting Exemption

Waiver request for the February Board meeting.

From: Jennifer Sacco [<mailto:JSacco@ahfinfo.com>]
Sent: Wednesday, January 21, 2015 3:13 PM
To: Joe Fontenot
Subject: PDMP Reporting Exemption

Hello,

My name is Jen Sacco and I am a pharmacist at American Homecare Federation, Inc. (AHF, Inc.) (LA permit PHY.007045-NR, 31 Moody Road Enfield CT 06083). Our DEA number is FA4345535.

AHF is a specialty pharmacy for bleeding disorders, focusing on hemophilia, licensed in 45+ states nationwide. We mainly dispense recombinant and plasma derived factor products and little to no controlled substances. Since we do not, nor do we plan to, dispense any controlled substances to Louisiana residents, I was hoping to be able to complete a waiver/exemption form from reporting.

Thank you very much for your time and please feel free to contact me with any questions!

Best Regards,
Jen

Jennifer Sacco Pharm.D.

jsacco@ahfinfo.com | ahfinfo.com | diplomat.is


p: 800.243.4621, ext. 1112 | c: 413.244.5888 | f: 860.763.7022



"Take good care of patients, and the rest falls into place."

— DALE HAGERMAN, DIPLOMAT CO-FOUNDER

Confidentiality Statement: This electronic message is intended only for the individual or entity to which it is addressed. It may contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify us immediately by email or telephone at 800.243.4621. Thank you.





To: Board of Pharmacy
From: AnovoRx Group, LLC
NABP 444-5640

Re: Credentialing Update
Continued Qualification for PDMP Waiver

AnovoRx Group, LLC ("Anovo") respectfully informs you that AnovoRx Group, LLC continues its business model of NOT dispensing controlled substances.

Despite having a DEA registration, AnovoRx continues to qualify for an exception from prescription drug monitoring program requirements. AnovoRx Group's pharmacist in charge hereby swears and attests in front of a notary that:


1. Anovo does not purchase or possess controlled substances or any drugs that are classified as restricted drugs by your state.
2. Anovo does not in the future intend to purchase or possess controlled substances or any drugs that are classified as restricted drugs by your state.
3. Anovo does not now, nor has it ever, nor does it intend in the future, to dispense, ship or deliver controlled substances or any drugs that are classified as restricted drugs by your state.
4. Anovo does not now, nor has it ever, nor does it intend in the future, to dispense, ship or deliver into your state controlled substances or any drugs that are classified as restricted drugs by your state.
5. Anovo is a specialty pharmacy that limits its inventory to specialty drugs and drugs to treat certain disease states, and its business model does not include providing controlled substances.
6. Anovo will notify your Board of Pharmacy of any change in circumstance that should result in Anovo possibly dispensing a controlled substance into your state.

AnovoRx acquired the DEA registration, a copy of which is enclosed, for the sole purpose of meeting state Medicaid provider participation requirements. Some state Medicaid programs require pharmacy providers to have a DEA registration, even if the pharmacy will not dispense controlled substances.

Sincerely,

A handwritten signature in black ink, appearing to read "Brian A. Burford". The signature is fluid and cursive, written over a white background.

Brian A. Burford
Pharmacist-in-Charge
AnovoRx Group, LLC



ANOVORX GROUP, LLC
 SUITE 1
 1710 N SHELBY OAKS DRIVE
 MEMPHIS, TN 38134-7403-000



DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA4404721	06-30-2017	\$731
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3N,	RETAIL PHARMACY	03-11-2014
ANOVORX GROUP, LLC SUITE 1 1710 N SHELBY OAKS DRIVE MEMPHIS, TN 38134-7403		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
 UNITED STATES DEPARTMENT OF JUSTICE
 DRUG ENFORCEMENT ADMINISTRATION
 WASHINGTON D.C. 20537

Sections 304 and 1008 (21 USC 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
 UNITED STATES DEPARTMENT OF JUSTICE
 DRUG ENFORCEMENT ADMINISTRATION
 WASHINGTON D.C. 20537

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA4404721	06-30-2017	\$731
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3N,	RETAIL PHARMACY	03-11-2014
ANOVORX GROUP, LLC SUITE 1 1710 N SHELBY OAKS DRIVE MEMPHIS, TN 38134-7403		

RECEIVED

JAN 28 2015

LA BOARD OF PHARMACY

Sections 304 and 1008 (21 USC 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (4/07)



4252 NW 120th Avenue
Coral Springs, Florida 33085

P: 800-700-4442
F: 954-607-5741

January 7, 2015

Arriva Medical, LLC
500 Eagles Landing Drive
Suite B
Lakeland, FL 33810
(866) 336-4103

LA License Number: PHY.006898-NR
DEA Registration: FA4338441

RE: Exemption/Waiver Request for Arriva Medical, LLC.

To Whom It May Concern,

Please accept this written letter as a formal request for prescription drug monitoring exemption. Arriva Medical, LLC., does not stock or dispense controlled substances and wishes to obtain an exemption status for zero reporting.

Arriva Medical, LLC., is a full service pharmacy but we do not stock or dispense controlled substances.

Thank you for your consideration.

Sincerely,

Tamara Estrill-Lett, R.Ph.

12/30/2014

To: Louisiana Board of Pharmacy

From: Brentwood Behavioral Health Hospital

1006 Highland Ave. Shreveport, LA 71101

Pharmacy Permit- PHY.006970-HOS

DEA- FB4880010

Scope of Practice- Inpatient Pharmacy

I am writing this letter to request an exemption from the PMP program. Brentwood Behavioral Health operates in its entirety as an inpatient hospital, and does not as such fall within the definition of "dispenser" as stated in regulation 2901.

This institution does not and neither intends to dispense controlled substances or any other drug as out- patient prescriptions.

Thank you for your assistance in this matter.

Kawanda Williams, Pharm D

Pharmacist in Charge



February 2, 2015

cardinalhealth.com

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809

Re: request for exemption from controlled substance reporting

Louisiana license# PHY.007062-NRN
Cardinal Health 414, LLC
7920 Georgetown Rd., Suite 100
Indianapolis, IN 46268-5632

Dear Board,

Please allow this letter to serve as a request for exemption from controlled substance reporting.

The Cardinal Health Nuclear Pharmacy listed above does not dispense or maintain an inventory of controlled substances. In addition this pharmacy does not possess a DEA license.

Please remove the Cardinal Health pharmacy (PHY.007062-NRN) from the reporting requirement.

Sincerely,

A handwritten signature in blue ink that reads "Dawn Harmon".

Dawn Harmon, Licensing Administrator
Cardinal Health 414, LLC
Nuclear Pharmacy Services
Q&R Department
7000 Cardinal Place
Dublin, OH 43017
Tel (614) 757-7570
Fax (614) 652-4203
Dawn.Harmon@cardinalhealth.com



Danielle Clausen

From: Joe Fontenot
Sent: Friday, December 19, 2014 10:58 AM
To: Danielle Clausen
Subject: FW: Inpatient Activity PMP Waiver Request

Please add to the Board agenda.

From: Jon Lopez [<mailto:lcpharmacy@carmichaelsmed.com>]
Sent: Friday, December 19, 2014 10:13 AM
To: Joe Fontenot
Cc: lrc@carmichaelsmed.com; 'Byron D. Finn'; 'Nick Guillory'; henryh@carmichaelsmed.com
Subject: Inpatient Activity PMP Waiver Request

Joe,

We have 2 Pharmacy Permits (below) that service behavioral hospitals in the state of Louisiana. We are requesting a waiver to possibly exclude the Hospital Inpatient Activity from our daily PMP reporting. Under this scenario, we would continue to submit daily reporting for all non-Hospital Inpatient activity.

Carmichael's Pharmacy IHP
Pharmacy Permit: PHY.006051-IR
CDS Permit: CDS.039261-PHY
DEA: FC1110698

Carmichael's LTC of Crowley
Pharmacy Permit: PHY.006015-IR
CDS Permit: CDS.039198-PHY
DEA: FC0996946

We really appreciate you bringing this waiver request to the Board at your next scheduled meeting.

Thanks in advance,

Jonathan Lopez, Pharm D.
Carmichael's Infusion Pharmacist
Phone: 337-475-2701
E-mail: lcpharmacy@carmichaelsmed.com



Danielle Clausen

From: Joe Fontenot
Sent: Friday, December 19, 2014 10:58 AM
To: Danielle Clausen
Subject: FW: Inpatient Activity PMP Waiver Request

Please add to the Board agenda.

From: Jon Lopez [<mailto:lcpharmacy@carmichaelsmed.com>]
Sent: Friday, December 19, 2014 10:13 AM
To: Joe Fontenot
Cc: lrc@carmichaelsmed.com; 'Byron D. Finn'; 'Nick Guillory'; henryh@carmichaelsmed.com
Subject: Inpatient Activity PMP Waiver Request

Joe,

We have 2 Pharmacy Permits (below) that service behavioral hospitals in the state of Louisiana. We are requesting a waiver to possibly exclude the Hospital Inpatient Activity from our daily PMP reporting. Under this scenario, we would continue to submit daily reporting for all non-Hospital Inpatient activity.

Carmichael's Pharmacy IHP
Pharmacy Permit: PHY.006051-IR
CDS Permit: CDS.039261-PHY
DEA: FC1110698

Carmichael's LTC of Crowley
Pharmacy Permit: PHY.006015-IR
CDS Permit: CDS.039198-PHY
DEA: FC0996946

We really appreciate you bringing this waiver request to the Board at your next scheduled meeting.

Thanks in advance,

Jonathan Lopez, Pharm D.
Carmichael's Infusion Pharmacist
Phone: 337-475-2701
E-mail: lcpharmacy@carmichaelsmed.com



Danielle Clausen

From: Smith, Randy <randy.smith@christushealth.org>
Sent: Thursday, January 08, 2015 3:42 PM
To: Danielle Clausen
Cc: Smith, Randy
Subject: PMP EXEMPTION REQUEST

- * Requesting exemption from PMP Program for
- * Christus Schumpert Medical Center Pharmacy
- * DEA # BC7814329
- * Permit # PHY.006244-HOS
- * Scope of Practice is Hospital Inpatient Service (Rehab)
- * Requesting Exemption due to Prescription services are limited to inpatient order processing, via CPOM with no outpatient prescription processing. We are in the process of down sizing, resulting in no outpatient prescription services and no PMP services to report daily.

thank you Randy Smith RPH/PIC
and Terry Chauvin RPH/DOP

CONFIDENTIALITY NOTICE: Confidential information, such as identifiable patient health information or business information, is subject to protection under state and federal law. If you are not the intended recipient of this message, you may not disclose, print, copy or disseminate this information. If you have received this in error, please reply and notify the sender (only) and delete the message. Unauthorized interception of this e-mail is a violation of federal criminal law.



November 3, 2014

RE: Complete Medical Homecare PDMP exemption

To Whom It May Concern:

Complete Medical Homecare is diabetic pharmacy in Lenexa, KS. We dispense diabetic testing supplies, medications and insulin only.

Please review this written request for exemption from PDMP reporting as we do not stock or distribute any controlled substances, drugs of concern, or dangerous devices. There are no plans in the future to dispense any of the above products.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Jeff Hinchey', is written over a faint, illegible background.

Jeff Hinchey, PharmD

Pharmacist-In-Charge


Complete Medical Homecare

14309 W. 95th St

Lenexa, KS 66215

LA Pharmacy license #: PHY.006840-NR

DEA: FC4269800



Danielle Clausen

From: blan clan <blan_clan@bellsouth.net>
Sent: Sunday, January 11, 2015 9:58 PM
To: Danielle Clausen
Cc: Dennis Blanchard II
Subject: Fw: Subject: Consideration for a PMP Waiver (Revised)
Attachments: IMG_0003.jpg; IMG_0002.jpg; IMG_0001.jpg; IMG.jpg

On Sunday, January 11, 2015 9:52 PM, blan clan <blan_clan@bellsouth.net> wrote:

Hello Mrs. Clausen,
As per our correspondence, I am providing the requested information for consideration in obtaining a PMP wavier permit.

Louisiana Pharmacy Permit Number, Name, and Address:

PHY.006842-IR
HaloCare Specialty Therapeutics
34972 Old La Highway 16 Ste A
Denham Springs, LA 70706-0573

DEA Registration Number

FH4465604

Scope of Practice:

HaloCare is a specialty pharmacy whose main focus is high dollar, hard to find medications. Hemophilia, for instance, is a large part of our practice using medications such as Factor VII, Factor VIII, Stimate, and Amicar.

Detailed Explanation as to the Reasons for Requesting an Exemption:

HaloCare has been in business for 10 months and has never ordered nor dispensed any narcotics or drugs of concern. We have no front end and for all intents and purposes, we are a closed door pharmacy as we have nothing to offer walk in patients. Our prescriptions are e-script or faxed to us from hemophilia clinics and the medications are then FedEx'd all over the state. (Some outside the state). The main reason for obtaining a DEA number is for billing as some insurance companies insist upon it.

Statement Confirming that the Pharmacy does not nor Plan on Dispensing and Controlled Substances or drugs of Concern to La. Residents:

HaloCare has never dispensed nor do we plan to dispense any controlled substances or drugs of concern to Louisiana residents.

Your Consideration in this Matter is Greatly Appreciated,

Dennis Paul Blanchard II PIC
HaloCare Specialty Therapeutics
Phone: (855) 379-4250
Fax: (225) 243-7957

Danielle Clausen

From: Dwayne Steele <dstele@lacontinuingcare.com>
Sent: Tuesday, January 06, 2015 1:29 PM
To: Danielle Clausen
Subject: PMP Reporting Waiver Request

Good Afternoon Ms. Clausen:

I am sending this email to request a PMP reporting waiver for Louisiana Continuing Care Hospital. Our facility is an inpatient pharmacy and we do not dispense any out-patient prescriptions. The licensing information for the facility is:

Louisiana Continuing Care Hospital
1111 Medical Center Blvd, Suite S590
Marrero, LA 70131
LABP Number: PHY.006692-HOS
DEA Number: FL3643055

Thanks for your attention in this matter, and please feel free to contact me if any additional information is needed.

Sincerely,

Dwayne Steele
Director of Pharmacy
Louisiana Continuing Care Hospital
Marrero, LA 70131
(504) 349-6183 (O); (504) 349-6196(F)
Email: dstele@lacontinuingcare.com



Madison Parish Hospital

900 Johnson St. - PO Box 1559
Tallulah, LA 71282-1559

Joe Fontenot, R.Ph
Assistant Executive Director
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, La 70809-1700
jfontenot@pharmacy.la.gov
Phone (225) 922-0094
Fax (225) 923-5670

31December 31, 2014

Re: Madison Parish Hospital Pharmacy
Permit Number: PHY.003996-HOS
DEA Number: BM2048608


To Whom It May Concern,

My name is Mahdi Cezar. I am the Director of the Hospital Pharmacy at Madison Parish Hospital. I am writing to confirm that the pharmacy is strictly in-patient and does not dispense any out-patient prescriptions. The purpose of this letter is to officially inform you that the above referenced pharmacy does not plan on dispensing any controlled substances or drugs of concern to Louisiana residents out-patient.

I hope this letter will be sufficient for requesting an exemption to reporting. If I can be of further assistance, feel free to contact me.

With Kindest Regards,

Mahdi Cezar RPh MBA
Director of Pharmacy
Madison Parish Hospital
900 Johnson Street
Tallulah, LA 71282
mcezar@madisonparishhospital.com
office (318) 574-2374 ext 275
cell (337) 446-7453




T. Topolewski
Administrator

Phone (318) 574-2374
Fax (318) 574-2396



Interfaith Pharmacy



Board of Directors

January 26, 2015

Sanders Hearne, M.D.

President

Louisiana Board of Pharmacy
3388 Brentwood Dr
Baton Rouge, La 70809-1700

Jon Davis, M.D.

Vice-President

Brian Carnie

Secretary

Dear Louisiana Board of Pharmacy,

Lisa Barker

Treasurer

This letter is a request for exemption from PMP reporting. The Northwest Louisiana Interfaith Pharmacy is a charitable pharmacy and does not have a DEA number. Our permit number is PHY.005105-CH. We are located at 909 Olive Street, Shreveport, La 71104. Our focus is dispensing free medicines to uninsured individuals with chronic disease or homeless individuals residing in area shelters.

Susan Crider R.Ph.

Pharmacist in Charge

We stopped dispensing any drugs of concern in August of 2014. We have filed "zero reports" through December of 2014. We no longer dispense any drugs of concern or have any plans to dispense them in the future. For this reason we are asking for an exemption.

Andrew Abshire

Andrew Crawford

Please contact us should you need any more information.

Hedy Hebert

Ellie Hudnall, M.D.

Sincerely,

Pete Johnson, R.Ph.

Susan Nickerson Crider,
Pharmacist-in-Charge

Janet Martin,
Executive Director

Joe Miciotto

Clare Nelson

Glenn Robinson

John Vanchiere, M.D

Danielle Clausen

From: Laurel Cohen <Laurel.Cohen@onco360.com>
Sent: Wednesday, February 18, 2015 4:09 PM
To: Danielle Clausen
Cc: Eric Saul
Subject: PDMP Reporting Exemption Request

Hello Danielle,

As per our earlier conversation here is the information that you require for our exemption to be granted.

OncoMed The Oncology Pharmacy of Buffalo NY LLC d/b/a Onco360 is an oncology pharmacy holding Louisiana non-resident license number PHY.007028-NR. The DEA # is FO2570807. Onco360 is requesting an exemption from PDMP reporting because the pharmacy does not carry or dispense any controlled substances. The pharmacy does not currently dispense controlled substance to any Louisiana residents and does not plan to do so in the future.

If there is any additional information required please let me know.

Kind regards,

Laurel P. Cohen
Licensing and Compliance Specialist
Onco360® Oncology Pharmacy
225 Community Drive Suite 100
Great Neck, N.Y. 11021
P: [516-869-0920](tel:516-869-0920) x1200 | F: [516-439-4266](tel:516-439-4266)
Laurel.Cohen@onco360.com



Follow Us

Please consider the environment before printing this email.

The information contained in this communication may be confidential, and is intended only for the use of the recipients named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this communication in error, please return it to the sender immediately and delete the original message and any copy of it from your computer system. If you have any questions concerning this message, please contact the sender.



**OUR LADY
OF THE ANGELS
HOSPITAL**

*Franciscan Missionaries of
Our Lady Health System*

12/30/14

**Joe Fontenot
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700,**

Our Lady of the Angels Hospital would like to opt out of the PMP as we do not dispense nor plan to future dispense any controlled medications to leave the hospital. We had previously opted out as LSU- Bogalusa but needed to do so again with our new DEA numbers as Our Lady of the Angels.

**Permit- PHY.006853-HOS
Our Lady of the Angels Hospital (inpatient, ER, outpatient)(not retail)
433 Plaza St
Bogalusa, LA 70427-3729
DEA- FO4434952**

**Our Lady of the Angels Hospital (acute unit)(not retail)
400 Memphis St
Bogalusa, LA 70427
DEA- FO4434964**

**Please let me know if you have any questions.
Thanks for your help,**

Tammy Belleau RPh

Senior Director of Pharmacy
St Elizabeth Hospital and Our Lady of the Angels Hospital

tammy.belleau@steh.com

St Elizabeth Hospital

1125 West Highway 30
Gonzales, LA 70737
Office: 225-647-5055
Cell: 225-315-4395
Fax: 225-647-8545

Our Lady of the Angels Hospital

433 Plaza Street
Bogalusa, LA 70427
Pharmacy: 985-730-6789
Cell: 225-315-4395
Fax: 985-730-6790

Our Lady of the Angels Hospital
433 Plaza Street
Bogalusa, LA 70427

P 985.730.6700
F 985.730.6709
www.oloah.org

Restore RX, Inc.

5169 Brunswick Road, Box 305
Brunswick, TN 38014
Phone: (901) 388-0507



FACSIMILE TRANSMITTAL

To: Louisiana Pharmacy Board

Fax #: 225-923-5670

Attn: Joe Fontenot, R.Ph.

From: Mike Kelly

Fax #: 901-388-0407

Pages: [#] 2

Date: December 3, 2014

Subject: Prescription Monitoring Program - Waiver

Dear Mr Fontenot:

Please accept this letter as our official request for an Exemption From Reporting Controlled Substance Prescriptions for Restore Rx, Inc. License number PHY.006484-OS.

We specialize in handling many medications that require continuous temperature control and are primarily useful in treating conditions such as hemophilia, cancers, Aids/HIV, and other rare illnesses. Please note that our pharmacy does not perform any compounding, nor will we provide controlled medications to patients in the State of Louisiana.

Should you have any questions regarding this request or if you require additional documentation, please give me a call at 877-388-0507 extension 302.

Sincerely:

Michael W. Kelly, RPhT
Director Pharmacy Operations




This message is from Restore RX, Inc. This message may contain legally privileged or confidential information intended only for the individual or entity identified above as the addressee. If you are not the addressee, or this message is addressed to you in error, you are not authorized to read, copy or distribute this message. Please notify the sender by phone at (877) 388 0507 or by fax at (901) 388 0407. Delivery of this message to any person other than the intended recipient(s) is not intended in any way to waive confidentiality or a privilege. All personal messages express views only of the sender, which are not attributed to Restore RX, Inc. and may not be copied or distributed without this message.

TO: LOUISIANA BOARD OF PHARMACY
FROM: MAX E. DAUGHTRY R.PH.
SUBJECT: EXEMPTION FOR REPORTING TO PMP

I AM MAX E. DAUGHTRY R.PH., (PIC), DIRECTOR OF PHARMACY FOR THE SPECIALTY HOSPITAL OF WINNFIELD . I AM REQUESTING AN EXEMPTION FOR REPORTING TO THE "PRESCRIPTION MONITORING PROGRAM". I DO NOT DISPENSE ANY OUTPATIENT PRESCRIPTIONS. I ONLY SERVE IN-PATIENTS AND HAVE NO PLANS ON DISPENSING ANY CONTROLLED SUBSTANCES OR DRUGS OF CONCERN TO LOUISIANA RESIDENTS. I HAVE BEEN ON STAFF/DIRECTOR OF PHARMACY FOR 10 YEARS AND WE HAVE NEVER DISPENSED TO OUTPATIENTS. ALSO, WE DO NOT FILL PRESCRIPTIONS FOR OUR HOSPITAL STAFF NOR DO I INTEND ON STARTING. PLEASE CONSIDER MY REQUEST FOR BEING EXEMPT FROM THE LOUISIANA PMP PROGRAM. BELOW IS THE INFORMATION REQUESTED:

1. SPECIALTY HOSPITAL OF WINNFIELD
915 FIRST STREET
WINNFIELD, LA 71483
PERMIT NUMBER: PHY.005967-HOS
DEA #. BS8986210
SCOPE OF PRACTICE: LONG TERM ACUTE CARE HOSPITAL – IN-PATIENT ONLY

SPECIALTY HOSPITAL OF WINNFIELD IS A LONG-TERM ACUTE CARE HOSPITAL THAT IS STRICTLY IN-PATIENT AND ~~DOES~~^{DOES} NOT DISPENSE ANY OUT-PATIENT PRESCRIPTIONS.


MAX E. DAUGHTRY R.PH. DATE

12/10/14



Danielle Clausen

From: Joe Fontenot
Sent: Monday, December 29, 2014 2:23 PM
To: Danielle Clausen
Subject: FW: Exemption from Louisiana Prescription Monitoring Program

Waiver request for the next Board meeting

From: Hamner, Janene Peyton [<mailto:djhamner@lgh.org>]
Sent: Monday, December 29, 2014 2:18 PM
To: Joe Fontenot
Subject: Exemption from Louisiana Prescription Monitoring Program

Dear Mr. Fontenot,

Please excuse the first email. I failed to enter a subject line.

I am the Pharmacist in Charge at St. Martin Hospital in Breaux Bridge, LA which is a member of the LGH system with Lafayette General Medical Center being the main campus. While checking on the status of the computer update for the Louisiana Prescription Monitoring Program, I found out about the option of exemption. I would like permission to be exempt from reporting due to our scope of practice strictly being an Acute Care Facility with In-patients, ED patients and Outpatient Infusion only. We do not dispense any controlled substances or drugs of concern to Louisiana residents nor do we plan to. The Pharmacy is strictly In-patient and does not dispense any Out-patient prescriptions. My Pharmacy Permit number and other information required for exemption is:

Pharmacy Permit PHY.006331-HOS
210 Champagne Blvd.
Breaux Bridge, LA 70517-3700
DEA Permit FS2336394

Please contact me if there is any additional information needed.

Sincerely,

Janene Hamner PD
St. Martin Hospital Pharmacy
210 Champagne Blvd.
P.O. Box 357
Breaux Bridge, LA 70517
Phone: 337-507-1222
Email: djhamner@lgh.org

Janene Hamner PD
St. Martin Hospital Pharmacy
210 Champagne Blvd.
P.O. Box 357

Danielle Clausen

From: Joe Fontenot
Sent: Monday, January 05, 2015 4:55 PM
To: Danielle Clausen
Subject: FW: PHY.006932-HOS

Waiver request

From: Lemoine, Loretta [<mailto:Loretta.Lemoine@uhsystem.com>]
Sent: Wednesday, December 31, 2014 11:15 AM
To: Joe Fontenot
Subject: PHY.006932-HOS

Mr. Fontenot -

I am writing to request an exemption to the reporting to the Prescription Monitoring Program for Louisiana Board of Pharmacy Permit
PHY.006932-HOS.
University Health Conway
4864 Jackson St
Monroe, La
71202-6400

Because we are operate a hospital/clinic pharmacy we do not dispense any controlled substances or drugs of concern for patient use outside of the facility.

We only dispense medications to patients for use at the facility.

We had previously been exempt on our previous license (EA Conway Pharmacy) and are requesting the same consideration with this license.

We at this time have no plans to dispense any controlled substances or drugs of concern to Louisiana residents.

Please let me know if you require any additional information regarding this exemption request.

Thank you -

Loretta Lemoine

Confidentiality Notice: This e-mail message from University Health System, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

TO: LOUISIANA BOARD OF PHARMACY

FROM: MAX E. DAUGHTRY R.PH.

SUBJECT: EXEMPTION FOR REPORTING TO PMP

I AM MAX E. DAUGHTRY R.PH., (PIC), DIRECTOR OF PHARMACY FOR THE WINN PARISH MEDICAL CENTER HOSPITAL. I AM REQUESTING AN EXEMPTION FOR REPORTING TO THE "PRESCRIPTION MONITORING PROGRAM". I DO NOT DISPENSE ANY OUTPATIENT PRESCRIPTIONS. I ONLY SERVE IN-PATIENTS AND HAVE NO PLANS ON DISPENSING ANY CONTROLLED SUBSTANCES OR DRUGS OF CONCERN TO LOUISIANA RESIDENTS. I HAVE BEEN ON STAFF/DIRECTOR OF PHARMACY FOR 37 YEARS AND WE HAVE NEVER DISPENSED TO OUTPATIENTS. ALSO, WE DO NOT FILL PRESCRIPTIONS FOR OUR HOSPITAL STAFF NOR DO I INTEND ON STARTING. PLEASE CONSIDER MY REQUEST FOR BEING EXEMPT FROM THE LOUISIANA PMP PROGRAM. BELOW IS THE INFORMATION REQUESTED:

1. WINN PARISH MEDICAL CENTER
301 W. BOUNDARY STREET
WINNFIELD, LA 71483
PERMIT NUMBER: PHY.006192-HOS
DEA #. FP1373771
SCOPE OF PRACTICE: ACUTE CARE HOSPITAL – IN-PATIENT ONLY

WINN PARISH MEDICAL CENTER IS AN ACUTE-CARE HOSPITAL THAT IS STRICTLY IN-PATIENT AND DOES NOT DISPENSE ANY OUT-PATIENT PRESCRIPTIONS.

Max E. Daughtry R.Ph. 12/10/14
MAX E. DAUGHTRY R.PH. DATE





Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of General Counsel

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 25, 2015

Agenda Item 10-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

Nov. 17	Leadership Mtg – LSBME at Board office
Jan. 14-15	NABP Inspection Blueprint Development Workshop – Mount Prospect, IL
Feb. 10	Southern Boards of Pharmacy Fly-in – Dallas, TX

2. **Reports** (all in the Boardroom Library)

- A. Census Reports
 1. Compliance Division – Practitioner Recovery Program & Discipline
 2. Credentials Division – CDS & Pharmacy Programs
- B. Credentials Division Production Reports
 1. Licensure Activity Report [new credentials in previous quarter]
 2. Application Activity Report [pending applications count]
- C. Exceptions Report
 1. PIC in Multiple Locations
 2. Resurrected Credentials / Special Work Permits
- D. Year-End Reports
 1. Boards & Commissions Office – Div of Administration
 2. Comprehensive Annual Financial Report – Joint Legislative Cmte on the Budget
 3. Document Production Report – Poynter Legislative Research Library
 4. Document Depository Program – La. State Library

3. **Examinations**

- A. MPJE – the results for the third trimester of 2014 are available.
- B. NAPLEX – the results for the third trimester of 2014 are available.
- C. PARE – our last administration of this test was in July 2014.
- D. PTCB – the results for the second half of 2014 are not yet available.

4. Operations

A. Credentials Division

We recently completed the renewal cycles for pharmacists, pharmacies, and CDS licenses for pharmacies

- Of the 8,105 pharmacists who were noticed for renewal, 92% of them renewed timely, and of that number, 93% did so online.
- Of the 1,902 pharmacies which were noticed for renewal, 94% of them renewed timely, and of that number, 89% did so online.
- Of the 1,395 pharmacies holding a CDS license which were noticed for renewal, 99.8% of them renewed timely, and of that number, 88% did so online.

B. Compliance Division

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,463 pharmacies within the state, as well as approximately 516 various types of facilities for CDS visits, including hospitals, rural health clinics, dialysis clinics, researchers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 252 cases pending from the prior fiscal year. We have entered 246 new cases and closed 294, leaving 204 cases currently open. Of the 294 cases closed so far this fiscal year, 64% were disposed of through staff activities and the balance through committee and Board action.

C. Administrative Division

As we reported at your last meeting, we are working with the Division of Administration to implement new policies and procedures that will change the way our office pay for certain of your travel expenses. As part of that process, you will be asked to approve a new set of policies for a Central Billing Account (CBA). As soon as we have all the processes in place, we will develop some written guidance for you to help you comply with those new requirements.

5. State Activities

A. Roadrunner Pharmacy & Southeast Louisiana Veterinary Medical Association

It appears this pharmacy stimulated a letter-writing campaign among the veterinarians located in the southeastern part of the state. We have also been contacted by the president of their local veterinary medical association. Their concerns center on the absence of the ability of pharmacists to compound veterinary medications for office use. Unfortunately, none of them contacted the Board office during the formal comment period of the rulemaking process. Copies of the 30 letters we received were posted in the Boardroom Library. The question is whether the Board wants to re-open the compounding rules to address compounding for office use in veterinary practice.

6. National Activities

A. National Association of Boards of Pharmacy (NABP)

For your planning purposes, the 2015 meeting will be held May 16-19 in New Orleans, LA. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

B. NABP-AACP District 6 Annual Meeting

For your planning purposes, the 2015 meeting will be held Sep 14-17 in Lake Tahoe, NV. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

C. MALTAGON

The host for this year's conference is the Kentucky Board of Pharmacy. When that meeting information is available, we will forward it to you. As a reminder, this conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

7. *International Activities*

A. International Pharmaceutical Federation (FIP)

The 75th World Congress of the International Pharmaceutical Federation will be held in Dusseldorf, Germany on Sep 28 – Oct 3. For your planning purposes, the next two hosting sites have also been identified: 2016 in Buenos Aires, Argentina and 2017 in Seoul, South Korea.

Respectfully submitted,
Malcolm J Broussard
Executive Director

Louisiana Board of Pharmacy
 Credentials Division
 Pharmacy Program

		06/30/06	06/30/07	06/30/08	06/30/09	06/30/10	06/30/11	06/30/12	06/30/13	06/30/14	02/16/15
PST-VI	LA	0	0	0	0	0	12	10	9	9	13
	NR	0	0	0	0	0	9	10	15	14	15
	Total	0	0	0	0	0	21	20	24	23	28
PST-GVI	LA	0	0	0	0	0	0	6	13	13	12
	NR	0	0	0	0	0	0	0	3	5	5
	Total	0	0	0	0	0	0	6	16	18	17
PST-M	LA	0	0	0	0	0	3	5	3	1	2
	NR	0	0	0	0	0	11	11	11	13	10
	Total	0	0	0	0	0	14	16	14	14	12
PST-G	LA	0	0	0	0	0	158	157	164	166	140
	NR	0	0	0	0	0	30	35	32	31	27
	Total	0	0	0	0	0	188	192	196	197	167
PST	LA	4,460	4,522	4,612	4,750	4,860	4,654	4,933	4,981	5,140	5,221
	NR	1,915	1,975	1,964	2,029	2,098	2,079	2,212	2,527	2,479	2,538
	Total	6,375	6,497	6,576	6,779	6,958	6,733	7,145	7,508	7,619	7,759
	PST	6,375	6,497	6,576	6,779	6,958	6,935	7,353	7,758	7,871	7,983
PNT	LA	980	1,079	1,074	1,035	965	907	938	942	948	973
	NR	109	117	67	84	153	137	128	128	127	162
	Total	1,089	1,196	1,141	1,119	1,118	1,044	1,066	1,070	1,075	1,135
PNT-FPG	Total	0	0	0	0	0	5	0	3	6	3
	PNT	1,089	1,196	1,141	1,119	1,118	1,049	1,066	1,073	1,081	1,138
CPT	LA	4,552	4,587	4,780	4,733	5,363	5,720	5,509	5,751	6,463	6,433
	NR	163	152	144	109	144	145	120	112	138	131
	Total	4,715	4,739	4,924	4,842	5,507	5,865	5,629	5,863	6,601	6,564
CPT-M	Total	0	0	0	0	0	1	0	1	2	1
	CPT	4,715	4,739	4,924	4,842	5,507	5,866	5,629	5,864	6,603	6,565
PTC	LA	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,820
	NR	32	32	23	32	35	35	39	37	37	34
	PTC	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,854
PHY	CH	12	12	11	12	14	12	12	12	12	12
	HOS	167	164	167	167	165	151	154	158	164	163
	HOX	0	0	0	0	0	19	18	14	11	8
	IN	35	36	37	37	27	14	10	12	12	11
	INX	0	0	0	0	0	11	14	13	11	10
	IR	681	620	588	592	587	570	568	558	583	585
	IRX	0	0	0	0	0	21	19	17	10	10
	NR	226	240	250	256	286	318	361	387	422	460
	NRN	0	0	0	0	0	0	0	0	9	9
	NRP	0	0	0	0	0	0	0	0	1	2
	NU	17	16	16	16	16	15	15	15	15	14
	PEN	0	0	0	0	0	0	0	0	0	0
	PEX	0	0	0	0	0	0	0	1	2	2
	SAT	0	0	0	0	0	0	0	0	1	3
RC	430	491	534	545	562	576	587	597	619	645	
PHY	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,872	1,934	
AMS	AMS	173	212	255	306	361	55	64	349	92	108
	AMS-X	0	0	0	0	0	301	302	289	359	354
	AMS	173	212	255	306	361	356	366	638	451	462
EDK	EDK	428	412	439	388	503	417	435	421	464	463
	EDK-X	0	0	0	0	0	13	13	10	10	10
	EDK	428	412	439	388	503	430	448	431	474	473
DME	LA							223	160	209	196
	NR								218	281	378
	DME								378	490	574
CDTM								41	41	47	
MAR								1,617	2,037	2,368	
SWP						58	78	126	38	55	
TOTAL									21,405	22,865	23,453

Louisiana Board of Pharmacy
 Credentials Division
 CDS Program

<i>Classification</i>	<u>06/30/08</u>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>06/30/14</u>	<u>02/16/15</u>
ACS Animal Control Shelter	0	0	1	1	1	1	1	1
AMS Automated Medication Sys	0	0	0	0	0	0	26	34
AMX Automated Medication Sys - Exempt	0	0	0	0	0	0	2	0
APN APRN	479	607	758	889	1,015	1,103	1,479	1,790
ASC Ambulatory Surgical Ctr	101	106	113	90	88	85	89	87
CRX Correctional Ctr - Exempt	0	0	0	7	6	5	6	5
DDS Dentist	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,108
DET Drug Detection / Canine	20	20	22	14	12	10	11	11
DEX Drug Detection / Canine - Exempt							1	1
DIS Distributor	322	363	400	279	288	273	324	321
DPM Podiatrist	153	161	165	139	136	118	133	133
DVM Veterinarian	936	1,000	1,065	922	901	852	1,002	1,031
DYS Dialysis Ctr	63	63	63	6	4	3	4	1
EMC Emergency Medical Ctr	17	17	18	14	16	17	22	22
EMS Emergency Medical Service	58	63	66	54	50	45	50	50
ETC Animal Euthanasia Tech - Cert	39	44	49	16	7	6	6	5
ETL Animal Euthanasia Tech - Lead	0	0	0	12	20	21	23	23
HOS Hospital	387	405	438	280	267	263	272	271
HOX Hospital - Exempt	0	0	0	12	14	5	6	7
LAB Laboratory	14	14	15	8	6	7	8	8
LAX Laboratory - Exempt	0	0	0	4	5	5	5	5
MD Physician	13,876	14,599	15,269	12,362	11,727	10,698	11,913	11,936
MDT Physician on Telemedicine	0	0	0	0	0	0	2	1
MED Medical Clinic	78	88	102	77	81	68	78	75
MEX Medical Clinic - Exempt	0	0	0	3	5	14	11	10
MFR Manufacturer	43	52	58	48	50	45	42	42
MIS Miscellaneous	73	58	59	11	10	9	11	12
MIX Miscellaneous - Exempt	0	0	0	9	4	3	2	1
MP Medical Psychologist	44	50	58	65	67	69	78	81
OD Optometrist	253	269	278	275	287	279	309	315
PA Physician Assistant	194	232	272	294	326	344	449	477
PHX Pharmacy - Exempt	0	0	0	50	47	41	30	24
PHY Pharmacy	0	0	0	1,307	1,318	1,329	1,357	1,369
REP Sales Representative	65	66	88	29	20	7	0	0
RES Researcher	110	119	156	109	110	98	113	113
RHC Rural Health Clinic	20	21	23	17	12	11	12	12
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	5
SAC Substance Abuse Clinic	14	14	17	7	9	9	9	8
SAX Subst. Abuse Clinc - Exempt	0	0	0	0	0	0	0	0
Total	19,536	20,698	21,916	19,437	18,957	17,745	20,009	20,395

Total Credentials Under Management

Pharmacy	16,407	16,601	17,818	18,260	18,625	21,405	22,865	23,453
CDS	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20,395</u>
Total	35,943	37,299	39,734	37,697	37,582	39,150	42,874	43,848

Louisiana Board of Pharmacy
Census Report

Type of Credential	3/17/1995	6/30/1996	3/19/1997	6/30/1998	6/30/1999	6/30/2000	6/30/2001	6/30/2002	6/30/2003	6/30/2004	6/30/2005
Pharmacists											
In-state	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486	4,532
Out-of-state	377	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484	1,686
TOTAL	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970	6,218
Pharmacy Interns											
In-state											
Out-of-state											
TOTAL							957	976	929	995	1,154
Pharmacy Technicians											
In-state											
Out-of-state											
TOTAL							3,216	3,453	3,505	4,114	4,455
Pharmacy Technician Candidates											
In-state											
Out-of-state											
TOTAL							2,896	2,372	1,336	1,069	1,074
Pharmacy Permits											
IR	651	634	636	609	621	585	584	576	573	633	729
RC	464	473	471	493	505	520	528	535	541	555	473
H	177	174	171	175	172	171	171	174	179	181	181
IN	46	45	38	39	19		17	18	19	27	36
NU	9	10	10	9	10		12	14	13	13	13
CH	4	4	4	7	4		8	9	11	12	12
PEN											
OS	122	152	168	175	216	223	262	313	353	339	200
PE	78	104	102	120	102			95	94	0	
CO	13	12	12	12	12		12	13	13	0	
TOTAL	1,564	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760	1,644
Equipment Permits											
AMS							0	109	136	158	174
EDK							468	461	474	444	471

Type of Credential	6/30/2006	6/30/2007	6/30/2008	6/30/2009	6/30/2010	6/30/2011	6/30/2012	6/30/2013	6/30/2014	2/16/2015
Pharmacists										
In-state	4,460	4,522	4,612	4,750	4,860	5,000	5,095	5,170	5,329	5,388
Out-of-state	1,915	1,975	1,964	2,029	2,098	2,179	2,258	2,588	2,542	2,595
TOTAL	6,375	6,497	6,576	6,779	6,958	7,179	7,353	7,758	7,871	7,983
Pharmacy Interns										
In-state	980	1,079	1,074	1,035	965	917	938	945	950	975
Out-of-state	109	117	67	84	153	137	128	128	131	163
TOTAL	1,089	1,196	1,141	1,119	1,118	1,054	1,066	1,073	1,081	1,136
Pharmacy Technicians										
In-state	4,552	4,587	4,780	4,733	5,363	5,722	5,509	5,752	6,463	6,433
Out-of-state	163	152	144	109	144	145	120	112	138	132
TOTAL	4,715	4,739	4,924	4,842	5,507	5,867	5,629	5,864	6,601	6,565
Pharmacy Technician Candidates										
In-state	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,820
Out-of-state	32	32	23	32	35	35	39	31	37	34
TOTAL	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,854
Pharmacy Permits										
IR	681	620	588	592	587	591	587	575	583	585
RC	430	491	534	545	562	576	587	597	619	645
H	167	164	167	167	165	170	172	172	175	171
IN	35	36	37	37	27	25	24	25	23	21
NU	17	16	16	16	16	15	15	15	15	14
CH	12	12	11	12	14	12	12	12	12	12
PEN								1	2	2
NR	226	240	250	256	286	318	361	387	432	460
TOTAL	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,861	1,910
Equipment Permits										
AMS	173	212	255	306	361	356	366	638	451	463
EDK	428	412	439	388	503	430	448	431	474	473
DME							223	378	490	574
Special Activity								41	41	47
CDTM								1,617	2,037	2,368
MAR										
Special Work Permit						58	78	126	38	55

Louisiana Board of Pharmacy
CDS Program - Census Report

Classification	6/30/2007	6/30/2008	6/30/2009	6/30/2010	6/30/2011	6/30/2012	6/30/2013	6/30/2014	2/16/2015
ACS Animal Control Shelter	0	0	0	1	1	1	1	1	1
AMS Automated Medication System	0	0	0	0	0	0	0	28	34
APN Advanced Practice Registered Nurse	346	479	607	758	889	1,015	1,103	1,479	1,790
ASC Ambulatory Surgical Center	94	101	106	113	90	88	85	89	87
CRX Correctional Center	0	0	0	0	7	6	5	6	5
DDS Dentist	2,090	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,108
DET Drug Detection Canine	20	20	20	22	14	12	10	11	12
DIS Distributor	285	322	363	400	279	288	273	324	321
DPM Podiatrist	147	153	161	165	139	136	118	133	133
DVM Veterinarian	870	936	1,000	1,065	922	901	852	1,002	1,031
DYS Dialysis Center	63	63	63	63	6	4	3	4	1
EMC Emergency Medical Center	17	17	17	18	14	16	17	22	22
EMS Emergency Medical Service	57	58	63	66	54	50	45	50	50
ETC Animal Euthanasia Tech - Cert	31	39	44	49	28	27	27	29	28
HOS Hospital	369	387	405	438	292	281	268	278	278
LAB Analytical Laboratory	13	14	14	15	12	11	12	13	13
MD Physician	13,195	13,876	14,599	15,269	12,362	11,727	10,698	11,913	11,936
MDT Physician on Telemedicine	0	0	0	0	0	0	0	2	1
MED Medical Clinic	73	78	88	102	80	86	82	89	85
MFR Manufacturer	36	43	52	58	48	50	45	42	42
MIS Other	74	73	58	59	20	14	12	13	13
MP Medical Psychologist	37	44	50	58	65	67	69	78	81
OD Optometrist	230	253	269	278	275	287	279	309	315
PA Physician's Assistant	170	194	232	272	294	326	344	449	477
PHY Pharmacy	0	0	0	0	1,357	1,365	1,370	1,387	1,393
REP Sales Representative	57	65	66	88	29	20	7	0	0
RES Researcher	100	110	119	156	109	110	98	113	113
RHC Rural Health Clinic	19	20	21	23	17	12	11	12	12
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	0	5
SAC Substance Abuse Clinic	14	14	14	17	7	9	9	9	8
TOTAL	18,407	19,502	20,663	21,916	19,437	18,957	17,745	20,009	20,395
Total Credentials Under Board Management									
Pharmacy Program	16,056	16,407	16,601	17,818	18,260	18,625	21,405	22,865	23,453
CDS Program	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20,395</u>
TOTAL	34,463	35,943	37,299	39,734	37,697	37,582	39,150	42,874	43,848

New Credentials Issued
4th Quarter 2014
October 1, 2014 - December 31, 2014

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	4
AMS	X	Automated Medication System - Exempt	9
Prefix Totals			13
CDS	APN	CDS License - APRN	105
CDS	ASC	CDS License - Ambulatory Surgical Center	1
CDS	DDS	CDS License - Dentist	13
CDS	DIS	CDS License - Distributor	3
CDS	DVM	CDS License - Veterinarian	12
CDS	ETL	CDS License - Animal Euthanasia Technician, Lead (AET-L)	2
CDS	HOS	CDS License - Hospital	3
CDS	MD	CDS License - Physician	92
CDS	MED	CDS License - Medical Clinic	1
CDS	MFR	CDS License - Manufacturer	3
CDS	OD	CDS License - Optometrist	4
CDS	PA	CDS License - Physician Assistant	11
CDS	PHX	CDS License - Pharmacy - Exempt	1
CDS	PHY	CDS License - Pharmacy	29
CDS	RES	CDS License - Researcher	3
CDS	ROF	CDS License - Registered Outsourcing Facility	2
CDS	SAC	CDS License - Substance Abuse Clinic	1
Prefix Totals			286
CDTM		Collaborative Drug Therapy Management (V)	2
CPT		Certified Pharmacy Technician	123
DME		Durable Medical Equipment (DME) Provider	108
EDK		Emergency Drug Kit	13
LB		Law Book	1
MA		Medication Administration (V)	84
PHY	HOS	Pharmacy - Hospital Inpatient	5
PHY	IR	Pharmacy - Community ~ Independent	13
PHY	IRX	Pharmacy - Community - Exempt	1
PHY	NR	Pharmacy - Nonresident	35
PHY	RC	Pharmacy - Community ~ Chain	14
PHY	SAT	Pharmacy - Hospital Off-Site Satellite	1
Prefix Totals			69
PIC		Pharmacist-in-Charge (V)	12
PMP	CDS	PMP - CDS Credential	370
PMP	PST	PMP - Pharmacist	56
Prefix Totals			426
PNT		Pharmacy Intern	92
PNT	FPG	Pharmacy Intern - Foreign Pharmacy Graduate	1
Prefix Totals			93
PST		Pharmacist	74
PTC		Pharmacy Technician Candidate	289
SWP		Special Work Permit	11
Grand Totals			1604



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 25, 2015

Agenda Item 10-L: Report of Executive Director

Section 2.C – Exceptions Report

1. **PIC at Multiple Pharmacies**

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

2. **Special Work Permits for military-trained applicants and their spouses**

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

3. **Special Work Permits**

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On November 13, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Karlesia Johnson Stowers. She had previously obtained PTC.018374 which expired on July 4, 2013. She is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.
- On November 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Adrienne Blaire Starks. She had previously obtained PTC.010707 which expired on November 9, 2008. She is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.
- On November 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Tiffany Denise Duhon. She had previously obtained PTC.013913 which expired on November 4, 2009. She is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.
- On November 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Christina Lavinia Green. She had previously obtained PTC.014053 which expired on December 16, 2009. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On November 26, 2014, Mr. Aron and Mr. Broussard concurred to grant a request from Daniel R. Fontenot. He had previously obtained PTC.004647 on May 20, 2008 which expired on November 19, 2009. He passed PTCB prior to obtaining the PTC registration but he did not complete the hours. We issued SWP.000454 with an expiration date of 12-31-2015. He must earn 600 hours of practical experience, documented on a Pharmacist's Affidavit, supplemented with a letter of competency from the supervising pharmacist.
- On December 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Tony Lee Hanson. He had previously obtained PTC.010411 which expired on October 4, 2005. He

is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.

- On December 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Nicole Renee Lee. She had previously obtained PTC.014762 which expired on August 1, 2010. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Loren Cerise Labbe. She had previously obtained PTC.013055 which expired on January 16, 2009. She is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.
- On December 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Corey Lee Justice. He had previously obtained PTC.012255 which expired on March 4, 2008. He is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience within one year from the date of issue.
- On December 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Lauren Elayna McKay. She had previously obtained PTC.019282 which expired on March 25, 2014. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 12, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Heaven Marie Leonard. She had previously obtained PTC.018050 which expired on April 12, 2013. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 12, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Chardae' Auriel Gray. She had previously obtained PTC.016713 which expired on February 24, 2012. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Yolanda Yvette Thomas. She had previously obtained PTC.011988 which expired on November 24, 2007. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 18, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Christina Caleah Davenport. She had previously obtained PTC.017799 which expired on February 10, 2013. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 24, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Tremaine Denise Nora. She had previously obtained PTC.013262 which expired on March 24, 2009. She was also issued a SWP.000023 on January 31, 2010 but failed to satisfy the requirements under that credential as well. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Andrienne Danielle Johnson. She had previously obtained PTC.019240 which expired on March 18, 2014. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On December 31, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Racquel Victoria Martin. She had previously obtained PTC.018996 which expired on December 20, 2013. Should she pass the PTCB by July 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 6, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Shambrick Shuntia Beaner. She had previously obtained PTC.017404 which expired on November 30, 2012. She is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience.
- On January 7, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Holly Christine Frank. She had previously obtained PTC.016050 which expired on August 22, 2011. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 7, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Altavia Desha King. She had previously obtained PTC.019401 which expired on April 26, 2014.

Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.

- On January 8, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Mychela Brandy Pream. She had previously obtained PTC.020011 which expired on November 9, 2014. She is PTCB-certified and was issued a special work permit to earn her remaining hours of practical experience.
- On January 9, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Alecia Renee Samuel. She had previously obtained PTC.019759 which expired on August 27, 2014. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 12, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of E'Osha Le'Shay Champs. She had previously obtained PTC.018355 which expired on September 29, 2013. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 13, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Raquel Devone Terrance. She had previously obtained PTC.014812 which expired on February 10, 2009. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 14, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Dwanna Maria Rayford. She had previously obtained PTC.009622 which expired on November 17, 2004. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 16, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Taquina LaTerria Wicker. She had previously obtained PTC.018733 which expired on October 13, 2013. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Justin Wallace Craig. He had previously obtained PTC.013338 which expired on April 18, 2009. He is PTCB-certified and was issued a special work permit to earn his remaining hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Thaddeus John Dufour. He had previously obtained PTC.014102 which expired on January 7, 2010. He is PTCB-certified and was issued a special work permit to earn his remaining hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Matthew Robert Baham. He had previously obtained PTC.013333 which expired on April 18, 2009. He is PTCB-certified and was issued a special work permit to earn his remaining hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Tameka De'et Banks. She had previously obtained PTC.012213 which expired on February 27, 2008. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Marsharika Maria Jordan. She had previously obtained PTC.019403 which expired on October 26, 2014. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Laura Marie Harris. She had previously obtained PTC.015075 which expired on November 18, 2010. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On January 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Alicia Victoria Leon. She had previously obtained PTC.019748 which expired on August 27, 2014. Should she pass the PTCB by August 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On February 11, 2015, Mr. Aron and Mr. Finalet concurred to grant a request of Sharon Nieves. She had previously obtained PTC.019913 which expired on October 17, 2014. She was assigned to military active duty and could not complete her hours. The office issued her a special work permit to earn 600 hours of practical experience.

Board of Pharmacy

Contact Person: Mr. Malcolm J. Broussard, Executive Director

Mailing Address: 3388 Brentwood Drive
Baton Rouge, LA 70809-1700

Phone Number: 2259256481

Fax Number: 2259235669

Board Email: info@pharmacy.la.gov

Website: www.pharmacy.la.gov

Legal Authority: La. R.S. 37:1171 and La. R.S. 40:973

Year Created: 1888

Organizational

Placement: Dept. of Health & Hospitals (La. R.S. 36:803)

Purpose/Function:

The purpose of the Board is to protect the public health, safety and welfare by the effective control and regulation of the practice of pharmacy; the licensure of pharmacists; and the licensure, permitting, certification, registration, control and regulation of all persons and sites, in or out of this state, that sell drugs or devices to consumers and/or patients, or assist in the practice of pharmacy, within the state.

The Board shall also serve as the controlled substance authority for the state, issuing controlled dangerous substance licenses to all qualified applicants desiring to manufacture, distribute, prescribe or dispense controlled dangerous substances within the state. Further, the Board shall monitor its clients for compliance with the laws and rules relative to their activities with controlled dangerous substances.

Budget Message:

Due to continued growth in the health care sector, the Board anticipates slight growth in the number of credentials under management. In addition, new types of permits (e.g., durable medical equipment [DME]) requiring inspection have been added. Although we had hoped to serve those additional clients with no additional growth in personnel costs, we have found it necessary to replace previously vacated positions.

Number of Entity Members:

Number Authorized: 17

Number Currently Serving: 17

Number of Entity Meetings:

Actual number in prior year: 4

Estimated number in current year: 4

The Entity is:

Active Inactive Not fully organized Disbanded Never fully organized

Do members receive per diem, salaries, and/or travel expense reimbursements?

Yes No

Excluding member per diem, salaries, and travel expense reimbursements, does the entity receive or expend funds?

Yes No

Entity Member Per Diem:

Amount Authorized: \$75

per meeting per meeting day per day spent on board business None

Total entity member per diem:

Prior year actual: \$27,900

Current year budgeted: \$31,000

Entity Member Salaries:

Prior year actual: \$0

Current year budgeted: \$0

Entity Member Travel Expense Reimbursement:

Prior year actual: \$58,140

Current year budgeted: \$63,000

Number and Type of Authorized Employee Positions:

Classified: 14

Unclassified: 3

Part-time: 0

Entity Fiscal Year End:

4/30

6/30

7/31

9/30

10/31

12/31

Other (identify date)

None

Participation in State Employee Benefit Programs:

Employees:

participate in state retirement system(s) and/or state group insurance program(s)

do not participate in state benefit programs

Members:

participate in state retirement system(s) and/or state group insurance program(s)

do not participate in state benefit programs

Notes:

Summary Statement of Actual and Budgeted Means of Financing for Years Shown

Means of Financing	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
State General Fund (Direct)	\$0	\$0	\$0
State General Fund By:			
Interagency Transfers	\$0	\$0	\$0
Fees & Self Generated Revenues			
1) Licenses	\$2,150,890	\$2,135,500	\$0
2) Examinations	\$109,000	\$108,000	\$0
3) Enforcement Actions	\$276,198	\$314,000	\$0
4) Sale of Goods and Services	\$13,495	\$14,000	\$0
5) Administrative Fees	\$23,230	\$22,500	\$0
6) Prescription Monitoring Program	\$462,825	\$465,000	\$0
7) Miscellaneous	\$820	\$1,000	\$0
8) Investments	\$22,936	\$0	\$0
Statutory Dedications:			
Other Means of Financing	\$0	\$0	\$0
Interim Emergency Board	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0
Total Means of Financing	\$3,059,394	\$3,060,000	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Summary Statement of Actual and Budgeted Expenditures/Expenses For Years Shown

Category of Expenditure/Expense	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
Salaries:			
Regular	\$1,193,177	\$1,334,100	\$0
Other Compensation	\$48,254	\$51,000	\$0
Related Benefits	\$604,051	\$772,800	\$0
Total Salaries	\$1,845,482	\$2,157,900	\$0
Operating Expenses:			
Travel	\$103,298	\$152,500	\$0
Operating Services	\$427,927	\$409,100	\$0
Supplies	\$17,630	\$20,000	\$0
Total Operating Expenses	\$548,855	\$581,600	\$0
Professional Services:			
Accounting	\$23,961	\$25,000	\$0
Management Consulting	\$0	\$0	\$0
Legal	\$35,908	\$30,000	\$0
Other	\$309,469	\$213,000	\$0
Professional Travel	\$0	\$0	\$0
Total Professional Services	\$369,338	\$268,000	\$0
Other Charges:			
Other Charges	\$0	\$0	\$0
Debt Service	\$0	\$0	\$0
Total Other Charges	\$0	\$0	\$0
Acquisitions and Major Repairs:			
Acquisitions	\$345	\$52,500	\$0
Major Repairs	\$0	\$0	\$0
Total Acquisitions & Major Repairs	\$345	\$52,500	\$0
Interagency Transfer	\$0	\$0	\$0
Total Expenditures	\$2,764,020	\$3,060,000	\$0
Number of Authorized Positions:			
Classified	14	14	0
Unclassified	3	3	0
Total Authorized Positions	17	17	0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Summary of Fund Balance

	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
Beginning Fund Balance/Net Assets	\$3,225,350	\$3,520,724	\$0
Total Means of Financing	\$3,059,394	\$3,060,000	\$0
Total Expenditures/Expenses and Transfers	\$(2,764,020)	\$(3,060,000)	\$0
Other Adjustments:			
Ending Fund Balance/Net Assets	\$3,520,724	\$3,520,724	\$0
Reservations of Fund Balance/Restrictions of Net Assets:			
OPEB	\$9,297,000	\$1,017,000	\$0
Debt Service Payable	\$1,032,300	\$885,000	\$0
Continuing Payroll Obligations	\$150,000	\$150,000	\$0
Homeland Maintenance	\$50,000	\$50,000	\$0
Unreserved Fund Balance/Unrestricted Net Assets	\$1,358,724	\$1,418,724	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Performance

Performance Indicators	6/30/2012 Actual	6/30/2013 Actual	6/30/2014 Actual	6/30/2015 Planned	6/30/2015 Estimated	6/30/2016 Planned
Licensing						
Licenses, Certificates, etc. Issued/Renewed	37,281	36,762	42,874	45,000	47,500	50,000
Employees Directly Involved in License Issue	3	3	3	3	3	3
Total Employees	17	17	17	17	17	17
Examining						
Exams Taken	777	901	931	950	975	1,000
Employees Directly Involved in License Issue	3	3	3	3	3	3
Number of Times Exams Given Per Year	4	4	4	4	4	4
Enforcement						
Actions Pending Beginning of Year	197	218	255	252	250	250
Actions Opened	410	392	479	500	500	500
Actions Closed/Concluded	389	355	482	500	500	500
End of Year Actions Pending	218	255	252	250	250	250
Dispositions of Enforcement Actions						
In Favor of Licensee	20	21	127	0	0	0
Against Licensee	160	159	304	0	0	0
Other	209	175	51	0	0	0
Total Dispositions	389	355	482	0	0	0
Employees Involved in Enforcement Proceedings	7	7	7	7	7	7
Anticipated Developments:						
Major Objectives/Assumptions:						

Means of Financing Detail of Self-Generated Revenue

Detail of Self-Generated Revenue	Number of Transactions	Prior Year 2014 Actual	Current Year 2015 Budgeted**	Projected Year 2016 Budgeted
License Fees	0	\$2,150,890	\$2,135,500	\$0
Examination Fees *(Including amounts paid to third parties by the board.)	0	\$109,000	\$0	\$0
Enforcement Actions (Fines) *(Including amounts collected on behalf of third parties by the board.)	0	\$276,198	\$314,000	\$0
Sale of Goods and Services	0	\$13,495	\$14,000	\$0
Other	0	\$509,811	\$488,500	\$0

* Third party refers to individuals outside the agency who administer exams on behalf of board or bring charges against a licensee.

** Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Salaries

Description	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
Salaries - Regular	\$1,193,177	\$1,334,100	\$0
Salaries - Overtime	\$0	\$0	\$0
Wages	\$20,354	\$20,000	\$0
Other Compensation	\$0	\$0	\$0
Compensation of Board Members	\$27,900	\$31,000	\$0
Sub-Total Salaries	\$1,241,431	\$1,385,100	\$0
Retirement Contributions - State Employees	\$371,283	\$494,000	\$0
Retirement Contributions - Other:			
F.I.C.A Tax & Medicare Tax	\$21,330	\$27,100	\$0
Unemployment Benefits	\$0	\$0	\$0
Group Insurance Contributions - State Employees	\$119,974	\$160,200	\$0
Group Insurance Contributions - Other:			
Other Related Benefits:			
OPEB	\$91,464	\$91,500	\$0
Sub-Total Related Benefits	\$604,051	\$772,800	\$0
Total Salaries	\$1,845,482	\$2,157,900	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Schedule of Travel Expenses

Description	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
In-State:			
Administrative	\$0	\$0	\$0
Conferences & Conventions	\$0	\$0	\$0
Field Travel	\$19,434	\$24,500	\$0
Board Members	\$31,043	\$33,000	\$0
Sub-Total In-State	\$50,477	\$57,500	\$0
Out-of-State:			
Administrative	\$3,154	\$30,000	\$0
Conferences & Conventions	\$7,079	\$15,000	\$0
Field Travel	\$0	\$0	\$0
Board Members	\$14,829	\$15,000	\$0
Sub-Total In-State	\$25,062	\$60,000	\$0
Total Travel	\$75,539	\$117,500	\$0
Total Mileage Reimbursement	\$27,759	\$35,000	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Schedule of Operating Expenses

Description	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted
Advertising	\$0	\$0	\$0
Printing	\$56,235	\$25,000	\$0
Insurance	\$6,272	\$7,500	\$0
Automotive Repairs	\$0	\$0	\$0
Other Maintenance	\$2,681	\$4,000	\$0
Rentals	\$2,952	\$18,000	\$0
Dues & Subscriptions	\$20,354	\$23,000	\$0
Postage	\$51,628	\$45,000	\$0
Telephone	\$15,629	\$150,000	\$0
Utilities	\$10,655	\$10,000	\$0
Other	\$256,249	\$118,100	\$0
Total Operating Services	\$422,655	\$400,600	\$0
Office Supplies	\$17,630	\$20,000	\$0
Operating Supplies:			
Medical	\$0	\$0	\$0
Food	\$0	\$0	\$0
Automotive	\$0	\$0	\$0
Other Operating Supplies	\$0	\$0	\$0
Repair & Maintenance Supplies:			
Automotive	\$0	\$0	\$0
Other	\$0	\$0	\$0
Total Supplies	\$17,630	\$20,000	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.

Schedule of Acquisitions & Major Repairs

Description	Prior Year 2014 Actual	Current Year 2015 Budgeted*	Projected Year 2016 Budgeted	Dollar Value of Current Inventory
Acquisitions:				
Land and Buildings	\$0	\$0	\$0	\$2,058,801
Bldgs., Grounds & Gen Plant	\$0	\$0	\$0	\$0
Automotive	\$0	\$0	\$0	\$0
Office	\$345	\$52,500	\$0	\$775,806
Educational	\$0	\$0	\$0	\$0
Communications	\$0	\$0	\$0	\$0
Other	\$0	\$0	\$0	\$0
Total Acquisitions	\$345	\$52,500	\$0	\$2,834,607
Major Repairs:				
Land	\$0	\$0	\$0	\$0
Buildings	\$0	\$0	\$0	\$0
Machinery & Equipment	\$0	\$0	\$0	\$0
Automotive	\$0	\$0	\$0	\$0
Bldgs., Grounds & Gen Plant	\$0	\$0	\$0	\$0
Farm & Heavy Movable	\$0	\$0	\$0	\$0
Household	\$0	\$0	\$0	\$0
Medical	\$0	\$0	\$0	\$0
Office	\$0	\$0	\$0	\$0
Educational, Recreational & Cultural	\$0	\$0	\$0	\$0
Boats & Aircraft	\$0	\$0	\$0	\$0
Communications	\$0	\$0	\$0	\$0
Total Major Repairs	\$0	\$0	\$0	\$0

* Current year should reflect most recent estimate of annual revenues/expenditures for the fiscal year in which you are presently operating.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



December 29, 2014

Daryl G. Purpera, CPA, CFE
Louisiana Legislative Auditor
PO Box 94397
Baton Rouge, LA 70804-9397

Via E-mail: DPurpera@lla.la.gov

Electronic Mail – Delivery Receipt Requested

Dear Mr. Purpera:

As required by La. R.S. 39:1335, the Comprehensive Budget for Fiscal Year 2015-2016 for the Louisiana Board of Pharmacy is enclosed. As you requested, I have also enclosed an extract from the relevant portion of the Minutes of the Board's quarterly meeting on November 13, 2014 documenting their approval of this budget. Finally, we have posted this information to the LaTrac website maintained by the Boards & Commissions office.

If you have any questions or need any additional information, please contact me directly at mbroussard@pharmacy.la.gov or 225.925.6481.

For the Board:

Malcolm J. Broussard
Executive Director

cc: Legislative Fiscal Officer
Via E-mail: CarpenterJ@legis.la.gov
Chair, Joint Legislative Committee on the Budget
Via E-mail: BouqueP@legis.la.gov
Chair, Senate Committee on Health and Welfare
Via E-mail: sh&w@legis.la.gov
Chair, House Committee on Health and Welfare
Via E-mail: MurrayD@legis.la.gov
Reference File



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



December 29, 2014

MINUTES EXTRACT

The following extract is from the Minutes of the November 13, 2014 meeting of the Louisiana Board of Pharmacy, held in Baton Rouge, Louisiana.

10. Committee Reports

A. Finance Committee

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre reported the committee had met the previous day to review two documents prepared by the staff. Mr. Pitre directed the members to the interim report for the current fiscal year, reviewed the highlights, and indicated the report was presented for information only and required no action by the Board. He then directed the members to the Proposed Budget for Fiscal Year 2015-2016. He indicated the committee members had reviewed the proposal and voted to recommend the adoption of the proposed budget as presented. He then moved,

Resolved, to approve and adopt the Proposed Budget for Fiscal Year 2015-2016. The motion was adopted after a unanimous vote in the affirmative.

Finally, he expressed his appreciation to the other committee members for their efforts the previous day.

I certify that I am the custodian of the Board's records and its seal, and that the foregoing is an accurate extract from the official records of the Board. Witness my hand and seal this 29th day of December in 2014.



Malcolm J. Broussard
Executive Director

Entity: Board of Pharmacy

ID#: 3467

Section: A

FY: 2015-2016

Contact Person: Malcolm J. Broussard
Title: Executive Director

Mailing Address: 3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Telephone: 225.925.6496
Facsimile: 225.925.6499
Email: mbroussard@pharmacy.la.gov
Website: <http://www.pharmacy.la.gov>

Legal Authorities: La R.S. 37:1171 and La. R.S. 40:973

Year Created: 1888

Organizational Placement: Dept. of Health and Hospitals
(La. R.S. 36:803)

Entity is: Active

Purpose/Function: The purpose of the Board of Pharmacy is to protect the public health, safety, and welfare by the effective control and regulation of the practice of pharmacy; the licensure of pharmacists; and the licensure, permitting, certification, registration, control, and regulation of all persons and sites, in or out of this state, that sell drugs or devices to consumers and/or patients, or assist in the practice of pharmacy, within the state.

The Board of Pharmacy shall also serve as the controlled substance authority for the state, issuing controlled dangerous substance licenses to all qualified applicants desiring to manufacture, distribute, prescribe or dispense controlled dangerous substances within the state. Further, the Board shall monitor its clients for compliance with the laws and rules relative to their activities with controlled dangerous substances.

Budget Message: The Board's revenue stream has benefitted from an unanticipated growth in numbers of credentials (14% over two prior years vs typical 4% per year). Due to continued growth in the health care sector, the Board anticipates 3-5% growth in the number of credentials under management.

The Board continues to seek opportunities for expense reduction, targeting printing and postage costs. We converted our quarterly newsletter from a periodical printed and mailed to one posted on our website. We have also initiated a transition to virtual (paperless) credentials, and we continue to increase our use of electronic vs printed communications. Finally, we also plan to make our final payment for the loan securing our office building, which will clear all debt.

Signature: Malcolm J. Broussard

Date: 12-29-2014

Entity: Board of Pharmacy

ID#: 3467

Section: A

FY: 2015-2016

Number of Entity Members:

Number Authorized:	17
Number Currently Serving:	17

Number of Entity Meetings:

Actual Number in Prior Year:	4
Estimated Number in Current Year:	4

Do members receive per diem, salaries, and/or travel expense reimbursements? Yes

Excluding member per diem, salaries, and travel expense reimbursements, does the entity receive or expend funds? Yes

Entity Fiscal Year End: 6/30

Entity Member Per Diem:

Amount Authorized: \$75 per day spent on board business

Total Entity Member Per Diem:

Prior Year Actual:	\$27,900
Current Year Budget:	\$31,000

Entity Member Salaries:

Total Entity Member Salaries:

Prior Year Actual:	0
Current Year Budget:	0

Entity Member Travel Reimbursement:

Total Entity Member Travel Expense Reimbursement:

Prior Year Actual:	\$58,140
Current Year Budget:	\$63,000

Number and Type of Authorized Employee Positions:

Classified:	17
Unclassified:	3
Part-time:	3

Employees **do** participate in state retirement system(s) and/or state group insurance program(s).

Members **do not** participate in state benefit programs.

Summary Statement of Actual and Budgeted Means of Financing for Years Shown

<u>Means of Financing</u>	<u>Prior Year FY 13-14 Actual</u>	<u>Current Year FY 14-15 Budgeted (A#1)</u>	<u>Projected Year FY 15-16 Budgeted</u>	<u>Total Projected Year Over or Under Current Year</u>
Fees & Self-Generated Revenue				
Licenses	2,150,890	2,135,500	2,140,500	5,000
Examinations	109,000	108,000	95,000	(13,000)
Enforcement Actions	276,198	314,000	272,000	-42,000
Sales of Goods & Services	13,495	14,000	14,000	0
Administrative Fees	23,230	22,500	22,500	0
Prescription Monitoring Program	462,825	465,000	465,000	0
Miscellaneous	820	1,000	1,000	0
Investments	22,936	0	0	0
Total Means of Financing	3,059,394	3,060,000	3,010,000	-50,000

Louisiana Board of Pharmacy Fiscal Year: July 1 through June 30

Summary Statement of Actual and Budgeted Expenditures for Years Shown

<u>Category of Expenditure</u>	<u>Prior Year FY 13-14 Actual</u>	<u>Current Year FY 14-15 Budgeted (A#1)</u>	<u>Projected Year FY 15-16 Budgeted</u>	<u>Total Projected Year Over or Under Current Year</u>
Salaries:				
Regular	1,193,177	1,334,100	1,334,100	0
Other Compensation	48,254	51,000	51,000	0
Related Benefits	604,051	772,800	772,800	0
TOTAL SALARIES	1,845,482	2,157,900	2,157,900	0
Operating Expenses:				
Travel	103,298	153,500	146,500	(7,000)
Operating Services	427,927	408,100	395,100	(13,000)
Office Supplies	17,630	20,000	20,000	0
TOTAL OPERATING EXPENSES	548,855	581,600	561,600	(20,000)
Professional Services:				
Accounting	23,961	25,000	25,000	0
Legal	35,908	30,000	30,000	0
Testing & Information Systems	97,303	98,000	108,000	10,000
Prescription Monitoring Program	195,791	80,000	80,000	0
Property Management	16,375	35,000	35,000	0
TOTAL PROFESSIONAL SERVICES	369,338	268,000	278,000	10,000
Acquisitions & Major Repairs:				
Acquisitions	345	52,500	12,500	(40,000)
Major Repairs	0	0	0	0
TOTAL ACQUISITIONS & REPAIRS	345	52,500	12,500	(40,000)
Number of Authorized Positions:				
Classified	19	19	19	0
Unclassified	3	3	3	0
Unfilled Vacant Positions	5	5	5	0
TOTAL AUTHORIZED POSITIONS	27	27	27	0

Summary of Fund Balance

	Prior Year FY 13-14 <u>Actual</u>	Current Year FY 14-15 <u>Budgeted (A#1)</u>	Projected Year FY 15-16 <u>Budgeted</u>
Beginning Fund Balance	3,225,350	3,520,724	3,520,724
Total Means of Financing	3,059,394	3,060,000	3,010,000
Total Expenditures	2,764,020	3,060,000	3,010,000
Other Adjustments	0	0	0
Ending Fund Balance	3,520,724	3,520,724	3,520,724
Reservations of Fund Balance	2,162,000	2,102,000	2,100,000
Unreserved Fund Balance	1,358,724	1,418,724	1,420,724
Notes			
Reservations of Fund Balance	<u>FY 13-14</u>	<u>FY 14-15</u>	<u>FY 15-16</u>
Other Post Employment Benefits	929,700	1,017,000	1,150,000
Debt Service Payable	1,032,300	885,000	750,000
Continuing Payroll Obligations	150,000	150,000	150,000
Homeland Maintenance	<u>50,000</u>	<u>50,000</u>	<u>50,000</u>
<i>Total</i>	2,162,000	2,102,000	2,100,000

Anticipated Developments:

Major Objectives/Assumptions:

Performance Indicators	FY 11-12	FY 12-13	FY 13-14	FY 14-15	FY 15-16
	6/30/2012 <u>Actual</u>	6/30/2013 <u>Actual</u>	6/30/2014 <u>Actual</u>	6/30/2015 <u>Planned</u>	6/30/2016 <u>Projected</u>
Licensing					
Pharmacists	7,353	7,758	7,871	7,900	8,000
Technicians	7,333	7,333	8,510	8,500	8,500
Students	1,066	1,073	1,081	1,100	1,100
Pharmacies	1,758	1,784	1,872	1,900	1,950
Emergency Drug Kits	448	431	474	475	475
Automated Med Systems	366	638	451	450	450
CDS Licenses	18,957	17,745	20,009	20,000	21,000
Employees in Licensing	3	3	3	3	3
Examinations					
Number of exams taken	777	901	931	900	900
Annual Frequency of Exams	4	4	4	4	4
Employees in Examinations	3	3	3	3	3
Enforcement					
Inspections	913	926	1,115	1,000	1,000
Audits Completed	2	4	1	0	0
Investigations Closed/Concluded	389	355	482	400	400
Violations Hearings	4	4	4	4	4
Cases Adjudicated	160	159	182	100	100
Pharmacists Disciplined	45	47	65	40	40
Interns Disciplined	3	2	1	0	0
Technicians Disciplined	42	36	58	30	30
Permits/CDS Licenses Disciplined	33	44	58	30	30
Interlocutory Actions	0	0	0	0	0
Total Number of Cases	180	180	223	150	150
Employees in Enforcement	7	7	7	7	7
Total Number of Employees	17	17	17	17	17

Means of Financing Detail of Self-Generated Revenue

Detail of Self-Generated Revenue (including legal citation of authorizations)	FY 13-14 Actual	FY 14-15 Budgeted (A#1)	FY 15-16 Projected	FY 15-16 O/U FY 14-15
LRS 37:1182.A.19 authorizes collection of fees; LRS 37:1184 contains itemized listing of fees				
LRS 40:1013 authorizes collection of fees for Prescription Monitoring Program				
Licenses				
Pharmacists	985,362	974,000	979,000	5,000
Technicians	349,725	347,000	347,000	0
Students	3,070	3,000	3,000	0
Permits	812,733	811,500	811,500	0
Examinations				
Pharmacists	47,700	45,000	45,000	0
Technicians	61,300	63,000	50,000	-13,000
Enforcement Actions	276,198	314,000	272,000	-42,000
Administrative Fees	23,230	22,500	22,500	0
Sale of Goods & Services	13,495	14,000	14,000	0
Prescription Monitoring Program	462,825	465,000	465,000	0
Miscellaneous	820	1,000	1,000	0
Investments	22,936	0	0	0

Salaries

<u>Description</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budgeted (A#1)</u>	<u>FY 15-16 Projected</u>	<u>FY 15-16 O/U FY 14-15</u>
Salaries - Regular	1,193,177	1,334,100	1,334,100	0
Salaries - Overtime	0	0	0	0
Wages	20,354	20,000	20,000	0
Other Compensation	0	0	0	0
Compensation of Board Members	27,900	31,000	31,000	0
Sub-Total Salaries & Other Compensation	1,241,431	1,385,100	1,385,100	0
Retirement Contributions - State Employees	371,283	494,000	494,000	0
Payroll Taxes (FICA, FUTA, Medicare)	21,330	27,100	27,100	0
Group Insurance Contributions - State Employees	119,974	160,200	160,200	0
Other Post Employment Benefits (OPEB)	91,464	91,500	91,500	0
Sub-Total Related Benefits	604,051	772,800	772,800	0
Total Salaries	1,845,482	2,157,900	2,157,900	0
Number of Classified Employees	14	14	14	0
Number of Unclassified Employees	3	3	3	0

Request for Salary and Merit Increases for Incumbents

Name	C/U	Position	Pay Grid	6/30/2014 Actual	6/30/2015 Budget	6/30/2016 Projected	Percent Increase	FY 15-16 Projection				
								Retirement	FICA	SEGBP	Medicare	
<i>Credentials Division</i>												
Able, Hannah R.	C	Admin Coordinator 3	AS-609	32,500	33,800	33,800	0%	Yes	No	Yes	Yes	
Branch, Karla D.	C	Admin Coordinator 3	AS-609	37,643	39,149	39,149	0%	Yes	No	Yes	Yes	
Chatman, Amicha R.	C	Admin Coordinator 3	AS-609	33,127	34,452	34,452	0%	Yes	No	Yes	Yes	
Howard, Latrice M.	C	Admin Coordinator 3	AS-609	32,816	34,129	34,129	0%	Yes	No	Yes	Yes	
Woods, Julia F.	C	Admin Coordinator 3	AS-609	34,452	35,830	35,830	0%	Yes	No	Yes	Yes	
(Vacancy)	C	Admin Coordinator 1	AS-605	0	35,000	35,000	0%	Yes	No	Yes	Yes	
Stevens, Sarah B.	C	Licensing Analyst-2	AS-611	37,272	38,763	38,763	0%	Yes	No	Yes	Yes	
<i>Compliance Division</i>												
Meador, Danielle C.	C	Admin Assistant 3	AS-609	26,957	28,035	28,035	0%	Yes	No	Yes	Yes	
Aaron, Cary D.	C	PST Compliance Officer	MS-525	102,000	106,080	106,080	0%	Yes	No	Yes	Yes	
Collins, Stephen L.	C	PST Compliance Officer	MS-525	102,948	107,066	107,066	0%	Yes	No	Yes	Yes	
Savoie, Huey J.	C	PST Compliance Officer	MS-525	102,948	107,066	107,066	0%	Yes	No	Yes	Yes	
Trisler, Rayland M.	C	PST Compliance Officer	MS-525	102,948	107,066	107,066	0%	Yes	No	Yes	Yes	
Whaley, Benjamin S.	C	PST Compliance Officer	MS-525	102,948	107,066	107,066	0%	Yes	No	Yes	Yes	
(Vacancy)	C	CPT Compliance Officer	AS-611	0	37,500	37,500	0%	Yes	No	Yes	Yes	
<i>Administrative Division</i>												
(Vacancy)	C	IT Tech Supp Spec 1	TS-310	0	0	0						
(Vacancy)	C	Admin Coordinator 1	AS-605	0	0	0						
Smith, Felicia B.	C	Admin Coordinator 3	AS-609	34,626	36,011	36,011	0%	Yes	No	Yes	Yes	
Villeneuve, Kelley L.	U	Office Manager		50,936	52,973	52,973	0%	Yes	No	Yes	Yes	
Finalet, Carlos M., III	U	General Counsel		116,324	120,977	120,977	0%	Yes	No	Yes	Yes	
Fontenot, M. Joseph	C	Asst Exec Director	MS-528	120,141	124,947	124,947	0%	Yes	No	Yes	Yes	
Broussard, Malcolm J.	U	Executive Director		142,446	148,144	148,144	0%	Yes	No	Yes	Yes	
TOTAL				1,213,032	1,334,054	1,334,054				1,334,054		

Compensation of Board or Commission Members

The statutory authority for payment of per diem is LRS 37:1178.
 As provided at LRS 37:1184.e, the per diem is \$75/day of board business.
 Since attendance varies at Board meetings, the only specific member data available is historical.
 No other expenses are paid except for per diem and travel expense reimbursement.

Name of Member	FY 13-14 Actual			FY 14-15 Budget			FY 15-16 Projected		
	Per Diem	Mileage	Subsistence	Per Diem	Mileage	Subsistence	Per Diem	Mileage	Subsistence
Aron, Carl W.	4,050	3,060	2,573	3,060	2,573	5,313			
Bond, Brian A.	3,000	1,730	2,580	1,730	2,580	1,924			
Burch, Clovis S.	1,575	1,403	2,099	1,403	2,099	802			
Dartez, Ryan M.	825	430	1,242	430	1,242	0			
Hall, Jacqueline L.	825	347	1,009	347	1,009	0			
Indovina, Richard M.	1,725	729	1,204	729	1,204	2,000			
McKay, Marty R.	1,575	938	1,672	938	1,672	0			
Melancon, Chris B.	1,575	729	296	729	296	0			
Milano, Diane G.	825	427	709	427	709	0			
Moore, Ronald E.	600	0	0	0	0	0			
Pitre, Blake P.	1,875	734	1,389	734	1,389	1,878			
Rabb, T. Morris	2,100	1,499	1,596	1,499	1,596	2,000			
Reed, Pamela G.	2,325	0	0	0	0	2,000			
Resweber, Donald	1,350	582	713	582	713	1,827			
Simonson, Deborah H.	600	536	1,345	536	1,345	1,274			
Soileau, Richard A.	2,025	709	1,226	709	1,226	1,927			
Valentine, Rhonny K.	900	1,314	438	1,314	438	0			
TOTAL	27,750	15,167	20,091	15,167	20,091	20,945	31,000	19,000	44,000

Number of Board Members Authorized: 17

Schedule of Travel Expense (22)

Description	FY 13-14 Actual	FY 14-15 Budget (A#1)	FY 15-16 Projected	FY 15-16 O/U FY 14-15
In-State:				
Administrative	0	0	0	0
Conferences & Conventions	0	0	0	0
Field Travel	3,912	8,000	6,000	(2,000)
Board Members	22,670	26,000	26,000	0
<i>Sub-Total In-State</i>	26,582	34,000	32,000	(2,000)
Out-of-State:				
Administrative	3,154	30,000	30,000	0
Conferences & Conventions	7,079	15,000	10,000	(5,000)
Field Travel	0	0	0	0
Board Members	20,142	18,000	18,000	0
<i>Sub-Total Out-of-State</i>	30,375	63,000	58,000	(5,000)
Rental Vehicles for Compliance Officers				
Rental Rates	11,544	13,500	13,500	0
Fuel Costs	3,978	4,000	4,000	0
<i>Sub-Total for Vehicle Rentals</i>	15,522	17,500	17,500	0
Total Travel	72,479	114,500	107,500	(7,000)
Total Mileage Reimbursement	30,819	39,000	39,000	0

Notes:

Schedule of Operating Expenses

<u>Description</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Projected</u>	<u>FY 15-16 O/U FY 14-15</u>
Rentals - Office & Equipment	2,952	18,000	15,000	-3,000
Equipment Maintenance	2,681	4,000	3,000	-1,000
Telephone	15,629	15,000	18,000	3,000
Printing	56,235	25,000	17,000	-8,000
Postage	51,628	45,000	52,000	7,000
Utilities	10,655	10,000	11,000	1,000
Dues & Subscriptions	20,354	23,000	10,000	-13,000
Penalties	0	0	0	0
Trust Fund Fees	0	0	0	0
Financial Service Charges	52,466	50,000	53,000	3,000
Office Meeting Expenses	47	500	500	0
Board Members Miscellaneous Expenses	0	0	0	0
Miscellaneous	0	0	0	0
Depreciation	141,772	141,000	142,000	1,000
Interest Payments on Bldg Loan	63,000	63,000	60,000	-3,000
Total Operating Expenses	417,419	394,500	381,500	-13,000
Office Supplies	17,630	20,000	20,000	0
Operating Supplies				
Repairs & Maintenance Supplies				
Total Supplies	17,630	20,000	20,000	0

Detail of Professional Service Contracts

<u>Contractor - Purpose of Contract</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Projected</u>	<u>FY 15-16 O/U FY 14-15</u>
Accounting - General Russell F. Champagne Kolder, Champagne, Slaven, LLC Certified Public Accountants 113 East Bridge Street Breaux Bridge, LA 70517	19,432	20,000	20,000	0
Accounting - Legislative Auditor Baxley & Associates, LLC P. O. Box 482 Plaquemine, LA 70765	4,300	5,000	5,000	0
Legal - Prosecuting Attorney Celia R. Cangelosi 5551 Corporate Blvd Ste B-01 Baton Rouge, LA 70821-3036	20,562	25,000	25,000	0
Legal - Counsel to Hearing Officer E. Wade Shows Shows, Cali & Berthelot 628 Saint Louis St Baton Rouge, LA 70802	9,090	5,000	5,000	0
Testing & Information Systems - Network Support Services Essential Solutions, LLC 343 Third Street, Suite 400 Baton Rouge, LA 70801	30,968	40,000	45,000	5,000

Detail of Professional Service Contracts (cont.)

<u>Contractor - Purpose of Contract</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Projected</u>	<u>FY 15-16 O/U FY 14-15</u>
Testing & Information Systems - Licensure Information System Iron Data Corporation 8601 Six Forks Rd ste 540 Raleigh, NC 27615	63,746	53,000	58,000	5,000
Testing & Information Systems - Prescription Monitoring Program Health Information Designs, LLC 391 Industry Dr Auburn, AL 36832	51,000	0	0	0
Testing & Information Systems - Prescription Monitoring Program Optimum Technology One Crossroads Center 100 E Campus View Blvd Ste 380 Columbus, OH 43235	45,500	80,000	80,000	0

BC-10

Schedule of Other Charges

<u>Description</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Projected</u>	<u>FY 15-16 O/U FY 14-15</u>
Office of Risk Management	6,272	7,500	7,500	0
Civil Service Assessment	4,236	6,100	6,100	0

Schedule of Acquisitions & Major Repairs

<u>Description</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Protected</u>	<u>FY 15-16 O/U FY 14-15</u>	<u>Dollar Value of Current Inventory</u>
<i>Acquisitions</i>					
Lot 5-A, Towne Ctr Business Park					<u>9/30/2014</u> 709,080
Land & Office Bldg - 3388 Brentwood Dr					1,349,721
Office Equipment	345	52,500	12,500	(40,000)	214,496
Office Furniture					152,750
Software - Licensure & Website					408,560
Accumulated Depreciation					(693,018)
Total Acquisitions	345	52,500	12,500	(40,000)	2,141,589
<i>Major Repairs</i>					
Land					
Buildings					
Machinery & Equipment					
Automotive					
Bldgs., Grounds, & Gen. Plant					
Farm & Heavy Movable					
Household					
Medical					
Office					
Educational, Research, & Cultural					
Boats & Aircraft					
Communications					
Total Major Repairs	0	0	0	0	0

Schedule of In-Kind Assistance

<u>Description</u>	<u>Value of In-Kind Assistance</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Budget (A#1)</u>	<u>FY 15-16 Projected</u>
None		0	0	0



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



MEMORANDUM

To: Frances C Thomas, Director
David R Poynter Legislative Research Library

From: Malcolm J Broussard
Executive Director

Date: January 6, 2015

Re: Annual Report

The following report(s) are submitted to the library, in both printed and electronic form, in compliance with the provisions of La. R.S. 24:772.A.3:

07-01-2014 *Annual Report for Fiscal Year 2013-2014* (which includes the annual report for the Board's Prescription Monitoring Program, submitted to the legislature as required by La. R.S. 40:1010. This report is also available in the Public Library section of the Board's website at www.pharmacy.la.gov.)

In the event you have any questions or need additional information, please contact me directly at mbroussard@pharmacy.la.gov or 225.925.6481.



PUBLIC DOCUMENT DEPOSITORY PROGRAM

STATE AGENCY PUBLICATIONS REPORT FORM

All Louisiana state agencies, as defined by R.S. RS 25:121.1, are required to submit a complete list of the agency's publications semiannually. Please type your agency's report in this form and submit the form on or before **January 31** and **July 31** each year. The completed form may be emailed to docs@state.lib.la.us or sent via fax, mail, or hand-delivery to the address given at the bottom of this form.

Your Name:	Malcolm J Broussard	Email:	mbroussard@pharmacy.la.gov	
Job Title / Position:	Executive Director	Title:	Mr.	Phone: 2259256481
Agency/Institution Name:	Louisiana Board of Pharmacy			
Agency Web Page:	www.pharmacy.la.gov	Are you the liaison officer?	<input checked="" type="radio"/> Yes	<input type="radio"/> No
Liaison Name:		Liaison Email:		
Liaison Job Title:		Liaison Phone:		

NEW DOCUMENTS

List any new (never previously published) public documents here.

Publication Title:	Publication Date:	Publication Frequency:	Currently Published Format(s):
Board Meeting Minutes	05-07-2014 & 08-06-2014	quarterly	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital
PMP Advisory Council Meeting Minutes	07-09-2014	quarterly	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital
Bulletin No. 14-05	09-15-2014	as needed	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital
Board's Annual Report for 2014	07-01-2014	annual	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital
Declaratory Statement: Medication Therapy Management in the Practice of Pharmacy	8-06-2014	once	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital

CONTINUING DOCUMENTS

List here all currently published (that have also been previously published) documents that have not changed (e.g., in title, frequency, format, or scope) since the last publications report.

Publication Title:	Publication Frequency:	Currently Published Format(s):
Louisiana Board of Pharmacy News	quarterly	<input type="checkbox"/> Hard Copy <input checked="" type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital

CHANGED DOCUMENTS

List here any documents that have changed, including changes to title, frequency (e.g., monthly to semiannual), or format (e.g., print to digital). If a document becomes digital-only, list it here and send the digital document as an email attachment to docs@state.lib.la.us; do not merely send a link to the document.

Publication Title:	Publication Frequency:	Currently Published Format(s):
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital

CEASED DOCUMENTS

List all documents here that the agency has ceased (since the last report) to publish, with the date of the last issue/edition.

Publication Title:	Last Issue Published:	Former Format(s):
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
		<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital

DOCUMENTS UNABLE TO SUBMIT

List any documents that cannot be deposited; provide the reason.

Publication Title:	Reason Not Submitted:	Date / Issue:	Currently Published Format(s):
			<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital
			<input type="checkbox"/> Hard Copy <input type="checkbox"/> Digital

RECORDER OF DOCUMENTS
 STATE LIBRARY OF LOUISIANA
 701 NORTH 4TH STREET
 BATON ROUGE, LA 70802
 PHONE 225.342.4929
 FAX 225.219.4804

For Recorder's Office Only:	
Date Received:	



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Roster of Agency Publications

Minutes of Board Meetings and Administrative Hearings

The board generally meets on a calendar quarter basis. The minutes for a board meeting are approved at the next regular meeting and then posted on the board's website. These documents exist in electronic form only; they are not commercially printed.

Newsletters

The board publishes a quarterly newsletter in a collaborative effort with the National Association of Boards of Pharmacy (NABP) Foundation. Both parties contribute content for the newsletter, which is published in January, April, July, and October. This newsletter exists in electronic form only and is posted on the websites for both NABP and the board.

Bulletins

As the need arises, the board may publish a bulletin for all of its licensees or some portion thereof. These electronic documents are distributed by email and are also posted on the board's website.

Guidance Documents

As the need arises, the board may publish compliance policy guidance documents on certain topics for its licensees. These electronic documents are distributed by email and are also posted on the board's website.

Laws & Regulations

The board publishes a compilation of the laws and rules relevant to pharmacy practice in Louisiana. This publication exists in electronic form only and is posted on the board's website.

Directory of Government Agencies & Private Organizations

As a service to its licensees, the board publishes a directory of government agencies and private organizations with some connection to the education, practice, and regulation of the pharmacy profession. The publication exists in electronic form only and is posted on the board's website.

Annual Reports

The board publishes an annual report on its activities. The report exists in electronic form only and is posted on the board's website. The board also submits a comprehensive annual financial report to the legislative auditor.

Commissioned Reports

From time to time, the legislature requests the board's assistance on certain pharmacy-related issues in public health and safety. When requested, the board will prepare commissioned reports for submission to the legislature. These documents exist in electronic form only and are posted on the board's website.

Prescription Monitoring Program (PMP)

The PMP Advisory Council meets quarterly. The minutes for a meeting are approved at the subsequent meeting and then posted on the board's website.

Inventory of Agency Publications

(Revised 01-05-2015)

Minutes of Board Meetings & Administrative Hearings

2014 – Feb. 12-13, May 7, **Aug. 6**
2013 – Jan. 29, Mar. 6-7, Aug. 14-15, Nov. 6-7.
2012 – Feb. 1-2, May 2-3, Aug. 22-23, Dec. 12-13.
2011 – Feb. 16-17, May 4-5, Aug. 17, Nov. 16-17.
2010 – Feb. 3, May 5-6, Aug. 11-12, Nov. 9-10.
2009 – Feb. 11-12, May 6-7, Aug. 5-6, Nov. 18-19.
2008 – Feb. 21-22, May 7-8, Aug. 6-7, Nov. 13.
2007 – Mar. 6-7, May 9-10, Aug. 15-16, Nov. 14-15.
2006 – Feb. 15-16, May 17-18, Aug. 15-16, Oct. 5-6, Nov. 9, Dec. 6-7.
2005 – Feb. 17, May 11-12, Aug. 17-18, Nov. 9.
2004 – Feb. 11-12, May 5-6, July 29, Aug. 18-19, Nov. 17-18.
2003 – Feb. 11-12, Feb. 19-20, May 22-23, Aug. 20-21, Nov. 19-20.
2002 – Feb. 20-21, May 8-9, Aug. 21, Nov. 20-21.
2001 – Feb. 8, May 16-17, Aug. 15-16, Nov. 14-15.
2000 – Feb. 10, Apr. 26-27, Aug. 16-17, Nov. 28-29.

For meeting minutes prior to 2000, please contact the board office for assistance.

Newsletters

This document is published in January, April, July, and October. Electronic copies for every year from 2000 forward are posted on the website. Editions from 1999 to 1982 are available in the board office.

Bulletins

<i>Issue No.</i>	<i>Date of Issue</i>	<i>Title</i>
14-05	09-15-2014	Hydrocodone Re-Scheduled by the DEA
14-04	07-15-2014	New State Laws Affecting Pharmacy Practice
14-03	07-15-2014	New State & Federal Requirements for Certain Controlled Substances
14-02	01-15-2014	FDA Actions re Certain Drug Products
14-01	01-01-2014	Law Book Update No. 7 (total replacement of all printed pages)
13-03	08-15-2013	Nonresident Pharmacies
13-02	05-01-2013	Law Book Update No. 6 (total replacement of all printed pages)
13-01	01-07-2013	Notice of Emergency Rule & Delayed Publication of 2013 Law Book
12-01	01-01-2012	Law Book Update No. 5 (total replacement of all printed pages)
11-01	01-31-2011	Law Book Update No. 4 (total replacement of all printed pages)
10-01	08-15-2010	New Laws – New Rules – New Website – New Licensure System
09-03	09-15-2009	Immunization Information & Emergency Order
09-02	07-25-2009	New Laws – New Controlled Substances
09-01	04-15-2009	Expedited Partner Therapy
08-03	08-15-2008	PMP, New Laws, & New Rules
08-02	04-07-2008	Technician Renewal Process
08-01	03-10-2008	Board Member Elections and CDTM
07-01	08-15-2007	New Laws & Rules
06-04	11-20-2006	Notice of Regulatory Activity re Project 2006-3
06-03	09-01-2006	Repeal of Certified Pharmacist Preceptor Program
06-02	09-01-2006	Law Book Update No. 3 (total replacement of all printed pages)
06-01	01-30-2006	Notice of Regulatory Activity re §705 and 907 of Board Rules
05-04	08-15-2005	Recent Changes in Pharmacy and Related Laws
05-03	03-04-2005	Electronic Transmission of Prescriptions
05-02	01-31-2005	Prescriptive Authority for Physician Assistants & Medical Psychologists
05-01	01-01-2005	Law Book Update No. 2

04-03	12-15-2004	New Regulation and Other Important Information
04-02	09-15-2004	Law Book Update No. 1
04-01	09-04-2004	Recent Changes in Pharmacy Laws

Guidance Documents

<i>Date of Issue</i>	<i>Title</i>
08-06-2014	Medication Therapy Management in the Practice of Pharmacy
08-01-2012	Act 651 of 2012 Legislature – Pharmacist Immunizations in Health Professional Shortage Areas
08-01-2010	Act 287 Of 2010 Legislature & Pharmacist Immunization Recordkeeping
08-01-2010	Medication Disposal Programs
08-01-2010	Prescribers with Authority for Controlled Substances
05-01-2009	Buprenorphine in Treatment of Opiate Addiction
10-15-2008	Medication Guides (MedGuides®)

Laws & Regulations

The current edition of this electronic reference was published January 1, 2014. The following previous editions are still available: 04-15-2013, 01-01-2012 and 01-01-2011.

Directory of Government Agencies & Private Organizations

The current edition of this electronic reference is included within the Louisiana Pharmacy Law Book, and was last published January 1, 2014.

Annual Reports

Once approved by the board, typically during their summer session, these electronic reports are posted on the board's website. The reports from 2001 forward are posted on the website. The comprehensive annual financial reports audited by the legislative auditor are available from the board office.

Commissioned Reports

The following special reports were commissioned by the Louisiana Legislature, and are posted on the board's website:

<i>Date of Issue</i>	<i>Title</i>
02-01-2012	<i>Administration of Immunizations in Louisiana</i> , issued in response to Senate Resolution 122 of 2011 Legislature
02-01-2012	<i>Legislative Workgroup on Electronic Prescribing</i> , issued in response to House Resolution 108 and Senate Resolution 81 of 2011 Legislature
03-11-2009	<i>Generic Substitution for Epilepsy Medication</i> , issued in response to House Concurrent Resolution 198 of 2008 Legislature
07-14-2008	<i>Prescription Monitoring Program Update</i> , issued in response to Senate Concurrent Resolution 102 of 2008 Legislature
01-24-2006	<i>Final Report of Prescription Monitoring Program Task Force</i> , issued in response to House Concurrent Resolution 98 of 2005 Legislature
04-20-2005	<i>Recycling of Unused Previously Dispensed Prescription Drugs</i> , issued in response to House Concurrent Resolution 292 of 2004 Legislature

Prescription Monitoring Program (PMP)

Minutes from the meetings of the PMP Advisory Council (and its predecessor PMP Task Force) are posted on the board's website:

- 2014 – Jan. 8, Apr. 9, Jul. 9
- 2013 – Jan. 9, Apr. 10, Jul. 10, Oct. 9
- 2012 – Jan. 11, Apr. 11, Jul. 11, Oct. 10.
- 2011 – Jan. 12, Apr. 13, Jul. 13, Oct. 12.

2010 – Jan. 13, Apr. 14, Jul. 14, Oct. 13.

2009 – Jan. 7, Apr. 8, Jul. 8, Oct. 14.

2008 – Jan. 16, Apr. 16, Jul. 9, Oct. 29.

2007 – Jan. 10, Apr. 11.

2006 – Jan. 24.

2005 – Jan. 12, Mar. 16, May 18, Aug. 4, Oct. 26, Nov. 30.

The following PMP-related guidance documents are posted on the board's website:

<i>Date of Issue</i>	<i>Title</i>
02-17-2014	Dispenser's Implementation Guide



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

September 1 – December 31, 2014

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


February 25, 2015

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM School of Pharmacy	03
Cumulative Report (since January 2000) for ULM School of Pharmacy	09
Current Trimester Report for Xavier College of Pharmacy	13
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: September 1, 2014 - December 31, 2014

School Name: University Louisiana Monroe

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Candidates

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	3	66.67	78.00	5.57
School 2	30	90.00	81.97	4.99
State	113	84.96	81.13	5.87
National	5058	90.87	81.79	5.50

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	6	83.33	78.50	3.94
School 2	33	87.88	81.42	5.40
State	156	82.69	80.13	5.70
National	6320	88.50	81.08	5.59

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 3 Candidate Summary Report

Test Window: September 1, 2014 - December 31, 2014

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	83	12/02/2014	05/10/2014	Y	TX
2	Pass	82	10/29/2014	05/10/2014	N	LA
3	Pass	78	10/22/2014	05/10/2014	Y	GA
4	Pass	79	09/12/2014	05/10/2014	Y	LA
5	Pass	77	09/10/2014	05/10/2014	N	LA
6	Pass	85	09/13/2014	05/11/2013	Y	TN
7	Pass	88	09/08/2014	05/11/2013	Y	NY
8	Pass	86	10/11/2014	05/19/2012	Y	SC
9	Pass	78	11/19/2014	05/17/2008	N	LA
10	Pass	82	10/20/2014	05/17/2008	Y	TX
11	Pass	86	11/22/2014	12/01/1999	Y	CO
12	Pass	82	09/03/2014	12/21/1996	Y	TN
13	Pass	83	10/04/2014	12/01/1996	Y	LA
14	Pass	80	12/23/2014	08/14/1993	Y	MA
15	Pass	85	11/22/2014	08/14/1993	Y	MI
16	Pass	84	12/16/2014	12/19/1992	Y	AL
17	Pass	84	11/24/2014	12/01/1992	Y	AL
18	Fail	72	09/20/2014	08/15/1992	Y	LA
19	Pass	86	12/16/2014	08/01/1992	Y	MS
20	Pass	84	11/11/2014	08/16/1991	Y	OR
21	Pass	81	09/11/2014	08/16/1991	Y	ID
22	Pass	88	10/07/2014	05/18/1990	Y	AL
23	Pass	88	12/31/2014	08/15/1988	Y	KS
24	Pass	84	12/16/2014	12/18/1986	Y	TX
25	Pass	82	11/19/2014	05/11/1984	Y	AL
26	Pass	84	11/18/2014	05/14/1982	N	MT
27	Pass	81	11/10/2014	05/14/1982	Y	WV
28	Pass	81	10/22/2014	05/14/1982	Y	AL
29	Fail	69	12/10/2014	03/18/1982	N	FL
30	Fail	70	11/08/2014	03/18/1982	Y	FL
31	Pass	83	10/14/2014	12/01/1981	Y	MS
32	Pass	84	11/03/2014	05/09/1981	Y	KY
33	Pass	85	10/09/2014	12/17/1977	Y	MI
34	Pass	77	10/28/2014	08/13/1976	Y	OK
35	Pass	78	10/16/2014	12/01/1974	Y	MS
36	Pass	75	09/10/2014	12/01/1974	N	TN
37	Fail	67	12/12/2014	05/20/1974	Y	TX
38	Fail	73	12/16/2014	01/01/1970	Y	FL
39	Pass	84	12/15/2014	05/19/1966	Y	MS

National Statistics for All Candidates

Mean Scaled Score: 81.08
Standard Deviation: 5.59
Range: 57 - 100
Passing Rate (%): 88.50

National Statistics for First-Time Candidates

Mean Scaled Score: 81.79
Standard Deviation: 5.50
Range: 57 - 100
Passing Rate (%): 90.87

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 4 National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 6320)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	11	0.2%
65 - 69	104	1.9%
70 - 74	607	11.5%
75 - 79	1698	38.4%
80 - 84	2237	73.8%
85 - 89	1255	93.6%
90 - 94	327	98.8%
95 - 100	76	100.0%

**Table 5 National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 5058)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.1%
60 - 64	3	0.1%
65 - 69	57	1.2%
70 - 74	398	9.1%
75 - 79	1197	32.8%
80 - 84	1864	69.6%
85 - 89	1149	92.4%
90 - 94	310	98.5%
95 - 100	76	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	4	126	87	47	94	30	32	122	39			
* <i>testing in same/different state</i>		72 / 54	11 / 34	11 / 36	40 / 54	2 / 28	5 / 27	62 / 60	6 / 33			
Mean Scale Score - School *	82.25	82.44/82.70	80.09/79.85	81.45/84.03	82.50/82.59	80.50/82.79	79.40/81.41	81.44/83.32	78.50/81.42			
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13			
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08			
School Pass Rate: *	100.00	97.22/90.74	90.91/85.29	100/97.22	95.00/98.15	100 / 92.86	100 / 85.19	95.16/96.67	83.33/87.88			
* <i>testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69			
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50			
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	4	124	70	44	93	28	29	119	33			
* <i>testing in same/different state</i>		72 / 52	10 / 29	10 / 34	39 / 54	1 / 27	5 / 24	62 / 57	3 / 30			
Mean Scaled Score - School *	82.25	82.44/83.02	80.62/79.90	81.80/84.26	82.77/82.59	82.00/83.19	79.40/82.29	81.44/83.58	78.00/81.97			
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13			
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79			
School Pass Rate: *	100.00	97.22/92.31	89.66/90.00	100.00/97.06	97.44/98.15	100 / 96.30	100 / 91.67	95.16/98.25	66.67/90.00			
* <i>testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96			
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87			

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)


University of Louisiana at Monroe

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: September 1, 2014 - December 31, 2014

School Name: Xavier University of Louisiana

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Candidates

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	24	62.50	77.33	5.14
School 2	74	91.89	80.86	4.63
State	113	84.96	81.13	5.87
National	5058	90.87	81.79	5.50

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	43	65.12	77.05	4.52
School 2	85	90.59	80.62	4.64
State	156	82.69	80.13	5.70
National	6320	88.50	81.08	5.59

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 3 Candidate Summary Report

Test Window: September 1, 2014 - December 31, 2014

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	79	10/21/2014	08/02/2014	Y	TX
2	Fail	69	12/30/2014	06/28/2014	Y	LA
3	Pass	85	11/03/2014	06/28/2014	Y	TX
4	Pass	77	10/14/2014	06/28/2014	Y	AL
5	Pass	81	09/17/2014	06/28/2014	Y	LA
6	Fail	73	09/15/2014	06/28/2014	Y	LA
7	Pass	84	12/16/2014	05/10/2014	Y	LA
8	Fail	73	12/15/2014	05/10/2014	Y	LA
9	Pass	80	12/15/2014	05/10/2014	Y	LA
10	Pass	83	12/09/2014	05/10/2014	N	GA
11	Pass	76	12/08/2014	05/10/2014	N	LA
12	Pass	79	11/25/2014	05/10/2014	N	MS
13	Pass	76	11/24/2014	05/10/2014	N	LA
14	Fail	74	11/24/2014	05/10/2014	Y	LA
15	Fail	72	11/22/2014	05/10/2014	N	LA
16	Fail	71	11/21/2014	05/10/2014	N	LA
17	Pass	84	11/20/2014	05/10/2014	Y	AL
18	Pass	79	11/19/2014	05/10/2014	N	LA
19	Fail	72	11/13/2014	05/10/2014	N	LA
20	Pass	83	11/08/2014	05/10/2014	Y	MS
21	Pass	77	10/31/2014	05/10/2014	N	LA
22	Fail	74	10/31/2014	05/10/2014	N	LA
23	Pass	80	10/31/2014	05/10/2014	N	LA
24	Fail	72	10/18/2014	05/10/2014	Y	GA
25	Fail	73	10/17/2014	05/10/2014	Y	LA
26	Fail	73	10/08/2014	05/10/2014	Y	LA
27	Pass	83	10/04/2014	05/10/2014	Y	IL
28	Fail	73	09/29/2014	05/10/2014	N	LA
29	Fail	69	09/29/2014	05/10/2014	Y	LA
30	Pass	85	09/29/2014	05/10/2014	Y	MS
31	Pass	77	09/29/2014	05/10/2014	N	LA
32	Pass	83	09/26/2014	05/10/2014	Y	MS
33	Pass	75	09/25/2014	05/10/2014	Y	LA
34	Pass	76	09/20/2014	05/10/2014	N	LA
35	Pass	76	09/18/2014	05/10/2014	Y	MS
36	Pass	82	09/17/2014	05/10/2014	N	TX
37	Pass	83	09/16/2014	05/10/2014	Y	OK
38	Pass	83	09/16/2014	05/10/2014	Y	TX
39	Fail	72	09/15/2014	05/10/2014	N	LA
40	Pass	79	09/15/2014	05/10/2014	N	LA
41	Pass	79	09/15/2014	05/10/2014	N	LA
42	Fail	71	09/15/2014	05/10/2014	Y	MS
43	Pass	79	09/15/2014	05/10/2014	Y	LA
44	Pass	79	09/13/2014	05/10/2014	Y	AZ

Table 3 Candidate Summary Report

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
45	Pass	79	09/12/2014	05/10/2014	Y	LA
46	Pass	79	09/10/2014	05/10/2014	N	LA
47	Pass	81	09/10/2014	05/10/2014	Y	MS
48	Pass	79	09/09/2014	05/10/2014	N	LA
49	Pass	85	09/08/2014	05/10/2014	N	LA
50	Pass	86	09/05/2014	05/10/2014	N	WA
51	Pass	81	09/05/2014	05/10/2014	N	LA
52	Pass	77	09/04/2014	05/10/2014	Y	TX
53	Fail	72	09/04/2014	05/10/2014	Y	LA
54	Pass	80	09/03/2014	05/10/2014	Y	CO
55	Pass	80	09/03/2014	05/10/2014	Y	LA
56	Pass	84	09/03/2014	05/10/2014	Y	LA
57	Pass	79	09/02/2014	05/10/2014	Y	LA
58	Pass	88	09/02/2014	05/10/2014	Y	LA
59	Pass	78	09/02/2014	05/10/2014	Y	LA
60	Fail	73	09/02/2014	05/10/2014	Y	LA
61	Pass	82	09/02/2014	05/10/2014	Y	TX
62	Pass	76	10/03/2014	12/13/2013	N	IL
63	Pass	82	12/30/2014	05/11/2013	Y	MS
64	Pass	85	11/14/2014	05/11/2013	Y	NY
65	Pass	89	10/01/2014	05/11/2013	Y	TX
66	Pass	82	09/24/2014	05/11/2013	N	AZ
67	Pass	77	09/13/2014	05/11/2013	Y	TX
68	Pass	81	09/04/2014	05/11/2013	Y	LA
69	Pass	84	12/23/2014	05/12/2012	Y	TX
70	Pass	76	12/09/2014	05/12/2012	Y	LA
71	Fail	71	12/09/2014	05/12/2012	Y	TX
72	Pass	81	11/25/2014	05/12/2012	Y	MS
73	Fail	72	10/28/2014	05/12/2012	N	TX
74	Pass	84	09/20/2014	05/12/2012	Y	TX
75	Pass	79	12/20/2014	12/11/2011	Y	TX
76	Pass	81	12/17/2014	05/08/2010	Y	KY
77	Pass	85	11/06/2014	05/08/2010	Y	AZ
78	Pass	83	10/03/2014	05/08/2010	Y	AZ
79	Pass	82	09/26/2014	05/08/2010	Y	KY
80	Pass	76	09/24/2014	05/08/2010	Y	AL
81	Pass	78	09/24/2014	05/08/2010	Y	WA
82	Pass	84	09/16/2014	05/08/2010	Y	TN
83	Pass	84	09/12/2014	05/08/2010	Y	OK
84	Pass	79	09/08/2014	05/08/2010	Y	WV
85	Pass	81	12/06/2014	05/09/2009	N	TX
86	Pass	82	10/09/2014	05/09/2009	Y	AZ
87	Pass	83	11/05/2014	05/12/2007	Y	TX
88	Pass	80	09/02/2014	05/12/2007	Y	UT

Table 3 Candidate Summary Report

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
89	Pass	78	12/16/2014	05/20/2006	Y	NY
90	Pass	94	12/02/2014	05/01/2005	Y	TX
91	Pass	81	11/24/2014	05/01/2005	Y	TX
92	Pass	84	09/23/2014	05/01/2005	Y	IL
93	Fail	68	09/09/2014	05/01/2005	Y	MS
94	Pass	78	12/09/2014	05/08/2004	Y	NE
95	Pass	80	11/21/2014	05/08/2004	Y	AL
96	Pass	79	11/10/2014	05/08/2004	Y	WV
97	Pass	81	10/17/2014	05/08/2004	Y	OR
98	Pass	78	12/11/2014	05/01/2004	Y	AL
99	Pass	82	09/13/2014	05/01/2004	Y	OR
100	Pass	83	11/14/2014	05/01/2002	Y	NM
101	Pass	77	10/24/2014	05/01/2002	Y	LA
102	Pass	89	10/09/2014	05/01/2002	Y	AZ
103	Pass	80	12/19/2014	05/01/2001	Y	AL
104	Pass	79	11/11/2014	05/01/2001	Y	TX
105	Fail	71	10/25/2014	01/22/2001	N	NY
106	Pass	75	12/18/2014	05/01/2000	Y	GA
107	Pass	78	11/15/2014	05/01/2000	N	TN
108	Fail	73	09/20/2014	05/01/2000	Y	TN
109	Pass	81	09/15/2014	05/19/1997	Y	IL
110	Pass	88	12/01/2014	05/12/1997	Y	AZ
111	Pass	90	12/10/2014	12/16/1996	Y	MI
112	Pass	81	11/01/2014	05/13/1995	Y	AL
113	Pass	79	10/30/2014	05/11/1993	Y	AL
114	Pass	79	11/17/2014	05/01/1993	Y	GA
115	Pass	81	11/10/2014	05/01/1993	Y	AL
116	Pass	86	11/03/2014	05/01/1993	Y	MI
117	Pass	79	12/29/2014	12/14/1992	N	WV
118	Fail	71	10/10/2014	12/14/1992	Y	WV
119	Pass	86	12/23/2014	05/09/1992	Y	LA
120	Pass	85	09/06/2014	05/10/1989	Y	DE
121	Pass	77	11/19/2014	05/18/1986	Y	MI
122	Pass	88	10/27/2014	05/18/1986	Y	TN
123	Pass	82	10/18/2014	05/15/1983	Y	DC
124	Pass	78	10/10/2014	05/15/1983	Y	MD
125	Pass	79	12/12/2014	12/19/1979	Y	GA
126	Pass	80	11/25/2014	12/19/1979	Y	SC
127	Pass	87	10/16/2014	05/01/1978	Y	TX
128	Pass	78	12/23/2014	12/20/1974	Y	TN

National Statistics for All Candidates

Mean Scaled Score: 81.08
Standard Deviation: 5.59
Range: 57 - 100
Passing Rate (%): 88.50

National Statistics for First-Time Candidates

Mean Scaled Score: 81.79
Standard Deviation: 5.50
Range: 57 - 100
Passing Rate (%): 90.87

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 4 National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 6320)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	11	0.2%
65 - 69	104	1.9%
70 - 74	607	11.5%
75 - 79	1698	38.4%
80 - 84	2237	73.8%
85 - 89	1255	93.6%
90 - 94	327	98.8%
95 - 100	76	100.0%

**Table 5 National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 5058)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.1%
60 - 64	3	0.1%
65 - 69	57	1.2%
70 - 74	398	9.1%
75 - 79	1197	32.8%
80 - 84	1864	69.6%
85 - 89	1149	92.4%
90 - 94	310	98.5%
95 - 100	76	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	181	87	53	188	115	52	193	128			
<i>* testing in same/different state</i>		94 / 87	23 / 65	6 / 47	95 / 93	46 / 69	12 / 40	82 / 111	43 / 85			
Mean Scaled Score - School *	79.69	79.27/78.48	76.96/79.95	78.17/79.09	79.46/79.55	77.33/78.72	76 / 79.28	78.35/79.98	77.05/80.62			
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13			
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08			
School Pass Rate: *	84.62	84.04/81.61	60.87/86.15	83.33/76.60	85.26/81.72	71.74/76.81	50 / 82.50	76.83/90.09	65.12/90.59			
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69			
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50			
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	9	163	70	43	171	86	43	176	98			
<i>* testing in same/different state</i>		87 / 76	11 / 54	3 / 40	89 / 82	31 / 55	8 / 35	76 / 100	24 / 74			
Mean Scaled Score - School *	79.78	79.34/78.70	77.55/80.57	81.33/79.38	79.66/79.94	77.03/78.85	76.63/79.31	78.83/80.23	77.33/80.86			
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13			
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79			
School Pass Rate: *	88.89	83.91/84.24	63.64/87.04	100 / 77.50	87.64/82.93	67.74/74.55	50 / 80	80.26/90.00	62.5 / 91.89			
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96			
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87			

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

September 1 – December 31, 2014

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


February 25, 2015

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	10
Current Trimester Report for Xavier College of Pharmacy	14
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: September 1, 2014 - December 31, 2014

School Name: University Louisiana Monroe

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	3	66.67	92.00	26.85	12.00	1.73	11.67	1.53	12.67	1.15
State	19	73.68	83.84	22.08	11.47	1.35	10.95	1.22	11.16	2.32
National	1359	85.36	93.94	17.88	11.99	1.28	11.90	1.35	12.29	1.72

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	11	63.64	82.27	15.41	11.00	1.34	11.36	1.03	11.82	0.98
State	34	70.59	80.88	17.64	11.12	1.20	11.00	1.07	11.03	1.83
National	2298	79.77	89.22	19.00	11.69	1.31	11.66	1.37	11.88	1.77

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2013). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2013) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.88	12.83	12.05	10.86
Mean Area 2 Scaled Score	13.68	12.69	11.93	10.74
Mean Area 3 Scaled Score	13.95	12.98	12.24	10.92
Mean Overall Scaled Score	119.26	107.79	96.71	74.67
Scaled Score Range	[138, 114]	[113, 104]	[103, 91]	[90, 0]
# Examinees per bin	3,748	3,748	3,748	3,748

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.67 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2013) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.63	10.18
Mean Area 2 Scaled Score	12.49	10.01
Mean Area 3 Scaled Score	12.77	10.13
Mean Overall Scaled Score	103.64	60.39
Scaled Score Range	[138, 75]	[74, 0]
# Examinees per bin	13,593	1,399

Table 5 Candidate Summary Report

Test Window: September 1, 2014 - December 31, 2014

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Fail	69	10	10	10	12/23/2014	05/10/2014	N
2	Pass	76	10	11	12	12/16/2014	05/10/2014	N
3	Pass	82	11	11	12	11/12/2014	05/10/2014	N
4	Pass	95	13	11	11	11/08/2014	05/10/2014	N
5	Pass	82	10	13	11	10/31/2014	05/10/2014	N
6	Pass	83	11	11	12	10/21/2014	05/10/2014	N
7	Fail	68	10	11	12	10/21/2014	05/10/2014	N
8	Fail	74	10	12	12	10/20/2014	05/10/2014	N
9	Fail	61	10	10	12	09/08/2014	05/10/2014	Y
10	Pass	108	13	13	12	09/04/2014	05/10/2014	Y
11	Pass	107	13	12	14	09/10/2014	03/10/2014	Y

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 89.22
Standard Deviation: 19.00
Range: 14 - 131
Passing Rate (%): 79.77

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 93.94
Standard Deviation: 17.88
Range: 22 - 131
Passing Rate (%): 85.36

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 6 National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 2298)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	1	0.0%
15 - 19	4	0.2%
20 - 24	4	0.4%
25 - 29	4	0.6%
30 - 34	7	0.9%
35 - 39	10	1.3%
40 - 44	15	2.0%
45 - 49	25	3.1%
50 - 54	37	4.7%
55 - 59	53	7.0%
60 - 64	77	10.4%
65 - 69	87	14.2%
70 - 74	129	19.8%
75 - 79	184	27.9%
80 - 84	220	37.5%
85 - 89	225	47.3%
90 - 94	261	58.7%
95 - 99	244	69.4%
100 - 104	197	78.0%
105 - 109	167	85.3%
110 - 114	146	91.7%
115 - 119	112	96.6%
120 - 124	59	99.2%
125 - 129	16	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**Table 7 National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 1359)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	2	0.1%
25 - 29	0	0.1%
30 - 34	2	0.3%
35 - 39	3	0.5%
40 - 44	3	0.7%
45 - 49	11	1.6%
50 - 54	15	2.7%
55 - 59	19	4.1%
60 - 64	33	6.5%
65 - 69	45	9.9%
70 - 74	57	14.1%
75 - 79	87	20.5%
80 - 84	93	27.4%
85 - 89	122	36.4%
90 - 94	152	47.7%
95 - 99	149	58.7%
100 - 104	143	69.3%
105 - 109	132	79.1%
110 - 114	120	88.0%
115 - 119	97	95.2%
120 - 124	50	98.9%
125 - 129	13	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)


University of Louisiana at Monroe

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	6	80	17	3	40	7	1	68	11			
Mean Scaled Score - School	75.33	97.14	85.41	92.00	100.45	88.43	101.00	95.10	82.27			
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88			
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22			
School Pass Rate:	83.33	92.50	82.35	100.00	90.00	100.00	100.00	89.71	63.64			
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59			
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77			
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	80	9	3	38	4	1	68	3			
Mean Scaled Score - School	49.50	97.14	87.11	92.00	101.68	92.00	101.00	95.10	92.00			
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.34			
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94			
School Pass Rate:	50.00	92.50	77.78	100.00	92.11	100.00	100.00	89.71	66.67			
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68			
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36			



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: September 1, 2014 - December 31, 2014

School Name: Xavier University of Louisiana

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	18	72.22	82.33	21.44	11.56	1.38	10.89	1.28	10.94	2.44
State	19	73.68	83.84	22.08	11.47	1.35	10.95	1.22	11.16	2.32
National	1359	85.36	93.94	17.88	11.99	1.28	11.90	1.35	12.29	1.72

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	27	70.37	80.41	21.61	11.37	1.39	10.85	1.32	11.00	2.09
State	34	70.59	80.88	17.64	11.12	1.20	11.00	1.07	11.03	1.83
National	2298	79.77	89.22	19.00	11.69	1.31	11.66	1.37	11.88	1.77

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2013). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2013) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.88	12.83	12.05	10.86
Mean Area 2 Scaled Score	13.68	12.69	11.93	10.74
Mean Area 3 Scaled Score	13.95	12.98	12.24	10.92
Mean Overall Scaled Score	119.26	107.79	96.71	74.67
Scaled Score Range	[138, 114]	[113, 104]	[103, 91]	[90, 0]
# Examinees per bin	3,748	3,748	3,748	3,748

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.67 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2013) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.63	10.18
Mean Area 2 Scaled Score	12.49	10.01
Mean Area 3 Scaled Score	12.77	10.13
Mean Overall Scaled Score	103.64	60.39
Scaled Score Range	[138, 75]	[74, 0]
# Examinees per bin	13,593	1,399

Table 5 Candidate Summary Report

Test Window: September 1, 2014 - December 31, 2014

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	108	13	13	14	10/07/2014	08/02/2014	Y
2	Fail	61	10	10	9	12/30/2014	06/28/2014	Y
3	Pass	75	12	10	6	12/23/2014	06/28/2014	Y
4	Fail	55	10	9	10	09/26/2014	06/28/2014	Y
5	Fail	56	11	9	10	09/12/2014	06/28/2014	Y
6	Pass	101	13	11	13	09/02/2014	06/28/2014	Y
7	Pass	99	12	13	13	12/09/2014	05/10/2014	N
8	Pass	80	12	10	10	12/04/2014	05/10/2014	N
9	Fail	31	8	10	6	11/20/2014	05/10/2014	Y
10	Pass	92	12	12	11	11/18/2014	05/10/2014	N
11	Pass	109	13	12	14	11/13/2014	05/10/2014	Y
12	Pass	78	11	10	11	10/21/2014	05/10/2014	Y
13	Pass	96	13	10	13	10/02/2014	05/10/2014	Y
14	Fail	74	11	11	11	09/25/2014	05/10/2014	Y
15	Pass	77	12	10	10	09/25/2014	05/10/2014	Y
16	Pass	96	12	12	14	09/22/2014	05/10/2014	Y
17	Pass	82	11	10	12	09/09/2014	05/10/2014	Y
18	Pass	101	13	12	11	09/08/2014	05/10/2014	Y
19	Pass	106	13	13	9	09/08/2014	05/10/2014	Y
20	Pass	83	11	12	11	09/04/2014	05/10/2014	Y
21	Pass	93	11	12	13	09/04/2014	05/10/2014	Y
22	Pass	99	13	11	12	10/07/2014	12/13/2013	N
23	Fail	55	9	10	9	09/22/2014	12/13/2013	N
24	Pass	89	11	12	12	10/21/2014	05/11/2013	N
25	Pass	80	11	10	11	09/05/2014	05/11/2013	N
26	Fail	64	10	11	12	12/20/2014	05/07/2011	N
27	Fail	31	9	8	10	09/11/2014	05/08/2008	N

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 89.22
Standard Deviation: 19.00
Range: 14 - 131
Passing Rate (%): 79.77

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 93.94
Standard Deviation: 17.88
Range: 22 - 131
Passing Rate (%): 85.36

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 6 National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 2298)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	1	0.0%
15 - 19	4	0.2%
20 - 24	4	0.4%
25 - 29	4	0.6%
30 - 34	7	0.9%
35 - 39	10	1.3%
40 - 44	15	2.0%
45 - 49	25	3.1%
50 - 54	37	4.7%
55 - 59	53	7.0%
60 - 64	77	10.4%
65 - 69	87	14.2%
70 - 74	129	19.8%
75 - 79	184	27.9%
80 - 84	220	37.5%
85 - 89	225	47.3%
90 - 94	261	58.7%
95 - 99	244	69.4%
100 - 104	197	78.0%
105 - 109	167	85.3%
110 - 114	146	91.7%
115 - 119	112	96.6%
120 - 124	59	99.2%
125 - 129	16	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**Table 7 National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 1359)**

Test Window: September 1, 2014 - December 31, 2014

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	2	0.1%
25 - 29	0	0.1%
30 - 34	2	0.3%
35 - 39	3	0.5%
40 - 44	3	0.7%
45 - 49	11	1.6%
50 - 54	15	2.7%
55 - 59	19	4.1%
60 - 64	33	6.5%
65 - 69	45	9.9%
70 - 74	57	14.1%
75 - 79	87	20.5%
80 - 84	93	27.4%
85 - 89	122	36.4%
90 - 94	152	47.7%
95 - 99	149	58.7%
100 - 104	143	69.3%
105 - 109	132	79.1%
110 - 114	120	88.0%
115 - 119	97	95.2%
120 - 124	50	98.9%
125 - 129	13	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	120	21	10	136	43	18	138	27			
Mean Scaled Score - School	76.69	95.13	83.24	68.67	95.13	81.47	70.72	96.29	80.41			
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88			
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22			
School Pass Rate:	46.15	90.00	61.90	40.00	86.03	65.12	50.00	92.75	70.37			
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59			
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77			
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	111	12	1	131	29	3	131	18			
Mean Scaled Score - School	84.67	97.71	95.58	47.00	96.65	82.76	61.00	97.15	82.33			
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.84			
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94			
School Pass Rate:	66.67	93.69	91.67	0.00	89.31	68.97	66.67	93.89	72.22			
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68			
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36			



My name is Curt Ritchie, DVM and I am a practicing veterinarian based out of Baton Rouge, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Dr Curt C Ritchie
Perkins Road Veterinary Hospital
5215 Perkins Rd
Baton Rouge LA 70808



125-ck

My name is Brett Berryhill and I am a practicing veterinarian based out of Baton Rouge, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,



162 Staring Lane
Baton Rouge, LA 70810
(225) 766-8333
Brett A. Berryhill, DVM
Lucie B. Berryhill, DVM
A Professional Corporation
www.dogandcatdocs.com





CRS-CK

My name is Renee Carter and I am a practicing veterinarian based out of Baton Rouge, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,



Renee Carter



CP5-CK

My name is Ronald J. Pritchett, DVM and I am a practicing veterinarian based out of Baton Rouge, Louisiana (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Ronald J. Pritchett, DVM





CPS-EK

My name is Katie Maher and I am a practicing veterinarian based out of Carlingen LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

D. Maher





My name is William Wheat and I am a practicing veterinarian based out of Hammond, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

William Wheat





CPS-OK

My name is FRED MAHER and I am a practicing veterinarian based out of COVINGTON LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-2K

My name is Stephene Abbott, DVM and I am a practicing veterinarian based out of Covington, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS TK

My name is Edward Amundson DVM and I am a practicing veterinarian based out of Zachary, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Edward Amundson DVM





CDS-CK

My name is Jason St-Roman and I am a practicing veterinarian based out of Zachary, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-EP

My name is leigh Gilbert O'Brien and I am a practicing veterinarian based out of Zachary, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,


1/21/15





CDS-OK

My name is Gordon J. Pirie DVM and I am a practicing veterinarian based out of Baker, Louisiana 70714 (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Gordon J. Pirie, DVM





205-CK

My name is Fenton Lipscomb and I am a practicing veterinarian based out of Gonzales LA 70727 (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Fenton R. Lipscomb, DVM





CD 5-CK

My name is Gilbert Griffith and I am a practicing veterinarian based out of Prairieville, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.


The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

GRIFFITH VETERINARY CENTER
18015 AUTUMN VIEW DRIVE
PRAIRIEVILLE, LA 70769
(225) 622-2568

Sincerely,

Gilbert Griffith

1 20 2015





CDS-ok

My name is Robert Folsom DVM and I am a practicing veterinarian based out of Prairieville, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.


Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Robert Folsom

ASCENSION PARISH ANIMAL HOSP.
P.O. BOX 628
PRAIRIEVILLE, LA 70780





CPS-EK

My name is Jonathan Duvach and I am a practicing veterinarian based out of Thousand Oaks CA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,







CDS-OK

My name is Kimberly Deskin Ruth and I am a practicing veterinarian based out of Thibodaux, La. (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Kimberly Deskin Ruth





CDS-OK

My name is Dr. Leslie Pence and I am a practicing veterinarian based out of Metairie, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Dr. Leslie Pence





CPS-OK

My name is Rosey Kelley and I am a practicing veterinarian based out of Gonzales CA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-CK

My name is Robert Braquet, DVM and I am a practicing veterinarian based out of Animal Care Center of Gonzales (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Animal Care Center of Gonzales
14076 Highway 44
Gonzales, LA 70737





CDS-CK

My name is GARY T LEVY and I am a practicing veterinarian based out of NEW ORLEANS, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-OK

My name is Dr. Gregory Rich and I am a practicing veterinarian based out of Metairie Louisiana (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-CK

My name is CLARE GUYCHARD and I am a practicing veterinarian based out of NEW ORLEANS, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





CDS-OK

My name is AMANDA PERKINS and I am a practicing veterinarian based out of Metairie, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,







CMS-DK

My name is PATRICK M^C SWEENEY and I am a practicing veterinarian based out of METAIRIE (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,





2/12/15

CDS-OK

My name is Bernhard H. Mayer and I am a practicing veterinarian based out of Westwego (New Orleans) LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.


Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

I thank you for your consideration of the above described matter, even if it's in the form of a form letter.

Sincerely,

Bernhard H. Mayer





CDS-OK

My name is Rhett Mouton and I am a practicing veterinarian based out of Baton Rouge, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.


Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

 DVM





CDS-01C

My name is Kristen Kulinski and I am a practicing veterinarian based out of Baton Rouge LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Kristen Kulinski DVM MS





CDS-OK

My name is Elizabeth Braun and I am a practicing veterinarian based out of Pa Prairieville, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.


There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Elizabeth Braun, DVM





2.
My name is LIZ Fzeile and I am a practicing veterinarian based out of Zachary, LA (your town and state of residence). I would like to share with the State Board of Pharmacy how current regulations are negatively impacting our practice. We care for a large number of companion animals within the state. We have seen more and more FDA approved drugs disappear from our shelves and must resort to compounding pharmacies to replace these vital medications.

My main objective with this statement is to inform you of a growing need for quality compounded medications on which our patients depend, particularly in the face of allocation shortages, backordered and discontinued medications and the growing need for customized solutions for companion pets.

Often time's regulators are not fully aware of the fundamental difference of how a veterinary practice operates when compared to a human practice. Veterinarians are expected by you and me to treat our pets on the spot for emergency care. One simple example would be if your pet ate something they shouldn't have. Let's hope it is not poisonous but the veterinarian wants to induce vomiting which requires Apomorphine. That medication is no longer available proprietarily or as an FDA approved drug. Without the medication on the shelf, the dog or cat could die. Only a compound on the shelf could save the pet.

There are countless examples of where FDA approved drugs have disappeared or never been made available for the veterinary practice. Today I am asking that this regulatory board keep in mind the unique medication requirements of the veterinary practice when reviewing or writing regulations pertaining to compounding. Asking vets to place single pet names on medication bottles to meet the letter of the law knowing they are used for multiple pets at the clinic is simply wrong. Restrictive regulations preventing the purchase of office use compounds for the veterinary practice is also wrong.

Today, we simply want to remind the board that veterinarians do practice differently and continue to clarify the need for veterinary office use compounds and the ability to dispense a small amount, up to 10 days' worth, for acute care. The states of Tennessee and Virginia have recently exempted veterinarians from certain patient specific rules understanding this unique role for veterinary practices.

The veterinary community is very upset with potential regulations tying their hands with regard to meeting their oath. Thank you for your time and please contact me if you have any questions for your deliberations.

Sincerely,

Dr. Liz Fzeile





Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Announcements

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 25, 2015

Agenda Item 11: Announcements

Mar. 4	Violations Committee Informal Conference
Mar. 18-19	FDA Intergovernmental Mtg on Pharmacy Compounding
Mar. 19-20	MPJE Item Development Workshop – Mount Prospect, IL
Mar. 27-30	APhA Annual Meeting – San Diego, CA
Apr. 3	Good Friday – <i>Board office closed</i>
Apr. 8	La. Pharmacy Congress PMP Advisory Council
Apr. 13	2015 Legislature convenes
Apr. 16	.Pharmacy Executive Board – Mount Prospect, IL
Apr. 22-24	National Prescription Drug Abuse Summit – Atlanta, GA
Apr. 25-28	NACDS Annual Meeting – Palm Beach, FL
May 16-19	NABP Annual Meeting – New Orleans, LA
May 21-23	LSHP Annual Meeting – New Orleans, LA
May 25	Memorial Day – <i>Board office closed</i>
May 26	Reinstatement, Impairment, & Executive Committees
May 27	Board Meeting
May 28	Administrative Hearing